Herpes simplex virus mRNA vaccine

The mRNA vaccines for HSV, encoding modified glycoproteins and intracellular proteins, address the limitations of existing vaccines by inducing robust immune responses to prevent and treat HSV infections safely.

JP2024545152AInactive Publication Date: 2024-12-05MODERNATX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534381
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-10
Filing Date
2022-12-07
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current vaccines for herpes simplex virus (HSV) are either ineffective or pose a risk of latent infection, and there is a need for a safe and effective vaccine that can prevent and treat HSV infections.

Method used

Development of mRNA vaccines that encode modified HSV proteins, including glycoproteins B, C, and D, and intracellular proteins ICP0 and ICP4, designed to elicit a balanced humoral and cellular immune response, with modifications to improve antibody and T cell responses, reducing the risk of pathogenic Th2 cells and enhancing immunogenicity.

Benefits of technology

The mRNA vaccines induce potent neutralizing antibodies and T cell responses, effectively preventing HSV infection and reducing the duration of outbreaks, while minimizing the risk of latent infection and immunosuppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545152000001_ABST
    Figure 2024545152000001_ABST
Patent Text Reader

Abstract

Provided herein are messenger ribonucleic acid (mRNA) vaccines that encode multiple herpes simplex virus (HSV) antigens involved in viral attachment and entry. Also provided are methods of using the vaccines and compositions comprising the vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 63 / 287,208, filed December 8, 2021, and U.S. Provisional Application No. 63 / 298,112, filed January 10, 2022, each of which is incorporated herein by reference in its entirety.

[0002] Reference to the Electronic Sequence Listing The contents of the electronic sequence listing (M137870195WO00-SEQ-NTJ.xml, size: 214,658 bytes, and creation date: December 7, 2022) are incorporated herein by reference in their entirety. [Background technology]

[0003] Herpes simplex virus (HSV) is a double-stranded, linear DNA virus of the family Herpesviridae, belonging to one of two subtypes (HSV-1 or HSV-2). These neuroinvasive viruses establish latent infections in nerve ganglia, and sporadic episodes of reactivation and replication result in recurrent symptomatic periods known as "outbreaks." During such outbreaks, replication-competent viral particles are abundant in the affected area, allowing transmission of HSV via contact with the affected area. HSV affects many people worldwide. The World Health Organization estimates that 67% of people under 50 years of age are infected with HSV-1, while 11% of people aged 15-49 years are infected with HSV-2.

[0004] Currently, antiviral medications, including acyclovir (Zovirax®), famciclovir (Famvir®), and valacyclovir (Valtrex®), are the only FDA-approved treatments people can take to fight HSV. Herpes viruses are more complex and elusive than most viruses, making vaccine development difficult. Indeed, several companies that oversaw clinical trials for herpes vaccines over the past few years have subsequently abandoned the research. For example, in June 2018, one company announced that its Phase II clinical trial of an HSV-2 vaccine did not meet its "primary endpoint." In September 2017, another company announced it was considering "strategic alternatives" to its herpes vaccine but ultimately discontinued funding for the vaccine.

[0005] Symptomatic infections with other Herpesviridae are often prevented by the use of live-attenuated vaccines, such as attenuated varicella-zoster virus (VZV) for the prevention of chickenpox and shingles. Clinical trials using live-attenuated HSV vaccines are ongoing, but there remains an associated risk that the live virus will establish a latent infection in vaccinated subjects, predisposing them to outbreaks later in life. Therefore, there remains an urgent need to develop a safe and effective HSV vaccine. Summary of the Invention

[0006] The messenger ribonucleic acid (mRNA) vaccines provided herein safely direct the body's cellular machinery to produce multiple modified HSV proteins designed to have therapeutic immunogenic activity both inside and outside the cell. These HSV mRNA vaccines contain multiple mRNA polynucleotides, each encoding a different intracellularly or cell surface-expressed protein strategically designed to elicit improved and balanced humoral and cellular immune responses against HSV. Furthermore, the intracellular HSV antigens are designed to prevent the harmful effects of HSV protein expression. Modifications to surface-expressed HSV glycoproteins improve expression and antibody responses, while modifications to HSV intracellular proteins result in improved CD8 expression, which can eliminate cells in which HSV has re-emerged from latency or actively replicating and expressing wild-type protein counterparts. + Strikingly, modified HSV intracellular proteins produced after mRNA vaccination inhibit the generation of pathogenic glycoprotein-specific Th2 cells without impairing the generation of immunoprotective glycoprotein-specific Th1 cells or glycoprotein-specific antibodies.

[0007] HSV mRNA vaccination, in some embodiments, results in the expression of HSV glycoprotein B (gB), HSV glycoprotein C (gC), and / or HSV glycoprotein D (gD) by somatic cells in a manner similar to that when the proteins are expressed by the native virus, eliciting the production of glycoprotein-specific antibodies and T cells (e.g., Th1 cells that produce proinflammatory IFN-γ and CD8+ T cells that eliminate infected cells). Because each of HSV glycoproteins B, C, and D is required for viral entry, multivalent mRNA vaccines against these antigens generate potent neutralizing antibody responses that limit (e.g., prevent) and / or treat HSV infection. Modifications to these antigens have been shown herein to improve antibody responses. For example, deletion of the cytoplasmic tail of HSV gC elicits higher antibody titers compared to the wild-type (unmodified) form. As another example, mutation of residue 327 (eg, F327A) of HSV gC abrogates the binding and sequestration of human C3b, thereby exposing immunologically important gC epitopes that are otherwise masked by C3b.

[0008] Antibodies generated in response to the HSV mRNA vaccines provided herein possess multiple antiviral activities useful for preventing or alleviating HSV infection. For example, neutralizing activity against HSV particles prevents cell infection in a microneutralization assay. Furthermore, the induced antibodies promote antibody-dependent cell-mediated cytotoxicity, which leads to clearance of virus-infected cells. Furthermore, the antibodies prevent cell-to-cell spread by HSV particles, in which HSV released from one cell migrates to and infects neighboring cells. Therefore, in addition to their prophylactic use in preventing HSV infection in naive or recently exposed subjects, the vaccines of the present disclosure are also useful therapeutically, such as for shortening the duration of HSV outbreaks or preventing reactivation of latent HSV infection.

[0009] HSV mRNA vaccination, in other aspects, also induces expression of the HSV intracellular proteins ICP0 and / or ICP4, which are expressed inside host cells early in the reactivation of latent infection. These intracellular proteins are, in some embodiments, modified to prevent the deleterious effects of HSV protein expression, and, as described above, induce CD8 expression, which allows HSV to eliminate cells that have re-emerged from latency or are actively replicating. + Modifications to intracellular HSV proteins can induce T cell responses, for example: (i) the well-known CD8 + These include (i) internal truncations to remove regions of the protein interspersed with T cell epitopes, thereby increasing the epitope density of the modified protein (e.g., ICP0 and / or ICP4), and / or (ii) to disrupt or remove functional portions of the protein to improve safety or immunogenicity. In some embodiments, intracellular HSV proteins are modified with a disrupted nuclear localization signal to promote cytosolic retention, proteasomal processing, and epitope presentation to CD8+ T cells. Furthermore, while wild-type ICP0 and ICP4, for example, inhibit innate immune functions to promote viral replication (e.g., via the USP7-binding domain, involved in inhibiting Toll-like receptor signaling, or the RING finger domain, involved in inhibiting the antiviral interferon response), these domains are not associated with immunogenic CD8 T cells. + They can be disrupted to reduce or eliminate their immunosuppressive function while retaining the T cell epitopes.

[0010] Thus, compositions containing mRNAs collectively encoding HSV gB, gC, gD, ICP0, and ICP4 are useful for generating glycoprotein-specific antibodies and robust antiviral Th1 cell responses that control viral replication, while limiting the generation of pathogenic Th2 cells that exacerbate HSV-2 infection.

[0011] Some embodiments relate to a herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein B (gB) that comprises a truncated C-terminus compared to wild-type HSV gB; (b) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC); (c) an mRNA comprising an open reading frame encoding HSV glycoprotein D (gD); (d) an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0); (e) an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4); and (f) a lipid nanoparticle.

[0012] In some embodiments, the HSV gB comprises a truncated cytoplasmic tail. In some embodiments, the HSV gB does not comprise a cytoplasmic tail.

[0013] In some embodiments, the HSV gC comprises an F327A substitution and a truncated C-terminus relative to wild-type HSV gC. In some embodiments, the HSV gC comprises a truncated cytoplasmic tail. In some embodiments, the HSV gB and / or HSV gC do not comprise a cytoplasmic tail.

[0014] In some embodiments, the HSV ICP0 lacks a nuclear localization signal and / or a RING finger domain.

[0015] In some embodiments, the HSV ICP0 comprises a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP0.

[0016] In some embodiments, the HSV ICP4 lacks a nuclear localization signal and / or a RING finger domain.

[0017] In some embodiments, the HSV ICP4 comprises a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP4.

[0018] Another embodiment relates to a herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein B (gB) that comprises a truncated C-terminus compared to wild-type HSV gB; (b) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC) that comprises a truncated C-terminus compared to wild-type HSV gC; (c) an mRNA comprising an open reading frame encoding HSV glycoprotein D (gD); (d) an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0) that comprises a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP0; (e) an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4) that comprises a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP4; and (f) a lipid nanoparticle.

[0019] A further aspect relates to a herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein B (gB), optionally wherein gB comprises a truncated C-terminus compared to wild-type HSV gB; (b) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC) comprising an F327A substitution and a truncated C-terminus compared to wild-type HSV gC; (c) an mRNA comprising an open reading frame encoding wild-type HSV glycoprotein D (gD); and (d) a lipid nanoparticle.

[0020] In some embodiments, the method further comprises an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0), which contains a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP0.

[0021] In some embodiments, the method further comprises an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4) that contains a higher density of CD8+ T-cell epitopes compared to wild-type HSV ICP4.

[0022] In some embodiments, the HSV gB and / or HSV gC comprise a truncated cytoplasmic tail. In some embodiments, the HSV gB and / or HSV gC do not comprise a cytoplasmic tail.

[0023] Yet another embodiment relates to a herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC) comprising an F327A substitution and a truncated C-terminus relative to wild-type HSV gC; (b) an mRNA comprising an open reading frame encoding wild-type HSV glycoprotein D (gD); (c) an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0) comprising a higher density of CD8+ T-cell epitopes relative to wild-type HSV ICP0; (d) an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4) comprising a higher density of CD8+ T-cell epitopes relative to wild-type HSV ICP4; and (e) a lipid nanoparticle.

[0024] In some embodiments, the HSV gC comprises a truncated cytoplasmic tail.

[0025] In some embodiments, the HSV gC does not include the cytoplasmic tail.

[0026] In some embodiments, the vaccine induces a Th1-polarized CD4+ T cell-mediated immune response against HSV gC, gB, and / or gD.

[0027] In some embodiments, the vaccine induces more Th1 cells specific for an antigen selected from HSV gB, gC, or gD than Th2 cells specific for that antigen.

[0028] In some embodiments, the population of CD4+ T cells specific for an antigen selected from HSV gB, gC, or gD comprises greater than 50% Th1 cells.

[0029] In some embodiments, each of HSV gB, gC, and gD comprises a transmembrane domain.

[0030] In some embodiments, (a) HSV gB has a length of about 798 amino acids, (b) HSV gC has a length of about 469 amino acids, (c) HSV ICP0 comprises a truncation in the nuclear localization signal, RING finger domain, and / or USP7 binding domain compared to wild-type HSV ICP0, and / or (d) HSV ICP4 comprises a truncation in the nuclear localization signal and / or DNA binding domain compared to wild-type HSV ICP4.

[0031] In some embodiments, the HSV ICP0 does not contain a nuclear localization signal, does not contain a USP7 binding domain, and / or does not contain a RING finger domain.

[0032] In some embodiments, the HSV ICP0 does not contain a nuclear localization signal and / or contains a truncated DNA binding domain.

[0033] In some embodiments, (a) HSV gB comprises an amino acid sequence at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO:54; (b) HSV gC comprises an amino acid sequence at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO:63; (c) HSV gD comprises an amino acid sequence at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO:39; (d) HSV ICP0 comprises an amino acid sequence at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO:47; and / or (e) HSV ICP4 comprises an amino acid sequence at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO:49.

[0034] In some embodiments, the molar ratio of (c) and (d) mRNA to (a), (b), and (c) mRNA is 0.8:1 or less.

[0035] In some embodiments, one or more mRNAs comprise a chemical modification.

[0036] In some embodiments, 100% of the uracil nucleotides of one or more mRNAs comprise a chemical modification.

[0037] In some embodiments, the chemical modification is 1-methylpseudouracil.

[0038] In some embodiments, the lipid nanoparticles comprise an ionic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.

[0039] In some embodiments, the lipid nanoparticles comprise 40-50 mol % ionic lipid, 5-15 mol % neutral lipid, 30-50 mol % sterol, and 0.5-3 mol % PEG-modified lipid.

[0040] In some embodiments, the ionic lipid is Compound (I): [ka] The structure of The neutral lipid is distearoylphosphatidylcholine (DSPC), the sterol is cholesterol, and / or The PEG-modified lipid is 1,2 dimyristoyl-sn-glycerol, methoxypolyethylene glycol (PEG-DMG).

[0041] Some aspects relate to methods comprising administering to a subject a vaccine according to any one of the preceding aspects or embodiments.

[0042] In some embodiments, the subject has an HSV infection or has been exposed to HSV.

[0043] In some embodiments, the vaccine is administered in an amount effective to prevent latent HSV infection in a subject.

[0044] In some embodiments, the vaccine is administered in an amount effective to prevent reactivation of a latent HSV infection in a subject, to prevent replication of HSV, to reduce the duration of an HSV infection in a subject, to reduce the number of replication-competent HSV particles in a subject, and / or to reduce the number of cells in a subject that contain an HSV genome.

[0045] In some embodiments, the vaccine induces a CD4+ T cell-mediated immune response against HSV gB, gC, and / or gD, wherein the CD4+ T cells bind to one or more CD4+ T cell epitopes of HSV gB, gC, or gD.

[0046] In some embodiments, at least 50% of the CD4+ T cells produce one or more cytokines selected from the group consisting of IFN-γ, IL-2, and TNF-α.

[0047] In some embodiments, less than 10% of the CD4+ T cells produce any one or more of IL-4, IL-5, IL-9, IL-10, or IL-13.

[0048] In some embodiments, the vaccine induces a CD8+ T cell-mediated immune response against HSV ICP0 and / or ICP4, wherein the CD8+ T cells bind to one or more CD8+ T cell epitopes of HSV ICP0 and / or ICP4.

[0049] In some embodiments, the CD8+ T cells are cytotoxic.

[0050] Another embodiment relates to a modified herpes simplex virus (HSV) intracellular protein 0 (ICP0) that contains fewer amino acids than wild-type HSV ICP0.

[0051] In some embodiments, the modified HSV ICP0 comprises a truncation in the nuclear localization signal compared to wild-type HSV ICP0.

[0052] In some embodiments, the modified HSV ICP0 does not contain a nuclear localization signal.

[0053] In some embodiments, the modified HSV ICP0 comprises a truncation in the RING finger domain compared to wild-type HSV ICP0.

[0054] In some embodiments, the modified HSV ICP0 does not comprise a RING finger domain.

[0055] In some embodiments, the modified HSV ICP0 comprises a truncation in the USP7 binding domain compared to wild-type HSV ICP0.

[0056] In some embodiments, the modified HSV ICP0 does not comprise the USP7 binding domain.

[0057] In some embodiments, the modified HSV ICP0 comprises a linker between the first portion of the modified HSV ICP0 and the second portion of the modified HSV ICP0.

[0058] In some embodiments, the linker comprises 2 to 10 glycine residues.

[0059] In some embodiments, the modified HSV ICP0 comprises an amino acid sequence having a length less than or equal to 65% of the length of wild-type HSV IPC0.

[0060] In some embodiments, the modified HSV ICP0 amino acid sequence contains at least 65% of the T cell epitopes of wild-type HSV ICP0.

[0061] In some embodiments, the modified HSV ICP0 comprises about 487 amino acids.

[0062] Another aspect relates to a ribonucleic acid (RNA) comprising an open reading frame encoding a modified HSV ICP0 according to any one of the preceding aspects or embodiments.

[0063] Yet another embodiment relates to a modified herpes simplex virus (HSV) intracellular protein 4 (ICP4) that contains fewer amino acids than wild-type HSV ICP4.

[0064] In some embodiments, the modified HSV ICP4 comprises a truncation in the nuclear localization signal compared to wild-type HSV ICP4.

[0065] In some embodiments, the modified HSV ICP4 does not contain a nuclear localization signal.

[0066] In some embodiments, the modified HSV ICP4 comprises a truncation in the DNA binding domain compared to wild-type HSV ICP4.

[0067] In some embodiments, the modified HSV ICP4 does not comprise a DNA binding domain.

[0068] In some embodiments, the modified HSV ICP4 comprises a linker between the first portion of the modified HSV ICP4 and the second portion of the modified HSV ICP4, hi some embodiments, the linker comprises 2 to 10 glycine residues.

[0069] In some embodiments, the modified HSV ICP4 comprises an amino acid sequence having a length that is 65% or less of the length of wild-type HSV ICP4.

[0070] In some embodiments, the modified HSV ICP4 amino acid sequence contains at least 65% of the T cell epitopes of wild-type HSV ICP4.

[0071] In some embodiments, the modified HSV ICP4 comprises about 687 amino acids.

[0072] Some aspects relate to a ribonucleic acid (RNA) comprising an open reading frame encoding a modified HSV ICP4 according to any one of the preceding aspects or embodiments.

[0073] Other aspects relate to herpes simplex virus (HSV) proteins comprising an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs: 54, 63, 47, and 49.

[0074] Yet another aspect relates to a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding an HSV protein according to any one of the preceding aspects or embodiments.

[0075] Yet another aspect relates to a messenger ribonucleic acid (mRNA) comprising an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of any one of SEQ ID NOs: 19, 28, 4, 12, and 14.

[0076] In some embodiments, the mRNA comprises a chemical modification.

[0077] In some embodiments, 100% of the uracil nucleotides of the mRNA comprise a chemical modification.

[0078] In some embodiments, the chemical modification is 1-methylpseudouracil. [Brief explanation of the drawings]

[0079] [Figure 1]

[0023] Figure 1 shows the variant HSV protein encoded by the mRNA of the vaccine composition evaluated in Example 1. SEQ ID NO: 78 (GGGSGGG) is shown. [Figure 2-1] 1 shows antibody responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. A shows the titer of anti-gB IgG in the serum. B shows the titer of anti-gC IgG in the serum. C shows the titer of anti-gD IgG in the serum. [Figure 2-2] 1 shows antibody responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. (D) Neutralizing antibody titers against HSV-2 strain MS. (E) Area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using HSV-1 strain KOS and sera collected on day 36. [Figure 2-3]1 shows the antibody responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. F indicates the extent to which the serum blocked the interaction between HSV-2 gC and the complement protein C3b. [Figure 3-1] 1 shows T cell responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. A shows CD4+ T cell responses to peptides of gB, gC, and gD. [Figure 3-2] Figure 1 shows T cell responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. Figure 2 shows CD8+ T cell responses to peptides of gB, gC, and gD. [Figure 3-3] 1 shows T cell responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. C shows CD4+ T cell responses to peptides of gB, gC, and gD. [Figure 3-4] Figure 1 shows T cell responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. Figure 2 shows CD4+ T cell responses to peptides of ICP0 and ICP4. Figure 3 shows CD8+ T cell responses to peptides of ICP0 and ICP4. [Figure 3-5] Figure 1 shows T cell responses in mice vaccinated with compositions comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and / or ICP4, as evaluated in Example 1. Figure 2 shows cumulative IFN-γ-producing CD4+ T cell responses across groups. Figure 3 shows cumulative IFN-γ-producing CD8+ T cell responses across groups. [Figure 4]

[0023] Figure 1 shows the variant HSV protein encoded by the mRNA of the vaccine composition evaluated in the experiment described in Example 2. SEQ ID NO: 78 (GGGSGGG) is shown. [Figure 5-1] 1 shows antibody responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. A shows the titer of anti-gB IgG in the serum. B shows the titer of anti-gC IgG in the serum. C shows the titer of anti-gD IgG in the serum. [Figure 5-2] 1 shows antibody responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. (D) shows neutralizing antibody titers against HSV-2 strain MS. (E) shows neutralizing antibody titers against HSV-1 strain KOS. [Figure 5-3] Figure 1 shows the antibody response in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. Figure 2 shows the area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using the HSV-1 KOS strain and serum collected on day 36. Figure 3 shows the extent to which the serum blocked the interaction between HSV-2 gC and the complement protein C3b. [Figure 6-1] A shows T cell responses in mice vaccinated with a composition containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. CD4+ T cell responses to peptides of gB, gC, and gD are shown. [Figure 6-2] B shows T cell responses in mice vaccinated with a composition containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. CD8+ T cell responses to peptides of gB, gC, and gD are shown. [Figure 6-3]Figure 1 shows T cell responses in mice vaccinated with a composition containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. Figure 2 shows CD4+ T cell responses to peptides of gB, gC, and gD. [Figure 6-4] Figure 1 shows T cell responses in mice vaccinated with a composition comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. Figure 2 shows CD4+ T cell responses to peptides of ICP0 and ICP4. Figure 3 shows CD8+ T cell responses to peptides of ICP0 and ICP4. [Figure 6-5] Figure 1 shows T cell responses in mice vaccinated with compositions comprising mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, as evaluated in Example 2. Figure 2 shows cumulative IFN-γ-producing CD4+ T cell responses across groups. Figure 3 shows cumulative IFN-γ-producing CD8+ T cell responses across groups. [Figure 7A] 1 shows antibody responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 with different untranslated regions (UTRs), as evaluated in Example 2. Anti-gB IgG titers in serum are shown. [Figure 7B] 1 shows antibody responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 with different untranslated regions (UTRs), as evaluated in Example 2. Anti-gC IgG titers in serum are shown. [Figure 7C] 1 shows antibody responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 with different untranslated regions (UTRs), as evaluated in Example 2. Anti-gD IgG titers in serum are shown. [Figure 7D] 1 shows antibody responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 with different untranslated regions (UTRs), as evaluated in Example 2. Neutralizing antibody titers against HSV-2 strain MS are shown. [Figure 7E] 1 shows the antibody response in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 with different untranslated regions (UTRs), as evaluated in Example 2. The area under the curve for an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using the HSV-1 KOS strain and sera collected on day 36 is shown. [Figure 8A] 1 shows T cell responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 that differ in their untranslated regions (UTRs), as evaluated in Example 2. 1 shows CD4+ T cell responses to peptides of gB, gC, gD, ICP0, or ICP4. [Figure 8B] 1 shows T cell responses in mice vaccinated with compositions containing mRNAs encoding HSV-2 gB, gC, gD, ICP0, and ICP4 that differ in their untranslated regions (UTRs), as evaluated in Example 2. 1 shows CD8+ T cell responses to peptides of gB, gC, gD, ICP0, or ICP4. [Figure 9] The inoculation, dosing, and sample collection schedules for the HSV challenge, treatment, and monitoring study in guinea pigs are outlined. Guinea pigs are inoculated with HSV-2 on day 0 and monitored for 14 days during the acute phase of infection. On days 21 and 35, guinea pigs are administered PBS as a negative control, a composition containing mRNA encoding HSV proteins, or another comparative vaccine as a positive control. Vaginal lesions are monitored daily. [Figure 10-1]

[0023] Figure 1 shows the design of mRNAs encoding truncated intracellular proteins (ICPs) of HSV and the immunogenicity of the truncated ICPs. A shows the location of epitopes in HSV ICP0 and the region of HSV ICP0 encoded by the mRNA. B shows the location of epitopes in HSV ICP4 and the region of ICP4 encoded by the mRNA. [Figure 10-2](C) shows the design of mRNAs encoding truncated intracellular proteins (ICPs) of HSV and the immunogenicity of the truncated ICPs. (D) shows the CD4+ T cell responses of mice immunized with two doses of mRNA encoding ICP0 and / or ICP4. (E) shows the CD8+ T cell responses of mice immunized with two doses of mRNA encoding ICP0 and / or ICP4. [Figure 11A] Figure 1 shows the in vitro expression of wild-type and modified HSV-2 glycoproteins. The total expression intensity of the different forms of HSV-2 gB (measured by % of cells expressing gB × median fluorescence intensity of gB+ cells) is shown. [Figure 11B] Figure 1 shows the in vitro expression of wild-type and modified HSV-2 glycoproteins.Frequency of cells expressing different forms of HSV-2 gC after transfection is shown. [Figure 11C] In vitro expression of wild-type and modified HSV-2 glycoproteins is shown. Median fluorescence intensity of gC+ cells is shown. [Figure 11D] Figure 1 shows the in vitro expression of wild-type and modified HSV-2 glycoproteins. The total expression intensity (measured by % of cells expressing gB x MFI of gB+ cells) is shown. [Figure 12] Figure 1 shows an overview of HSV antigens encoded by mRNAs in nucleic acid vaccines. A shows HSV proteins and variants that can be encoded by nucleic acid vaccines. B shows flow cytometry data for gB expression by cells transfected with mRNA encoding WT HSV gB (left) or mRNA encoding pre-fusion HSV gB (right). C shows the mean fluorescence intensity (MFI) of cells transfected with mRNA encoding WT HSV gB (left) or mRNA encoding pre-fusion HSV gB (right), incubated with serum from mice immunized with PBS control, mRNA encoding WT gB, or mRNA encoding pre-fusion gB, and then stained with labeled anti-mouse IgG. [Figure 13A]1 shows variant HSV proteins encoded by the mRNA of the nucleic acid vaccines provided herein. A variant of gB is shown. [Figure 13B] 1 shows variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. Variants of gC are shown. [Figure 13C] 1 shows variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. Variants of gD are shown. [Figure 13D] 1 shows variant HSV proteins encoded by the mRNA of the nucleic acid vaccines provided herein. 1 shows variants of gE. [Figure 13E]

[0023] Figure 1 shows variant HSV proteins encoded by the mRNA of the nucleic acid vaccines provided herein.

[0024] Figure 1 shows a variant of gH, including gH covalently linked to gL. SEQ ID NO: 121 (GSGGSGSGGSSGGGSGSGGSGGSGSGGRRRRR) is shown. [Figure 13F] 1 shows variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. Variants of gL are shown. [Figure 13G] 1 shows variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. A variant of gI is shown. [Figure 13H] 1 shows variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. Variants of ICP0 are shown. [Figure 13I]

[0023] Figure 1 shows the variant HSV proteins encoded by the mRNAs of the nucleic acid vaccines provided herein. A variant of HSV ICP4 is shown. SEQ ID NO: 78 (GGGSGGG) is shown. [Figure 14]Immunogenicity of a panel of vaccines containing mRNA encoding the prefusion H510P mutant of gB (gBpf), wild-type gB (gBwt), the C3b-binding F327A mutant of gC (gCmut), gD, soluble gE (sgE), or gH and gL (gHgL) is shown. Panels A-B show neutralizing antibody titers against HSV-1 strain F (A) or HSV-2 strain MS (B) in sera collected on day 36. Panel C shows the area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using sera collected on day 36. [Figure 15A] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Figure 2 shows neutralizing antibody titers against HSV-1 (left two bars) and HSV-2 (right two bars) in sera collected from mice vaccinated with mRNA encoding gCmut, gD, and either gBwt or gBpf. [Figure 15B] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-1 strain F in sera collected on day 36 are shown. [Figure 15C] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-2 strain MS in sera collected on day 36 are shown. [Figure 15D]Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-1 (left four bars) and HSV-2 (right four bars) are shown in sera collected from mice vaccinated with mRNA encoding gBwt, gCmut, and gD (basal), as well as sgE and / or gHgL. [Figure 15E] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Figure 2 shows neutralizing antibody titers against HSV-1 (left five bars) and HSV-2 (right five bars) in sera collected from mice vaccinated with mRNA encoding HSV gBwt, gCmut, and gD (basal), as well as sgE, gHgL, and / or ICP4. [Figure 15F] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-1 (left five bars) and HSV-2 (right five bars) are shown in sera collected from mice vaccinated with mRNA encoding HSV gBwt, gCmut, and gD (basal), as well as sgE, gHgL, ICP0, and / or ICP4. [Figure 15G]Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-1 strain F in sera collected on day 36 are shown when serum was supplemented with guinea pig complement to a final concentration of 2.5% (v / v). [Figure 15H] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing antibody titers against HSV-2 strain MS in sera collected on day 36 are shown when serum was supplemented with guinea pig complement to a final concentration of 2.5% (v / v). [Figure 15I] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Figure 2 shows neutralizing antibody titers against HSV-1 strain F in sera collected on day 36 when the sera were supplemented with hyperimmune serum generated in mice by immunization with soluble gE prior to the neutralization assay. [Figure 15J] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Figure 2 shows neutralizing antibody titers against HSV-2 strain MS in sera collected on day 36 when the sera were supplemented with hyperimmune serum generated in mice by immunization with soluble gE prior to the neutralization assay. [Figure 15K]Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Neutralizing titers against HSV-1 strain F in a cell-to-cell spread assay are shown. [Figure 15L]

[0023] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD, and optionally one or more other proteins. Area under the curve for antibody-dependent cell-mediated cytotoxicity (ADCC) assays using sera collected on day 36 is shown. [Figure 16A] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding (a) HSV ICP4, (b) HSV ICP0 and HSV ICP4, or (c) a combination of gB, gC, gD, and optionally one or more other proteins. Titers of anti-gB IgG in serum are shown. [Figure 16B] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding (a) HSV ICP4, (b) HSV ICP0 and HSV ICP4, or (c) a combination of gB, gC, gD, and optionally one or more other proteins. Titers of anti-gC IgG in serum are shown. [Figure 16C] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding (a) HSV ICP4, (b) HSV ICP0 and HSV ICP4, or (c) a combination of gB, gC, gD, and optionally one or more other proteins. Titers of anti-gD IgG in serum are shown. [Figure 16D]Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding (a) HSV ICP4, (b) HSV ICP0 and HSV ICP4, or (c) a combination of gB, gC, gD, and optionally one or more other proteins. Figure 2 shows anti-gHgL IgG titers in serum. [Figure 16E] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding (a) HSV ICP4, (b) HSV ICP0 and HSV ICP4, or (c) a combination of gB, gC, gD, and optionally one or more other proteins. Titers of anti-gE and anti-gI IgG in the serum are shown. [Figure 17A] Figure 1 shows T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD (also referred to as gD2), and optionally one or more other proteins. Mice were administered two doses of vaccine (once on days 0 and 22), and then euthanized on day 36, two weeks after the second dose, and spleens were collected for analysis of T cell responses. The percentage of viable lymphocytes in each group is shown. [Figure 17B] Figure 1 shows T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD (also referred to as gD2), and optionally one or more other proteins. Mice were administered two doses of vaccine (once on days 0 and 22) and then euthanized on day 36, two weeks after the second dose, and spleens were collected for analysis of T cell responses. The percentage of CD8+ T cells that were specific for HSV gB as measured by pentamer staining is shown. [Figure 17C]Figure 1 shows T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD (also referred to as gD2), and optionally one or more other proteins. Mice were administered two doses of vaccine (once on days 0 and 22) and then euthanized on day 36, two weeks after the second dose, and spleens were collected for analysis of T cell responses. Cytokine responses by gD-specific CD4+ and CD8+ T cells from intracellular cytokine staining (ICS) analysis are shown. [Figure 17D] Figure 1 shows T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV ICP4, HSV ICP0 and HSV ICP4, or a combination of gB, gC, gD (also referred to as gD2), and optionally one or more other proteins. Mice were administered two doses of vaccine (once on days 0 and 22) and then euthanized on day 36, two weeks after the second dose, and spleens were collected for analysis of T cell responses. Analysis of gL-specific CD4+ T cells and CD8+ T cells from ICS analysis is shown. [Figure 18-1]Figure 1 shows the antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after the first dose, and on day 36, 14 days after the second dose. Figure 2 shows neutralizing antibody titers against the HSV-1 F strain in serum on day 36 from mice immunized with a composition containing 2 μg of mRNA per antigen. Figure 3 shows neutralizing antibody titers against the HSV-1 F strain in serum on day 36 from mice immunized with a composition containing 0.4 μg of mRNA per antigen. Figure 4 shows neutralizing antibody titers against the HSV-2 MS strain in serum on day 36 from mice immunized with a composition containing 2 μg of mRNA per antigen. D shows neutralizing antibody titers against HSV-2 MS strain in sera on day 36 from mice immunized with a composition containing 0.4 μg of mRNA per antigen. [Figure 18-2] Figure 1 shows the antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after the first dose, and on day 36, 14 days after the second dose. Figure 2 shows the ADCC activity against cells infected with the HSV-1 KOS strain using day 36 serum from mice immunized with a composition containing 2 μg of mRNA per antigen. Figure 3 shows the ADCC activity against cells infected with the HSV-1 KOS strain using day 36 serum from mice immunized with a composition containing 0.4 μg of mRNA per antigen. [Figure 19A]

[0023] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding a combination of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Titers of anti-gB IgG in the serum are shown. [Figure 19B]

[0023] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gC IgG titers in the serum are shown. [Figure 19C]

[0023] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gD IgG titers in the serum are shown. [Figure 19D] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding a combination of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Titers of anti-gE / gI IgG in the serum are shown. [Figure 19E]

[0023] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding a combination of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gHgL IgG titers in the serum are shown. [Figure 20] Figure 1 shows T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding a combination of gB, gC, gD, and optionally one or more other proteins. Mice were immunized with two doses of a given vaccine (one administered on day 0 and the other on day 22), and then euthanized on day 36, two weeks after the second dose, and spleens were collected for analysis of T cell responses. The percentage of CD8+ T cells specific for the SSIEFAR1 (SEQ ID NO: 103) epitope of HSV gB is shown. [Figure 21A]

[0023] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gB IgG titers in the serum are shown. [Figure 21B]

[0023] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gC IgG titers in the serum are shown. [Figure 21C]

[0023] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Anti-gD IgG titers in the serum are shown. [Figure 21D] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Titers of anti-gE / gI IgG in the serum are shown. [Figure 21E]

[0033] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding combinations of gB, gC, gD, and optionally one or more other proteins. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Neutralizing antibody titers against HSV-1 F strain in serum on day 36 are shown. [Figure 21F]

[0033] Figure 1 shows HSV protein-specific antibody titers and antiviral activity of serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding gB, gC, gD, and optionally one or more other protein combinations. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose. Neutralizing antibody titers against the HSV-2 MS strain in serum on day 36 are shown. [Figure 21G]

[0039] Figure 1 shows HSV protein-specific antibody titers in serum collected from mice vaccinated with one of a panel of vaccines containing different doses of mRNA encoding gB, gC, gD, and optionally one or more other proteins, and the antiviral activity of those sera. Mice were administered two doses of the same mRNA vaccine on days 0 and 22, and serum was collected on day 21, three weeks after administration of the first dose, and on day 36, 14 days after administration of the second dose.

[0040] Figure 2 shows the ADCC activity of serum from day 36 against cells infected with HSV-1 KOS strain. [Figure 22A] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gC, gD, and variant gB. Neutralizing antibody titers against HSV-1 strain F in sera collected on day 36 are shown. [Figure 22B] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gC, gD, and variant gB. Neutralizing antibody titers against HSV-2 strain MS in sera collected on day 36 are shown. [Figure 22C] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gC, gD, and variant gB. The area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using sera collected on day 36 is shown. [Figure 22D]Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gC, gD, and variant gB. Figure 2 shows neutralizing antibody titers against the MS strain of HSV-2 in sera collected on day 36 from immunized mice in a follow-up experiment using mRNA encoding modified HSV-2 gB. [Figure 23] Figure 1 shows the antiviral activity of sera collected from mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gB, gC, gD, sgE, gL variants, and optionally gH. (A) Neutralizing antibody titers against HSV-2 strain MS. (B) Area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using sera collected on day 36. [Figure 24A] Figure 1 shows the antiviral activity of sera collected from mice immunized with one of a panel of vaccines containing individual mRNAs encoding HSV-2 gB, gC, gD, or sgE, or with a composition containing various ratios of mRNAs encoding gB, gC, and gD, and optionally sgE. Figure 2 shows neutralizing antibody titers against HSV-2 strain MS. [Figure 24B] 1 shows the antiviral activity of sera collected from mice immunized with one of a panel of vaccines containing individual mRNAs encoding HSV-2 gB, gC, gD, or sgE, or with a composition containing various ratios of mRNAs encoding gB, gC, and gD, and optionally sgE. The area under the curve for an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using the HSV-1 KOS strain and sera collected on day 36 is shown. [Figure 24C] Figure 1 shows the antiviral activity of sera collected from mice immunized with one of a panel of vaccines containing individual mRNAs encoding HSV-2 gB, gC, gD, or sgE, or with a composition containing various ratios of mRNAs encoding gB, gC, and gD, and optionally sgE. Figure 2 shows neutralizing antibody titers in sera collected on day 36 from immunized mice in a follow-up experiment using various ratios of mRNAs encoding HSV-2 gB. [Figure 25A] 1 shows antibody and T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4. Neutralizing antibody titers against the MS strain of HSV-2 in serum collected on day 36 are shown. [Figure 25B] 1 shows antibody and T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4. 2 shows CD4+ T cell responses in mice. [Figure 25C] 1 shows antibody and T cell responses in mice vaccinated with one of a panel of vaccines containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4, and the extent to which the sera blocked the interaction between HSV-2 gC and the complement protein C3b. [Figure 26] Figure 1 shows antibody and T cell responses in mice vaccinated with a composition containing mRNA encoding HSV-2 gB, gC, gD, ICP0, and ICP4. (A) Neutralizing antibody titers against HSV-2 strain MS. (B) Area under the curve of an antibody-dependent cell-mediated cytotoxicity (ADCC) assay using HSV-1 strain KOS and serum collected on day 36. (C) CD4+ and CD8+ T cell responses in mice from group 2. DETAILED DESCRIPTION OF THE INVENTION

[0080] Provided herein are messenger ribonucleic acid (mRNA) vaccines that build on the knowledge that modified mRNA can safely direct the body's cellular machinery to produce virtually any protein of interest, from naturally occurring proteins that may have therapeutic activity both inside and outside the cell to antibodies and other entirely novel protein constructs. The RNA (e.g., mRNA) vaccines of the present disclosure can be used, for example, to induce a balanced immune response against herpes simplex virus (HSV), including both cellular and humoral immunity, without the risk of potential insertional mutagenesis. Without wishing to be bound by theory, it is believed that RNA vaccines, as mRNA polynucleotides, are well-designed to generate the proper protein conformation upon translation. This is because RNA vaccines utilize the natural cellular machinery. Unlike conventional vaccines, which are produced ex vivo and may trigger undesirable cellular responses, RNA vaccines are presented to cell systems in a more natural manner.

[0081] Herpes simplex virus proteins Some embodiments of the present disclosure provide vaccines comprising RNA (e.g., mRNA) containing an open reading frame encoding a herpes simplex virus (HSV) protein. HSV is a double-stranded linear DNA virus of the Herpesviridae family. Two members of the herpes simplex virus family infect humans and are known as HSV-1 and HSV-2. Symptoms of HSV infection include the formation of blisters in the skin or mucous membranes of the mouth, lips, and / or genitals. HSV is a neuroinvasive virus that can cause sporadic, recurrent episodes of viral reactivation in infected individuals. HSV is transmitted by contact with an infected area of ​​skin during the viral activation phase. HSV is most commonly transmitted through the oral or genital mucosa, replicates in stratified squamous epithelium, and is subsequently incorporated into branched, unmyelinated sensory nerve fibers within the stratified squamous epithelium. The virus is then transported to the cell bodies of neurons in the dorsal root ganglia where it persists in a state of latent cellular infection (Cunningham AL et al. J Infect Dis. (2006) 194 (Supplement 1): S11-S18).

[0082] The terms "naturally occurring" and "wild-type" are used interchangeably herein. A naturally occurring HSV protein is an unmodified HSV protein from a naturally occurring herpes simplex virus (e.g., HSV-1 or HSV-2), i.e., an isolate occurring in nature. As is known in the art, a naturally occurring protein has not been genetically engineered. A naturally occurring protein has not been genetically (or otherwise) modified to substitute, remove, or add any amino acids. In some embodiments, a naturally occurring HSV isolate is HSV-2 strain HG52 (GenBank Accession No. Z86099.2). The amino acid sequences of gB, gC, gC, ICP0, and ICP4 of HSV-2 strain HG52 are provided in UniProt Accession Nos. P08666, Q89730, Q69467, P28284, and P90493, respectively.

[0083] In some embodiments, wild-type HSV gB comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, wild-type HSV gC comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, wild-type HSV gD comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, wild-type HSV gB comprises the amino acid sequence of SEQ ID NO: 112. In some embodiments, wild-type HSV gC comprises the amino acid sequence of SEQ ID NO: 114. In some embodiments, wild-type HSV gD comprises the amino acid sequence of SEQ ID NO: 116. In some embodiments, wild-type HSV ICP0 comprises the amino acid sequence of SEQ ID NO: 118. In some embodiments, wild-type HSV ICP4 comprises the amino acid sequence of SEQ ID NO: 120. Wild-type nucleic acid and / or protein sequences can be obtained, for example, by sequencing the genome or certain genes of one or more viral isolates and / or proteins expressed by the genome or certain genes of one or more viral isolates. Some aspects of the present disclosure provide vaccines comprising RNA (e.g., mRNA) having open reading frames encoding multiple HSV antigens, including HSV glycoprotein B (gB), glycoprotein C (gC), and glycoprotein D (gD). In some embodiments, the vaccine comprises a first RNA (e.g., mRNA) comprising an open reading frame encoding HSV glycoprotein B (gB), a second RNA (e.g., mRNA) comprising an open reading frame encoding HSV glycoprotein C (gC), and a third RNA (e.g., mRNA) comprising an open reading frame encoding HSV glycoprotein D (gD). Expression of gB, gC, and gD by cells containing the RNAs induces gB-, gC-, and gD-specific antibodies and T cells. Because HSV glycoproteins C, B, and D are required for viral entry, such trivalent vaccines are useful for generating potent neutralizing antibody responses that prevent or limit HSV infection.Additionally, the antigens encoded by the vaccine RNA can be modified relative to wild-type HSV antigens to improve the antibody response elicited by immunization (e.g., by stabilizing HSV gB in the prefusion state) or to prevent deleterious effects of HSV protein expression (e.g., complement sequestration or masking of epitopes by bound complement).

[0084] Glycoprotein B (gB) is a viral glycoprotein involved in the viral-cellular activity of herpes simplex virus (HSV) and is required for the fusion of the HSV envelope with the cellular membrane. gB is the most highly conserved of all surface glycoproteins and primarily functions as a fusion protein, constituting the central mechanism of fusion. gB, a class III membrane fusion glycoprotein, is a type 1 transmembrane protein trimer composed of five structural domains. Domain I contains two internal fusion loops and is thought to insert into the cellular membrane during virus-cell fusion. Domain II appears to interact with gH / gL during the fusion process, domain III contains an elongated alpha helix, and domain IV interacts with a cellular receptor. In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-1 gB. In other embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-2 gB. In some embodiments, wild-type HSV-1 gB comprises the amino acid sequence of SEQ ID NO: 111. In some embodiments, the wild-type HSV-2 gB comprises the amino acid sequence of SEQ ID NO:112.

[0085] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes a C-terminally truncated HSV-1 gB. C-terminally truncated HSV gB refers to an HSV gB lacking one or more amino acids present at the C-terminus of wild-type HSV gB. In some embodiments, the encoded HSV gB comprises a truncated cytoplasmic tail. In other embodiments, the HSV gB does not comprise a cytoplasmic tail. For example, wild-type HSV-2 gB having the amino acid sequence of SEQ ID NO: 112 (Accession No. P06763) comprises a 112 amino acid cytoplasmic tail (amino acids 793-904 of SEQ ID NO: 112); therefore, a modified HSV-2 gB that is C-terminally truncated compared to SEQ ID NO: 112 either (i) comprises a cytoplasmic tail that is shorter than 112 amino acids, or (ii) does not comprise a cytoplasmic tail. Similarly, wild-type HSV-1 gB, having the amino acid sequence of SEQ ID NO:111 (Accession No. P10211), contains a 109 amino acid long cytoplasmic tail (amino acids 796-904 of SEQ ID NO:111), and therefore, modified HSV-2 gB that is C-terminally truncated compared to SEQ ID NO:111 either (i) contains a cytoplasmic tail that is shorter than 109 amino acids, or (ii) does not contain a cytoplasmic tail.

[0086] In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 105 or less, 100 or less, 90 or less, 80 or less, 70 or less, 60 or less, 50 or less, 40 or less, 30 or less, 25 or less, 20 or less, 15 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail that is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length. In some embodiments, the HSV gB comprises a cytoplasmic tail that is 10-20, 20-30, 30-40, or 40-50 amino acids in length. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 20 or less amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 10 or less amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 8 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 6 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 5 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 4 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 3 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 2 or fewer amino acids. In some embodiments, the HSV gB comprises a cytoplasmic tail comprising 1 or fewer amino acids.

[0087] Truncation can be introduced by deleting one or more amino acids from the C-terminus of the cytoplasmic tail (e.g., amino acids 796-904 of SEQ ID NO: 112 or amino acids 793-904 of SEQ ID NO: 111). In some embodiments, the HSV gB encoded by the mRNA of a vaccine of the present disclosure lacks one or more amino acids present at the C-terminus of the wild-type sequence. In some embodiments, the encoded HSV gB lacks 1-112, 10-112, 20-112, 30-112, 40-112, 50-112, 60-112, 70-112, 80-112, 90-112, 100-112, 1-109, 10-109, 20-109, 30-109, 40-109, or 50-109 amino acids present at the C-terminus of the wild-type gB amino acid sequence. , 50–109, 60–109, 70–109, 80–109, 90–109, 100–109, 1–103, 10–103, 20–103, 30–103, 40–103, 50–103, 60–103, 70–103, 80–103, 90–103, or 100–103 amino acids missing.

[0088] In some embodiments, the mRNA of the present disclosure encodes HSV gB without the cytoplasmic tail. In some embodiments, the HSV gB comprises an extracellular domain and a transmembrane domain, and does not comprise the cytoplasmic tail.

[0089] Glycoprotein C (gC) is a glycoprotein involved in viral attachment to host cells. For example, gC functions as a host adhesion receptor, i.e., an attachment protein that mediates HSV-2 viral binding to cell surface heparan sulfate and / or chondroitin sulfate. gC plays a role in host immune evasion (also known as viral immune evasion) by inhibiting host complement cascade activation. In particular, gC binds to and / or interacts with host complement component C3b. This interaction then inhibits the host immune response by dysregulating the complement cascade (e.g., binding to host complement C3b and preventing virus neutralization).

[0090] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-1 gC. In other embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-2 gC. In some embodiments, the wild-type HSV-1 gC comprises the amino acid sequence of SEQ ID NO: 113. In some embodiments, the wild-type HSV-2 gC comprises the amino acid sequence of SEQ ID NO: 114.

[0091] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes a C-terminally truncated HSV gC. C-terminally truncated HSV gC refers to an HSV gC lacking one or more amino acids present at the C-terminus of wild-type HSV gC. In some embodiments, the encoded HSV gC comprises a truncated cytoplasmic tail. In other embodiments, the HSV gC does not comprise a cytoplasmic tail. For example, wild-type HSV-2 gC having the amino acid sequence of SEQ ID NO: 114 (Accession No. Q89730) comprises a 12-amino acid cytoplasmic tail (amino acids 469-480 of SEQ ID NO: 114); therefore, a modified HSV-2 gC that is C-terminally truncated compared to SEQ ID NO: 114 either (i) comprises a cytoplasmic tail with fewer than 12 amino acids, or (ii) does not comprise a cytoplasmic tail. Similarly, wild-type HSV-1 gC having the amino acid sequence of SEQ ID NO: 113 (Accession No. Q8UZ70) contains an 11 amino acid long cytoplasmic tail (amino acids 501-511 of SEQ ID NO: 113), and therefore, modified HSV-2 gC that is C-terminally truncated compared to SEQ ID NO: 113 either (i) contains a cytoplasmic tail that is shorter than 11 amino acids, or (ii) does not contain a cytoplasmic tail.

[0092] In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail that is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length. In some embodiments, the HSV gC comprises a cytoplasmic tail that is 1-2, 3-4, 4-5, 6-7, 8-9, or 9-10 amino acids in length. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 10 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 9 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 8 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 7 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 6 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 5 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 4 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 3 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 2 or fewer amino acids. In some embodiments, the HSV gC comprises a cytoplasmic tail comprising 1 or fewer amino acids.

[0093] Truncation can be introduced by deleting one or more amino acids anywhere in the cytoplasmic tail (e.g., amino acids 469-480 of SEQ ID NO: 114 or amino acids 501-511 of SEQ ID NO: 113). In some embodiments, the HSV gC encoded by the mRNA of a vaccine of the present disclosure lacks one or more amino acids present at the C-terminus of the wild-type sequence. In some embodiments, the encoded HSV gC lacks 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 amino acids present at the C-terminus of the wild-type gC amino acid sequence.

[0094] In some embodiments, the mRNA of the present disclosure encodes HSV gC without the cytoplasmic tail. In some embodiments, the HSV gC comprises an extracellular domain and a transmembrane domain, and does not comprise the cytoplasmic tail.

[0095] In some embodiments, the HSV gC encoded by the mRNA of a vaccine of the present disclosure comprises a substitution at a residue corresponding to F327 in wild-type HSV gC. In some embodiments, the HSV gC comprises an alanine (A) at the corresponding position in wild-type HSV gC. In some embodiments, the HSV gC comprises an aliphatic amino acid at a residue corresponding to amino acid 327 in wild-type HSV gC. Aliphatic amino acids are known in the art and include glycine (G), alanine (A), valine (V), leucine (L), and isoleucine. In some embodiments, the HSV gC comprises an F327A substitution at a residue corresponding to amino acid 327 in wild-type HSV gC. In some embodiments, the HSV gC comprises an amino acid that is not an aromatic amino acid at a residue corresponding to amino acid 327 in wild-type HSV gC. Aromatic amino acids are known in the art and include phenylalanine (F), tyrosine (Y), and tryptophan (W). In some embodiments, HSV gC comprising an amino acid other than phenylalanine (F) at the residue corresponding to amino acid 327 of wild-type HSV gC binds to C3b with lower affinity than wild-type HSV gC. In some embodiments, HSV gC comprising an amino acid other than F, Y, or W at the residue corresponding to amino acid 327 of wild-type HSV gC binds to C3b with lower affinity than wild-type HSV gC.

[0096] Glycoprotein D (gD) is an envelope glycoprotein that binds to cell surface receptors and / or participates in cell attachment via poliovirus receptor-related protein and / or herpesvirus entry mediator, facilitating virus entry. gD is proposed to bind to potential host cell entry receptors (tumor necrosis factor receptor superfamily member 14 (TNFRSF14) / herpesvirus entry mediator (HVEM), poliovirus receptor-related protein 1 (PVRL1), and / or poliovirus receptor-related protein 2 (PVRL2)) and recruit the fusion machinery (e.g., composed of gB and gH / gL), thereby triggering fusion with the host membrane. gD interacts with the host cell receptors TNFRSF14 and / or PVRL1 and / or PVRL2, and (1) with gB (via the profusion domain) (an interaction that may occur in the absence of related HSV glycoproteins, e.g., gH and / or gL), and (2) with the gH / gL heterodimer (via the profusion domain) (an interaction that may occur in the absence of gB). Thus, gD associates with the gB-gH / gL-gD complex. gD also interacts with the UL11 coat protein (via its C-terminus).

[0097] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-1 gD. In other embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-2 gD. In some embodiments, the wild-type HSV-1 gD comprises the amino acid sequence of SEQ ID NO: 115. In some embodiments, the wild-type HSV-2 gD comprises the amino acid sequence of SEQ ID NO: 116.

[0098] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes a C-terminally truncated HSV gD. C-terminally truncated HSV gD refers to an HSV gD lacking one or more amino acids present at the C-terminus of wild-type HSV gD. In some embodiments, the encoded HSV gD comprises a truncated cytoplasmic tail. In other embodiments, the HSV gD does not comprise a cytoplasmic tail. For example, wild-type HSV-2 gD having the amino acid sequence of SEQ ID NO: 116 (Accession No. P03172) comprises a 30-amino acid cytoplasmic tail (amino acids 364-393 of SEQ ID NO: 116). Therefore, a modified HSV-2 gD that is C-terminally truncated compared to SEQ ID NO: 116 either (i) comprises a cytoplasmic tail with fewer than 30 amino acids or (ii) does not comprise a cytoplasmic tail, while an HSV-2 gD with a wild-type cytoplasmic tail comprises all 30 amino acids corresponding to amino acids 364-393 of SEQ ID NO: 116. Similarly, wild-type HSV-1 gD having the amino acid sequence of SEQ ID NO: 115 (Accession No. Q69091) contains a 33 amino acid long cytoplasmic tail (amino acids 362-394 of SEQ ID NO: 115); therefore, modified HSV-2 gD that is C-terminally truncated compared to SEQ ID NO: 115 either (i) contains a cytoplasmic tail with fewer than 33 amino acids, or (ii) does not contain a cytoplasmic tail, whereas HSV-2 gD with a wild-type cytoplasmic tail contains all 33 amino acids corresponding to amino acids 362-394 of SEQ ID NO: 115.

[0099] In some embodiments, the HSV gD comprises a cytoplasmic tail comprising no more than 35, no more than 30, no more than 25, no more than 20, no more than 15, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 amino acid. In some embodiments, the HSV gD comprises a cytoplasmic tail that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33 amino acids in length. In some embodiments, the HSV gD comprises a cytoplasmic tail that is 1-2, 3-4, 4-5, 6-7, 8-9, 9-10, 10-15, 15-20, 20-25, 25-30, or 30-35 amino acids in length. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 10 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 9 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 8 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 7 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 6 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 5 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 4 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising 3 or fewer amino acids. In some embodiments, the HSV gD comprises a cytoplasmic tail comprising no more than two amino acids, hi some embodiments, the HSV gD comprises a cytoplasmic tail comprising no more than one amino acid.

[0100] Truncation can be introduced by deleting one or more amino acids anywhere in the cytoplasmic tail (e.g., amino acids 469-480 of SEQ ID NO: 116 or amino acids 501-511 of SEQ ID NO: 115). In some embodiments, the HSV gD encoded by the mRNA of a vaccine of the present disclosure lacks one or more amino acids present at the C-terminus of the wild-type sequence. In some embodiments, the encoded HSV gD lacks 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 amino acids present at the C-terminus of the wild-type gD amino acid sequence.

[0101] In some embodiments, the mRNA of the present disclosure encodes HSV gD without the cytoplasmic tail. In some embodiments, the HSV gD comprises the extracellular domain and the transmembrane domain, and does not include the cytoplasmic tail.

[0102] In some embodiments, the vaccines provided herein further comprise RNA (e.g., mRNA) having an open reading frame encoding HSV intracellular protein 0 (ICP0). In some embodiments, the vaccines provided herein further comprise RNA (e.g., mRNA) having an open reading frame encoding HSV intracellular protein 4 (ICP4). Intracellular expression of HSV ICP0 and / or ICP4 promotes the generation of ICP0-specific and ICP4-specific CD8+ T cells, respectively, that eliminate cells in which HSV is actively replicating and expressing ICP0 and ICP4. In some embodiments, the HSV ICP0 is a modified ICP0 that contains one or more internal deletions compared to the wild-type HSV ICP0 amino acid sequence. Such deletions may reduce the size of ICP0, thereby increasing the number of ICP0 proteins that can be produced from a given amount of amino acids. In some embodiments, the modified HSV ICP0 comprises an amino acid sequence that is 75% or less, 70% or less, or 65% or less in length of the wild-type HSV ICP0 amino acid sequence. In some embodiments, the modified HSV ICP0 comprises no more than 600, no more than 550, no more than 500, or no more than 487 amino acids. In some embodiments, the modified HSV ICP0 comprises about 487 amino acids.

[0103] In some embodiments, the modified HSV ICP4 comprises an amino acid sequence that is 75% or less, 70% or less, or 65% or less in length of the wild-type HSV ICP4 amino acid sequence. In some embodiments, the modified HSV ICP0 comprises 800 or less, 750 or less, 700 or less, or 687 or less amino acids. In some embodiments, the modified HSV ICP0 comprises about 687 amino acids.

[0104] In modified HSV ICP0 and / or ICP4, deletion of one or more regions of HSV ICP0 and / or ICP4 that contain few or no T cell epitopes can also increase the epitope density of the modified HSV ICP0 or ICP4 compared to the wild-type HSV ICP0 or ICP4 amino acid sequence, thereby enhancing the CD8+ T cell response elicited by the modified HSV ICP0 or ICP4. Deletions can also remove all or part of a domain of ICP0 or ICP4 to enhance the immunogenicity and / or safety of the modified HSV ICP0 or ICP4. For example, the modified HSV ICP0 or ICP4 can contain a deletion of a nuclear localization signal, which can promote retention of the modified HSV ICP0 or ICP4 in the cytoplasm and allow it to be more easily processed by the proteasome into epitopes for presentation to CD8+ T cells. As another example, a modified HSV ICP0 may contain a deletion in the USP7-binding domain, which inhibits Toll-like receptor-mediated signaling and thus prevents the innate immune response. See Daubeuf et al., Blood. 2009 113(114):3264-3275. Additionally, a modified HSV ICP0 may contain a deletion in the RING finger domain, which inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. See Lin et al., J Virol. 2004. 78(4):1674-1684. In some embodiments, a modified HSV ICP4 contains a deletion in the DNA-binding domain.

[0105] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-1 ICP0. In other embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-2 ICP0. In some embodiments, the wild-type HSV-1 ICP0 comprises the amino acid sequence of SEQ ID NO: 117. In some embodiments, the wild-type HSV-2 ICP0 comprises the amino acid sequence of SEQ ID NO: 118.

[0106] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes an HSV ICP0 with a truncation of one or more of the nuclear localization signal, the RING finger domain, or the USP7-binding domain. For example, HSV-2 ICP0 having the amino acid sequence of SEQ ID NO: 118 (Accession No. P28284) contains a nuclear localization signal at amino acids 468-549, a RING finger domain at amino acids 124-176, and a USP7-binding domain at amino acids 660-665. See Halford et al., PLoS One. 2010. 5(8):e12251, and Pfoh et al., PLoS Pathog. 2015. 11(6):e1004950. Thus, in SEQ ID NO: 118, the nuclear localization signal corresponds to amino acids 468-549, and therefore a modified ICP0 having a truncation in the nuclear localization signal compared to SEQ ID NO: 118 lacks one or more amino acids corresponding to amino acids 468-549 of SEQ ID NO: 118. In SEQ ID NO: 118, the RING finger domain corresponds to amino acids 124-176, and therefore a modified ICP0 having a truncation in the RING finger domain compared to SEQ ID NO: 118 lacks one or more amino acids corresponding to amino acids 124-176 of SEQ ID NO: 118. In SEQ ID NO: 118, the USP7-binding domain corresponds to amino acids 660-665, and therefore a modified ICP0 having a truncation in the USP7-binding domain compared to SEQ ID NO: 118 lacks one or more amino acids corresponding to amino acids 660-665 of SEQ ID NO: 118.

[0107] Some portions of ICP0 shortened or removed by truncation (e.g., the USP7-binding domain and / or the RING finger domain, and / or the nuclear localization signal) are located internally in wild-type HSV ICP0, and therefore truncations in these domains are internal truncations. HSV ICP0 containing truncations in one or more of these domains or signals is internally truncated so as to lack one or more amino acids present in that domain in the wild-type ICP0 sequence but include one or more amino acids adjacent to the deleted amino acid(s) in the wild-type ICP0 sequence. Additionally, the HSV ICP0 encoded by the mRNA of the vaccines of the present disclosure may include a truncated C-terminus and / or a truncated N-terminus. In some embodiments, modified HSV ICP0 is expressed at the C-terminus of the wild-type ICP0 amino acid sequence, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-200, 20-200, 30-200, 40-200, 50-200, 60-600, 70-700, 80-800, 90-900, 100-1200, 110-1400, 120-1600, 130-1400, 140-1500, 150-1600, 160-1700, 170-1800, 180-1900, 190-2000, 210-2200, 220-2300, 230-2400, 240-2500, 250-2600, 260-2700, 270-2800, 280-2900, 290-3000, 300-3100, 310-3200, 320-3300, 330-3400, 340-3500, 350-3600, 360-3700, 370-3800, 3 Lacking an amino acid sequence containing 0-200, 70-200, 80-200, 90-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 160-200, 170-200, 180-200, 190-200, 10-30, 30-50, 50-75, 75-100, 100-125, 125-150, 150-175, or 175-200 amino acids.In some embodiments, the modified HSV ICP0 is 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-200, 20-200, 30-200, 40-200, 50-200, 60-65, 70-75, 75-80, 80-85, 90-95, 100-120, 100-140, 100-150, 100-160, 100-170, 100-180, 100-190, 100-20 ... In some embodiments, the modified HSV lacks an amino acid sequence comprising 0 to 200, 70 to 200, 80 to 200, 90 to 200, 100 to 200, 110 to 200, 120 to 200, 130 to 200, 140 to 200, 150 to 200, 160 to 200, 170 to 200, 180 to 200, 190 to 200, 10 to 30, 30 to 50, 50 to 75, 75 to 100, 100 to 125, 125 to 150, 150 to 175, or 175 to 200 amino acids. ICP0 is expressed as 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-200, 20-200, 30-200, 40-200, 50-50, or 60-600 amino acids present between the N- and C-terminal amino acids of the wild-type ICP0 amino acid sequence. In some embodiments, the modified HSV ICP0 lacks an amino acid sequence comprising 0 to 200, 60 to 200, 70 to 200, 80 to 200, 90 to 200, 100 to 200, 110 to 200, 120 to 200, 130 to 200, 140 to 200, 150 to 200, 160 to 200, 170 to 200, 180 to 200, 190 to 200, 10 to 30, 30 to 50, 50 to 75, 75 to 100, 100 to 125, 125 to 150, 150 to 175, or 175 to 200 amino acids. In some embodiments, the modified HSV ICP0 lacks an amino acid sequence comprising 167 amino acids present at the N-terminus of wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 lacks an amino acid sequence comprising 12 amino acids present at the C-terminus of wild-type HSV ICP0.In some embodiments, the modified HSV ICP0 lacks an amino acid sequence comprising 170 amino acids located between the N-terminus and C-terminus of wild-type HSV ICP0.

[0108] In some embodiments, the modified HSV ICP0 comprises a truncated nuclear localization signal compared to wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a truncated nuclear localization signal that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the length of the nuclear localization signal of wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a truncated nuclear localization signal that comprises 75% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less amino acids. In some embodiments, the modified HSV ICP0 comprises a truncated nuclear localization signal comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids. In some embodiments, the truncated nuclear localization signal comprises 1 to 20, 1 to 15, 1 to 10, or 1 to 5 amino acids. In some embodiments, the truncated nuclear localization signal comprises 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid. In some embodiments, the modified HSV ICP0 does not comprise a nuclear localization signal. In some embodiments, the modified HSV ICP0 is present in the cytoplasm after translation of the mRNA encoding HSV ICP0. In some embodiments, the modified HSV ICP0 does not localize to the nucleus after translation of the mRNA encoding HSV ICP0.

[0109] In some embodiments, the modified HSV ICP0 comprises a truncated RING finger domain compared to wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a RING finger domain that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the length of the RING finger domain of wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a truncated RING finger domain that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less amino acids. In some embodiments, the modified HSV ICP0 comprises a truncated RING finger domain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids. In some embodiments, the truncated RING finger domain comprises 1 to 20, 1 to 15, 1 to 10, or 1 to 5 amino acids. In some embodiments, the truncated RING finger domain comprises 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid.

[0110] In some embodiments, the modified HSV ICP0 comprises a USP7 binding domain that is truncated relative to wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a USP7 binding domain that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the length of the USP7 binding domain of wild-type HSV ICP0. In some embodiments, the modified HSV ICP0 comprises a truncated USP7 binding domain that comprises 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less amino acids. In some embodiments, the modified HSV ICP0 comprises a truncated USP7 binding domain that comprises 1, 2, 3, 4, or 5 amino acids. In some embodiments, the truncated USP7 binding domain comprises 1 to 5 amino acids. In some embodiments, the truncated USP7 binding domain comprises 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid. In some embodiments, the modified HSV ICP0 does not comprise a RING finger domain. In some embodiments, the modified HSV ICP0 does not comprise a USP7-binding domain. In some embodiments, the modified HSV ICP0 does not bind to USP7 within cells.

[0111] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-1 ICP4. In other embodiments, the mRNA of the HSV vaccine of the present disclosure encodes HSV-2 ICP4. In some embodiments, the wild-type HSV-1 ICP4 comprises the amino acid sequence of SEQ ID NO: 119. In some embodiments, the wild-type HSV-2 ICP4 comprises the amino acid sequence of SEQ ID NO: 120.

[0112] In some embodiments, the mRNA of the HSV vaccine of the present disclosure encodes an HSV ICP4 having a truncation in one or more of the nuclear localization signal, the RING finger domain, or the DNA-binding domain. An HSV ICP4 having a truncation in a given domain refers to an HSV ICP4 lacking one or more amino acids present in that domain in wild-type HSV ICP4. For example, HSV-2 ICP4 having the amino acid sequence of SEQ ID NO: 120 (Accession No. P90493) contains a nuclear localization signal at amino acids 751-834 and a DNA-binding domain at amino acids 319-547. See, e.g., Mullen et al., J Virol. 1994. 68(5):3250-3266. Thus, in SEQ ID NO: 120, the nuclear localization signal corresponds to amino acids 751-834, and therefore, a modified ICP4 having a truncation in the nuclear localization signal compared to SEQ ID NO: 120 lacks one or more amino acids corresponding to amino acids 751-834 of SEQ ID NO: 120. In SEQ ID NO: 120, the DNA binding domain corresponds to amino acids 319 to 547, and therefore a modified ICP4 having a truncation in the DNA binding domain compared to SEQ ID NO: 120 lacks one or more amino acids corresponding to amino acids 319 to 547 of SEQ ID NO: 120.

[0113] Some portions of ICP4 shortened or removed by truncation (e.g., the DNA binding domain and / or nuclear localization signal) are located internally in wild-type HSV ICP4, and therefore truncations in these domains are internal truncations. HSV ICP4 containing truncations in one or more of these domains or signals is internally truncated so as to lack one or more amino acids present in the domain in the wild-type ICP4 sequence but include one or more amino acids adjacent to the deleted amino acid(s) in the wild-type ICP4 sequence. In addition, the HSV ICP4 encoded by the mRNA of the vaccines of the present disclosure may include a truncated C-terminus and / or a truncated N-terminus. In some embodiments, modified HSV ICP4 is present at the C-terminus of the wild-type ICP4 amino acid sequence: 1-400, 1-380, 1-360, 1-340, 1-320, 1-300, 1-280, 1-260, 1-240, 1-220, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1- 120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-400, 20-400, 30-400, 40-400, 50-400, 60-400, 70-400, 80-400, 90-400, 100 ~400, 110~400, 120~400, 130~400, 140~400, 150~400, 160~400, 170~400, 180~400, 190~400, 200~400, 220~400, 240~400, 260~400, 280~400, 300~400, 320~400, 340~40 Lacking an amino acid sequence containing 0, 360-400, 380-400, 10-30, 30-50, 50-75, 75-100, 100-125, 125-150, 150-175, 175-200, 200-240, 240-280, 280-320, 320-360, or 360-400 amino acids.In some embodiments, the modified HSV ICP4 comprises one or more of the following amino acids at the N-terminus of the wild-type ICP4 amino acid sequence: 1-400, 1-380, 1-360, 1-340, 1-320, 1-300, 1-280, 1-260, 1-240, 1-220, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1- 120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-400, 20-400, 30-400, 40-400, 50-400, 60-400, 70-400, 80-400, 90-400, 100 ~400, 110~400, 120~400, 130~400, 140~400, 150~400, 160~400, 170~400, 180~400, 190~400, 200~400, 220~400, 240~400, 260~400, 280~400, 300~400, 320~400, 340~40 Lacking an amino acid sequence containing 0, 360-400, 380-400, 10-30, 30-50, 50-75, 75-100, 100-125, 125-150, 150-175, 175-200, 200-240, 240-280, 280-320, 320-360, or 360-400 amino acids.In some embodiments, the modified HSV ICP4 comprises 1 to 400, 1 to 380, 1 to 360, 1 to 340, 1 to 320, 1 to 300, 1 to 280, 1 to 260, 1 to 240, 1 to 220, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 1 40, 1-130, 1-120, 1-110, 1-100, 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-25, 1-20, 1-10, or 1-5, 10-400, 20-400, 30-400, 40-400, 50-400, 60-400, 70-400, 80-400, 90- 400, 100-400, 110-400, 120-400, 130-400, 140-400, 150-400, 160-400, 170-400, 180-400, 190-400, 200-400, 220-400, 240-400, 260-400, 280-400, 300-400, 320-400, 34 In some embodiments, the modified HSV ICP4 lacks an amino acid sequence comprising 0 to 400, 360 to 400, 380 to 400, 10 to 30, 30 to 50, 50 to 75, 75 to 100, 100 to 125, 125 to 150, 150 to 175, 175 to 200, 200 to 240, 240 to 280, 280 to 320, 320 to 360, or 360 to 400 amino acids. In some embodiments, the modified HSV ICP4 lacks an amino acid sequence comprising 382 amino acids present at the N-terminus of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 lacks an amino acid sequence comprising 75 amino acids present at the C-terminus of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 lacks an amino acid sequence comprising 160-200 amino acids, an amino acid sequence comprising 1-10 amino acids, and an amino acid sequence comprising 11-30 amino acids, each of which is located between the N-terminus and C-terminus of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 lacks an amino acid sequence comprising 181 amino acids, an amino acid sequence comprising 5 amino acids, and an amino acid sequence comprising 16 amino acids, each of which is located between the N-terminus and C-terminus of wild-type HSV ICP4.In some embodiments, the modified HSV ICP4 lacks sequences corresponding to amino acids 1-382, 567-571, 614-629, 741-920, and 1244-1318 of wild-type ICP4.

[0114] In some embodiments, the modified HSV ICP4 comprises one or more substitutions at residues corresponding to amino acids 1060-1070 of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 substitutions at residues corresponding to amino acids 1060-1070 of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a substitution at a residue corresponding to amino acid 1064 of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a substitution at a residue corresponding to amino acid 1068 of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a substitution at a residue corresponding to amino acid 1069 of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises substitutions at residues corresponding to amino acids 1064, 1068, and 1069. In some embodiments, one or more substitutions are with an aliphatic amino acid. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 substitutions are substitutions with aliphatic amino acids. In some embodiments, one or more substitutions are alanine substitutions. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 substitutions are alanine substitutions. In some embodiments, the modified HSV ICP4 comprises a D1064A substitution compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a D1068A substitution compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a G1069A substitution compared to wild-type HSV ICP4.

[0115] In some embodiments, the modified HSV ICP4 comprises a nuclear localization signal that is truncated compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a nuclear localization signal that is truncated compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a truncated nuclear localization signal that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the length of the nuclear localization signal of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a truncated nuclear localization signal that comprises 75% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less amino acids. In some embodiments, the modified HSV ICP4 comprises a truncated nuclear localization signal comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids. In some embodiments, the truncated nuclear localization signal comprises 1 to 20, 1 to 15, 1 to 10, or 1 to 5 amino acids. In some embodiments, the truncated nuclear localization signal comprises 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid. In some embodiments, the modified HSV ICP4 does not comprise a nuclear localization signal. In some embodiments, the modified HSV ICP4 is present in the cytoplasm after translation of an mRNA encoding HSV ICP4. In some embodiments, the modified HSV ICP4 does not localize to the nucleus after translation of an mRNA encoding HSV ICP4. In some embodiments, the modified HSV ICP4 does not contain a nuclear localization signal. In some embodiments, the modified HSV ICP4 is present in the cytoplasm after translation of the mRNA encoding HSV ICP4. In some embodiments, the modified HSV ICP4 does not localize to the nucleus after translation of the mRNA encoding HSV ICP4.

[0116] In some embodiments, the modified HSV ICP4 comprises a DNA binding domain that is truncated compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a DNA binding domain that is truncated compared to wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a DNA binding domain that comprises 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the length of the DNA binding domain of wild-type HSV ICP4. In some embodiments, the modified HSV ICP4 comprises a truncated DNA binding domain comprising 200 or more, 180 or more, 160 or more, 140 or more, 120 or more, 100 or more, 90 or more, 80 or more, 70 or more, 60 or more, 50 or more, 40 or more, 30 or more, 25 or more, 20 or more, 15 or more, 10 or more, 9 or more, 8 or more, 7 or more, 6 or more, 5 or more, 4 or more, 3 or more, 2 or more, or 1 or more amino acids. In some embodiments, the modified HSV ICP4 comprises a truncated DNA binding domain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids. In some embodiments, the truncated DNA-binding domain comprises 1 to 50, 1 to 40, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, or 1 to 5 amino acids. In some embodiments, the truncated DNA-binding domain comprises 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid. In some embodiments, the modified HSV ICP4 does not comprise a DNA-binding domain. In some embodiments, the modified HSV ICP4 does not comprise a DNA-binding domain. In some embodiments, the modified HSV ICP4 does not bind to intracellular DNA.

[0117] In some embodiments, the modified ICP0 or ICP4 comprises a linker. The linker can be a 2A or GS linker, as described herein in the section entitled "Linkers and Cleavable Peptides." Alternatively, the linker can be another linker known in the art. The linker of the modified ICP0 or ICP4 can be in place of an internal truncation relative to the wild-type sequence of ICP0 or ICP4 (i.e., the amino acid sequence of the modified ICP0 or ICP4 comprises a deletion of one or more amino acids compared to the wild-type sequence, and comprises an insertion of a linker at the position previously occupied by the deleted amino acids). In some embodiments, the linker comprises 2 to 10 glycine residues. In some embodiments, the linker comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 glycine residues. In some embodiments, the linker comprises 2 to 20, 2 to 15, 2 to 10, 2 to 5, 2 to 3, 3 to 5, 5 to 7, 7 to 10, 10 to 15, 15 to 20, 3 to 10, 4 to 8, or 5 to 6 glycine residues. In some embodiments, the linker comprises 5 to 6 glycine residues. In some embodiments, the linker comprises the amino acid sequence GGGSGGG (SEQ ID NO: 78). In some embodiments, the modified ICP0 or ICP4 comprises a linker in place of one or more internal truncations from the wild-type sequence of ICP0 or ICP4. In some embodiments, the modified ICP0 or ICP4 comprises a linker in place of each internal truncation relative to wild-type ICP0 or ICP4, respectively. The linkers connecting the portions of the modified ICP0 or ICP4 can comprise the same amino acid sequence (e.g., each portion is connected by a linker having the amino acid sequence GGS). In other embodiments, the linkers connecting different pairs of modified ICP0 or ICP4 moieties can comprise different amino acid sequences (e.g., the first and second moieties are connected by a linker having the amino acid sequence GGG, and the second and third moieties are connected by a linker having the amino acid sequence GGS). The linkers connecting different pairs of moieties can be the same length or different lengths.

[0118] The vaccines of the present disclosure are useful for generating HSV-specific antibodies and T cells that are useful for prophylactically preventing HSV infection in subjects not yet exposed to HSV, as well as for preventing reactivation of latent HSV or shortening the duration of HSV outbreaks in subjects already infected with HSV.

[0119] In some embodiments, the vaccines provided herein further comprise an RNA (e.g., mRNA) having an open reading frame encoding HSV glycoprotein E (gE). Antibodies specific for HSV gE prevent HSV virions from sequestering other circulating antibodies, allowing HSV-specific neutralizing antibodies to more efficiently neutralize HSV particles.

[0120] The genomes of herpes simplex viruses (HSV-1 and HSV-2) contain approximately 85 open reading frames, allowing HSV to produce at least 85 unique proteins. These genes encode four major classes of proteins: (1) those associated with the outermost external lipid bilayer (envelope) of HSV, (2) the inner protein coat (capsid), (3) the intermediate complex connecting the envelope to the capsid coat, and (4) proteins responsible for replication and infection.

[0121] Examples of envelope proteins include UL1 (gL), UL10 (gM), UL20, UL22, UL27 (gB), UL43, UL44 (gC), UL45, UL49A, UL53 (gK), US4 (gG), US5 (gJ), US6 (gD), US7 (gI), US8 (gE), and US10. Examples of capsid proteins include UL6, UL18, UL19, UL35, and UL38. Examples of tegument proteins include UL11, UL13, UL21, UL36, UL37, UL41, UL45, UL46, UL47, UL48, UL49, US9, and US10. Other HSV proteins include UL2, UL3, UL4, UL5, UL7, UL8, UL9, UL12, UL14, UL15, UL16, UL17, UL23, UL24, UL25, UL26, UL26.5, UL28, UL29, UL30, UL31, UL32, UL33, UL34, UL39, UL40, UL42, UL50, UL51, UL52, UL54, UL55, UL56, US1, US2, US3, US81, US11, US12, ICP0, and ICP4.

[0122] Because the envelope (the outermost portion of the HSV particle) is the first to encounter a target cell, the present disclosure encompasses antigenic polypeptides associated with the envelope as immunogenic agents. Briefly, surface and membrane proteins (glycoprotein D (gD), glycoprotein B (gB), glycoprotein C (gC), glycoprotein H (gH), glycoprotein L (gL)) can be used as HSV vaccine antigens.

[0123] In epithelial cells, the heterodimeric glycoprotein E / glycoprotein I (gE / gI) is required for cell-to-cell spread of virus by sorting nascent virions to cell junctions. Once the virus reaches the cell junction, viral particles can spread extremely rapidly to neighboring cells through interactions with cellular receptors that accumulate at these junctions. By analogy, this correlates with basolateral spread in polarized cells. In neurons, gE / gI is essential for anterograde spread of infection throughout the host nervous system. Together with US9, the heterodimeric gE / gI is involved in sorting and transport of viral structural components to axon tips. The heterodimeric gE / gI functions as a receptor for the Fc portion of host IgG. Dissociation of gE / gI from IgG occurs at acidic pH and may be involved in bipolar cross-linking of anti-HSV antibodies and subsequent intracellular endocytosis and degradation, thereby interfering with host IgG-mediated immune responses. gE / gI interact with the VP22 coat protein (through its C-terminus), an interaction that is required for recruitment of VP22 to the Golgi apparatus and packaging of VP22 into virions.

[0124] In some embodiments, the HSV vaccines of the present disclosure comprise one or more RNAs (e.g., mRNAs) encoding HSV (HSV-1 or HSV-2) glycoproteins B, C, and D. In some embodiments, the HSV vaccines further comprise one or more RNAs encoding HSV (HSV-1 or HSV-2) glycoprotein E and intracellular protein 0 (ICP0).

[0125] In some embodiments, the HSV vaccine comprises RNA (e.g., mRNA) encoding an HSV (HSV-1 or HSV-2) protein that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to HSV (HSV-1 or HSV-2) glycoprotein B, and has HSV (HSV-1 or HSV-2) glycoprotein B activity.

[0126] In some embodiments, the HSV vaccine comprises RNA (e.g., mRNA) encoding an HSV (HSV-1 or HSV-2) protein that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to HSV (HSV-1 or HSV-2) glycoprotein C, and has HSV (HSV-1 or HSV-2) glycoprotein C activity.

[0127] In some embodiments, the HSV vaccine comprises RNA (e.g., mRNA) encoding an HSV (HSV-1 or HSV-2) protein that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to HSV (HSV-1 or HSV-2) glycoprotein D and has HSV (HSV-1 or HSV-2) glycoprotein D activity.

[0128] In some embodiments, the HSV vaccine comprises RNA (e.g., mRNA) encoding an HSV (HSV-1 or HSV-2) protein that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to HSV (HSV-1 or HSV-2) glycoprotein E, and has HSV (HSV-1 or HSV-2) glycoprotein E activity.

[0129] In some embodiments, the HSV vaccine comprises RNA (e.g., mRNA) encoding an HSV (HSV-1 or HSV-2) protein that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to HSV (HSV-1 or HSV-2) intracellular protein 0, and has HSV (HSV-1 or HSV-2) intracellular protein 0 activity.

[0130] Non-limiting examples of HSV proteins of the present disclosure are provided in Table 2.

[0131] The HSV RNA (e.g., mRNA) vaccines provided herein can be used to induce a balanced immune response, including both cellular and humoral immunity, without many of the risks associated with DNA vaccination.

[0132] The RNA (e.g., mRNA) of the present disclosure encodes an HSV protein of interest intended to enhance an immune response to HSV infection. Thus, the HSV proteins of the present disclosure are antigenic, i.e., they are antigens. Antigenicity is the ability to be specifically recognized by antibodies generated as a result of an immune response to a given substance, such as the HSV proteins of the present disclosure. Thus, an antigen is a protein that can induce an immune response (e.g., cause the immune system to produce antibodies against the antigen). In some embodiments, an antigen is an immunogen. Immunogenicity refers to the ability of a substance to induce both cellular and humoral immune responses. The compositions of the present disclosure do not themselves contain antigens, but rather comprise RNA (e.g., mRNA) having an open reading frame encoding a protein antigen (referred to herein simply as an "HSV protein") that is expressed by cells within a subject upon delivery to the subject. Delivery of RNA (e.g., mRNA) is achieved by formulating the RNA in an appropriate carrier or delivery vehicle (e.g., lipid nanoparticles) such that, upon administration to a cell, tissue, or subject, the RNA is taken up by the cell, which then expresses the protein(s) encoded by the RNA.

[0133] It will be understood that the term "protein" encompasses peptides and the term "antigen" encompasses antigenic fragments.

[0134] The vaccines of the present disclosure offer unique advantages over traditional protein-based vaccination approaches, such as recombinant protein production techniques, in which protein antigens are purified or produced in vitro. The vaccines of the present disclosure contain RNA (e.g., mRNA) encoding the desired HSV protein antigen(s), which, when introduced into the body, i.e., administered in vivo to a mammalian subject (e.g., a human), causes somatic cells to express the desired antigen(s). To facilitate delivery of the RNA (e.g., mRNA) to somatic cells, the RNA is encapsulated in lipid nanoparticles (LNPs). Once delivered and taken up by somatic cells, the RNA is translated in the cytosol, and the protein antigen is produced by the host cell machinery. The protein is presented, eliciting adaptive humoral and cellular immune responses. Because neutralizing antibodies are directed against the expressed protein, proteins are considered relevant target antigens for vaccine development.

[0135] Many proteins have a quaternary or three-dimensional structure comprising multiple polypeptides or several polypeptide chains that assemble into oligomeric molecules. As used herein, the term "subunit" refers to a single protein molecule, e.g., a polypeptide or polypeptide chain resulting from the processing of a nascent protein molecule, which assembles (or "co-assembles") with other protein molecules (e.g., subunits or chains) to form a protein complex. Proteins may have a relatively small number of subunits and thus be described as "oligomers," or may consist of many subunits and thus be described as "multimers." The subunits of an oligomeric or multimeric protein may be identical, homologous, or completely different, and may be specialized for different tasks.

[0136] A protein or protein subunit may further comprise a domain. As used herein, the term "domain" refers to a distinct functional and / or structural unit within a protein. Typically, a "domain" is responsible for a specific function or interaction and contributes to the overall role of the protein. Domains can exist in a variety of biological contexts. Similar domains (i.e., domains that share structural, functional, and / or sequence homology) may exist within a single protein or may exist in separate proteins with similar or different functions. Protein domains are often conserved portions of a given protein's tertiary structure or sequence and can function and exist independently of the rest of the protein or its subunits.

[0137] As used herein, the term "antigen" differs from the term "epitope," which refers to a substructure of an antigen. An epitope is a portion of an antigen to which an antibody binds. An epitope can be a peptide, e.g., a 7-10 amino acid peptide, or a glycosylated structure. While the art describes protein antigens, e.g., isolated proteins, that are delivered to subjects or immune cells in isolated form, the design, testing, validation, and production of protein antigens can be costly and time-consuming, especially when producing proteins on a large scale. In contrast, mRNA technology is amenable to the rapid design and testing of mRNAs encoding diverse antigens. Furthermore, rapid production of mRNA combined with formulation in an appropriate delivery vehicle (e.g., lipid nanoparticles) can proceed rapidly, allowing for the rapid, large-scale production of mRNA vaccines. Potential benefits also arise from the fact that the antigens encoded by the mRNAs disclosed herein are expressed by the subject's cells, e.g., the human body, and thus the subject, e.g., the human body, acts as a "factory" to produce the antigen, which then elicits the desired immune response.

[0138] The vaccines provided herein may contain RNA (e.g., mRNA) or multiple RNAs encoding two or more antigens of the same or different HSV strains. Also provided herein are combination vaccines containing RNA (e.g., mRNA) encoding one or more HSV antigens and one or more antigen(s) of different organisms. Thus, the vaccines of the present disclosure may be combination vaccines that target one or more antigens of the same strain / species, or one or more antigens of different strains / species, for example, antigens that induce immunity against organisms found in the same geographical area with a high risk of HSV infection, or organisms to which an individual is likely to be exposed when exposed to HSV.

[0139] The vaccines provided herein can include multiple RNAs encoding different antigens.

[0140] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 to (b) mRNA encoding HSV gB is less than or equal to 0.8: 1. In some embodiments, the molar ratio is about 0.65: 1.

[0141] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 to (b) mRNA encoding HSV gC is less than or equal to 1.1: 1. In some embodiments, the molar ratio is about 1.0: 1.

[0142] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 to (b) mRNA encoding HSV gD is less than or equal to 1.3: 1. In some embodiments, the molar ratio is about 1.2: 1.

[0143] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gB is less than or equal to 1.0: 1. In some embodiments, the molar ratio is about 0.9: 1.

[0144] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gC is less than or equal to 1.5: 1. In some embodiments, the molar ratio is about 1.4: 1.

[0145] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gD is less than or equal to 1.8: 1. In some embodiments, the molar ratio is about 1.6: 1.

[0146] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 and mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gB is less than or equal to 1.6: 1. In some embodiments, the molar ratio is about 1.5: 1.

[0147] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 and mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gC is less than or equal to 2.5: 1. In some embodiments, the molar ratio is about 2.4: 1.

[0148] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 and mRNA encoding HSV ICP4 to (b) mRNA encoding HSV gD is less than or equal to 2.9: 1. In some embodiments, the molar ratio is about 2.8: 1.

[0149] In some embodiments, the molar ratio of (a) mRNA encoding HSV ICP0 and ICP4 to (b) mRNA encoding HSV gB, gC, and gD is less than or equal to 0.8: 1. In some embodiments, the molar ratio is about 0.7: 1.

[0150] Variants of wild-type herpes simplex virus proteins In some embodiments, compositions of the present disclosure comprise RNA (e.g., mRNA) encoding an HSV protein variant. A protein variant is a protein (including full-length proteins and peptides) that differs in amino acid sequence compared to a wild-type, native, or reference amino acid sequence. A protein variant may have one or more substitutions, deletions, and / or insertions at certain positions within the amino acid sequence compared to the wild-type, native, or reference amino acid sequence. Typically, a protein variant has at least 50% identity to the wild-type, native, or reference sequence. In some embodiments, a protein variant has at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the wild-type, native, or reference sequence.

[0151] Protein variants encoded by RNA (e.g., mRNA) of the present disclosure may contain amino acid changes that confer any of a number of desirable properties, such as enhancing their immunogenicity, enhancing their expression, and / or improving their stability or PK / PD properties in a subject. Protein variants can be generated using conventional mutagenesis techniques and appropriately assayed to determine whether they possess the desired properties. Assays for determining the expression level and immunogenicity of proteins, including protein variants, are well known in the art. Similarly, the PK / PD properties of protein variants can be measured using art-recognized techniques (e.g., by determining the expression of the protein variant over time in a vaccinated subject and / or by confirming the durability of the induced immune response). The stability of protein variants encoded by RNA (e.g., mRNA) may be measured, for example, by assaying their thermal stability or stability upon urea denaturation, or using in silico predictions. Methods for such experiments and in silico determinations are known in the art. Other methods for determining the expression level of a protein variant, the immunogenicity and / or PK / PD properties of a protein variant may also be used.

[0152] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising the nucleotide sequence of any one of the sequences provided herein, or comprises a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the nucleotide sequence of any one of the sequences provided herein. See, e.g., SEQ ID NOS: 1-34, reproduced in Table 1 below.

[0153] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame encoding a protein comprising the amino acid sequence of any one of the sequences provided herein, or comprises an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the amino acid sequence of any one of the sequences provided herein. See, e.g., SEQ ID NOS: 35-68, reproduced in Table 2 below.

[0154] "Identity" refers to the relationship between two or more sequences (e.g., amino acid sequences or nucleotide sequences) as determined by comparing the sequences with one another. Identity also refers to the degree of sequence relatedness between or among sequences, as determined by the number of matches between strings of amino acids (polypeptides) or between strings of nucleotides (polynucleotides). Identity is a measure of the percent of exact matches between the smaller of two or more sequences, with gapped alignment (if any), as handled by a particular mathematical model or computer program (e.g., an "algorithm"). The identity of related polypeptides and polynucleotides can be readily calculated by known methods. "Percent identity" as applied to polypeptide or polynucleotide sequences is defined as the percentage of residues (amino acid or nucleic acid residues) in a candidate (first) polypeptide or polynucleotide sequence that are identical with the residues in a second polypeptide or polynucleotide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity.

[0155] Methods and computer programs for alignment are well known in the art. Identity depends on the calculation of percent identity, but it is understood that the value may vary depending on gaps and penalties introduced in the calculation. Generally, a particular polynucleotide or polypeptide variant has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (but less than 100%) sequence identity to a particular wild-type, native, or reference sequence, as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such alignment tools include, but are not limited to, those based on the BLAST suite (Altschul, S. F., et al. Nucleic Acids Res. 1997;25:3389-3402) and the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. J. Mol. Biol. 1981;147:195-197). A popular global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, SB & Wunsch, CDJ Mol. Biol. 1920;48:443-453). The Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) has also been developed, which is said to produce global alignments of nucleotide and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm.

[0156] Thus, polynucleotides and polypeptides containing substitutions, insertions, and / or deletions (e.g., indels) and covalent modifications relative to wild-type, native, or reference sequences, such as the polypeptide (e.g., protein) sequences disclosed herein, are included within the scope of the present disclosure. For example, sequence tags or amino acids, such as one or more lysine(s), can be added to a polypeptide sequence (e.g., at its N-terminus and / or C-terminus). Sequence tags can be used for detection, purification, and / or localization of the peptide. Lysines can be used to increase the solubility of the peptide or to enable biotinylation. Alternatively, amino acid residues located at the N- and / or C-terminal regions of a protein's amino acid sequence can be optionally deleted to result in a truncated sequence. Certain amino acids (e.g., C-terminal or N-terminal amino acids) can be deleted depending on the use of the sequence (e.g., expression of the sequence as part of a larger sequence that is soluble or linked to a solid support). In some embodiments, sequences for (or encoding) signal sequences, termination sequences, transmembrane domains, linkers, multimerization domains (e.g., fold-on regions), etc. are replaced with alternative sequences that achieve the same or similar function. In some embodiments, cavities within the protein core may be filled to improve stability, for example, by introducing larger amino acids. In other embodiments, buried hydrogen-bonding networks are replaced with hydrophobic residues to improve stability. In yet other embodiments, glycosylation sites are removed and replaced with appropriate residues. Such sequences are readily identifiable to one of skill in the art. It should also be understood that some of the sequences provided herein contain sequence tags or terminal peptide sequences (e.g., at the N- or C-terminus) that can be deleted (e.g., before use in preparing an RNA (e.g., mRNA) vaccine).

[0157] As will be recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered within the scope of the HSV proteins provided herein. For example, provided herein is any protein fragment (meaning a polypeptide sequence that is at least one amino acid residue shorter than but otherwise identical to the wild-type, native, or reference sequence) of a wild-type, native, or reference sequence, so long as the fragment is immunogenic and confers a protective immune response against HSV. In addition to protein variants that are identical to but truncated with a wild-type, native, or reference protein, in some embodiments, the protein contains 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations (e.g., substitutions, insertions, and / or deletions) as shown in any sequence provided or referenced herein. The length of the protein variant can range from about 4, 6, or 8 amino acids to the full-length protein.

[0158] Non-limiting examples of HSV protein variants and nucleotide sequences encoding HSV protein variants are provided in Tables 1 and 2. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19]

[0159] Some embodiments of the present disclosure provide a ribonucleic acid (RNA) comprising an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of any one of SEQ ID NOs: 1-35.

[0160] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:1.

[0161] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:2.

[0162] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:3.

[0163] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:4.

[0164] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:5.

[0165] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:6.

[0166] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:7.

[0167] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:8.

[0168] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:9.

[0169] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:10.

[0170] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:11.

[0171] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:12.

[0172] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:13.

[0173] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:14.

[0174] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:15.

[0175] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:16.

[0176] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:17.

[0177] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:18.

[0178] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:19.

[0179] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:20.

[0180] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:21.

[0181] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:22.

[0182] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:23.

[0183] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:24.

[0184] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:25.

[0185] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:26.

[0186] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:27.

[0187] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:28.

[0188] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:29.

[0189] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:30.

[0190] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:31.

[0191] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:32.

[0192] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:33.

[0193] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:34.

[0194] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of SEQ ID NO:35. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9]

[0195] Some embodiments of the present disclosure provide a herpes simplex virus (HSV) protein comprising an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs: 36-70.

[0196] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:36.

[0197] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:37.

[0198] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:38.

[0199] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:39.

[0200] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:40.

[0201] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:41.

[0202] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:42.

[0203] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:43.

[0204] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:44.

[0205] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:45.

[0206] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:46.

[0207] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:47.

[0208] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:48.

[0209] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:49.

[0210] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:50.

[0211] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:51.

[0212] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:52.

[0213] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:53.

[0214] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:54.

[0215] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:55.

[0216] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56.

[0217] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:57.

[0218] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:58.

[0219] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:59.

[0220] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:60.

[0221] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:61.

[0222] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:62.

[0223] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:63.

[0224] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:64.

[0225] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:65.

[0226] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:66.

[0227] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:67.

[0228] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:68.

[0229] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:69.

[0230] In some embodiments, the HSV protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:70.

[0231] signal peptide In some embodiments, the RNA (e.g., mRNA) has an ORF encoding a signal peptide fused to an HSV protein. Signal peptides, which typically comprise the N-terminal 15-60 amino acids of a protein, are required for translocation across membranes in the secretory pathway and thus universally control entry of most proteins into the secretory pathway in both eukaryotes and prokaryotes. In eukaryotes, the signal peptide of a nascent precursor protein (preprotein) directs ribosomes to the rough endoplasmic reticulum (ER) membrane and initiates transmembrane transport of the elongating peptide chain for processing. ER processing produces a mature protein, and the signal peptide is typically cleaved from the precursor protein by ER-resident signal peptidases of the host cell, or retained uncleaved, and functions as a membrane anchor. The signal peptide can also facilitate targeting of the protein to the cell membrane.

[0232] The signal peptide may be 15 to 60 amino acids in length, for example, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 amino acids in length. In some embodiments, the length of the signal peptide is 20-60, 25-60, 30-60, 35-60, 40-60, 45-60, 50-60, 55-60, 15-55, 20-55, 25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50, 35-50 , 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40, 20-40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30, 25-30, 15-25, 20-25, or 15-20 amino acids in length.

[0233] Signal peptides from heterologous genes (which naturally regulate the expression of genes other than HSV proteins) are known in the art and can be tested for desired properties before being incorporated into the nucleic acids of the present disclosure.

[0234] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame encoding an HSV protein fused to a signal peptide comprising an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the amino acid sequence of any one of the sequences provided herein. See, e.g., SEQ ID NOs: 71-75, reproduced in Table 3 below. In some embodiments, the mRNA comprises an open reading frame encoding an HSV protein comprising the endogenous signal peptide of a wild-type HSV protein (e.g., an mRNA encoding (wild-type or modified) HSV gB encodes the HSV gB signal peptide). [Table 3]

[0235] Fusion proteins In some embodiments, the RNA (e.g., mRNA) encodes a fusion protein. Thus, the encoded protein can comprise two or more proteins (e.g., proteins and / or protein fragments) joined together, with or without a linker. The fusion protein, in some embodiments, retains the functional properties of each individual (non-fused) protein.

[0236] In some embodiments, the fusion protein comprises two, three, four, five, six, seven, eight, nine, or ten of the following HSV proteins: gB, gC, gD, gE, gH, gL, gI, ICP0, and ICP4. Exemplary fusion proteins of the present disclosure are provided in Table 2. For example, in some embodiments, the RNA (e.g., mRNA) encodes a protein having at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from SEQ ID NOs: 36-70. In some embodiments, the RNA (e.g., mRNA) encodes a protein that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or identical to a sequence selected from SEQ ID NOs: 36-70. In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure comprise an ORF that has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from SEQ ID NOs: 1-35. In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure comprise an ORF having 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% identity to a sequence selected from SEQ ID NOs: 1-35.

[0237] Linkers and Cleavable Peptides In some embodiments, the RNA (e.g., mRNA) encoding the fusion protein further encodes a linker positioned between at least one or each domain of the fusion protein. The linker can be, for example, a cleavable linker or a protease-sensitive linker. In some embodiments, the linker is selected from the group consisting of an F2A linker, a P2A linker, a T2A linker, an E2A linker, and combinations thereof (see, e.g., WO 2017 / 127750). This family of self-cleaving peptide linkers, called 2A peptides, has been described in the art (see, e.g., Kim, J. Het al. PLoS ONE 2011;6:e18556). In some embodiments, the linker is an F2A linker.

[0238] In some embodiments, the linker is a GS linker. GS linkers are polypeptide linkers containing glycine and serine amino acid repeats. They contain flexible and hydrophilic residues and can be used to effect fusion of protein subunits without interfering with the folding and function of protein domains or forming secondary structures. In some embodiments, an RNA (e.g., mRNA) encodes a fusion protein containing a GS linker that is 3-20 amino acids long. For example, the GS linker can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids long (or at least that long). In some embodiments, the GS linker is 15 amino acids long (or at least 15 amino acids long) (e.g., GGSGGSGGSGGSGGG (SEQ ID NO: 76)). In some embodiments, the GS linker is 8 amino acids long (or at least 8 amino acids long) (e.g., GGGSGGGS (SEQ ID NO: 77)). In some embodiments, the GS linker is 7 amino acids long (or is at least 7 amino acids long) (e.g., GGGSGGG (SEQ ID NO: 78)). In some embodiments, the GS linker comprises the amino acid sequence GGGSGG (SEQ ID NO: 82). In some embodiments, the GS linker is 4 amino acids long (or is at least 4 amino acids long) (e.g., GGGS (SEQ ID NO: 79)). In some embodiments, the GS linker comprises (GGGS)n (SEQ ID NO: 80), where n is any integer from 1 to 5. In some embodiments, the GS linker is 4 amino acids long (or is at least 4 amino acids long) (e.g., GSGG (SEQ ID NO: 81)). In some embodiments, the GS linker comprises (GSGG)n (SEQ ID NO: 80), where n is any integer from 1 to 5. In some embodiments, the linker is, for example, a glycine linker having a length of 3 amino acids (or at least 3 amino acids long) (e.g., GGG). In some embodiments, the protein encoded by the RNA (eg, mRNA) comprises two or more linkers, which may be the same as or different from one another.

[0239] Those of skill in the art will understand that other art-recognized linkers may be suitable for use in the constructs of the present disclosure (e.g., encoded by the nucleic acids of the present disclosure). Those of skill in the art will also understand that other polycistronic constructs (RNAs (e.g., mRNAs) that separately encode multiple proteins within the same molecule) may be suitable for use as provided herein.

[0240] Nucleic acids encoding herpes simplex virus proteins Nucleic acids are composed of polymers of nucleotides (nucleotide monomers). Therefore, nucleic acids are also called polynucleotides. Nucleic acids can be or include, for example, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with a β-D-ribo configuration, α-LNA (a diastereomer of LNA) with an α-L-ribo configuration, 2′-amino-LNA with a 2′-amino functionalization, and 2′-amino-α-LNA with a 2′-amino functionalization), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA), and / or chimeras and / or combinations thereof.

[0241] The RNA (e.g., mRNA) of the present disclosure comprises an open reading frame (ORF) encoding an HSV protein. In some embodiments, the RNA (e.g., mRNA) further comprises a 5' untranslated region (UTR), a 3' UTR, a poly(A) tail, and / or a 5' cap analog.

[0242] messenger RNA Messenger RNA (mRNA) is RNA that encodes (at least one) protein (a naturally occurring, non-naturally occurring, or modified polymer of amino acids) and can be translated in vitro, in vivo, in situ, or ex vivo to produce the encoded protein. It is understood that mRNA is not self-amplifying RNA (saRNA) (for a comparison of mRNA and saRNA, see, e.g., Bloom K et al. Gene Therapy 2021;28:117-129). saRNA contains an alphavirus replicase sequence that encodes an RNA-dependent RNA polymerase. mRNA does not contain an alphavirus replicase sequence.

[0243] Unless otherwise indicated, the nucleic acid sequences described in this application may recite a "T" in a representative DNA sequence, but those of skill in the art will understand that if the sequence corresponds to an mRNA, the "T" is replaced with a "U." Thus, any DNA disclosed herein and identified by a particular sequence identification number also discloses the corresponding mRNA sequence complementary to that DNA, in which case each "T" in the DNA sequence is replaced with a "U."

[0244] Naturally occurring eukaryotic mRNA molecules may contain stabilizing elements (including, but not limited to, UTRs at the 5' end (5'UTR) and / or 3' end (3'UTR)) in addition to other structural features such as a 5'-cap structure or a 3'-poly(A) tail. Both the 5'UTR and 3'UTR are typically transcribed from genomic DNA and are elements of premature mRNAs. Structural features characteristic of mature mRNAs, such as the 5'-cap and 3'-poly(A) tail, are usually added to the transcribed (premature) mRNA during mRNA processing.

[0245] Exemplary sequences of mRNAs encoding HSV proteins of the present disclosure are provided in Table 1. In some embodiments, the mRNA comprises an ORF that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or identical to a sequence selected from SEQ ID NOs: 1-35. In some embodiments, the mRNA comprises a nucleotide sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or identical to a sequence selected from SEQ ID NOs: 1-35.

[0246] Untranslated Regions (UTRs) The mRNA of the present disclosure may contain one or more regions or portions that act or function as untranslated regions. The term "5' untranslated region" (UTR) refers to the region of an mRNA immediately upstream (i.e., 5') from the start codon (i.e., the first codon of an mRNA transcript that is translated by a ribosome) that does not encode a polypeptide. The term "3' untranslated region" (UTR) refers to the region of an mRNA immediately downstream (i.e., 3') from the stop codon (i.e., the codon of an mRNA transcript that signals the end of translation) that does not encode a polypeptide. When an RNA transcript is being produced, the 5' UTR may contain a promoter sequence. Such promoter sequences are known in the art. It is understood that such promoter sequences are absent from the vaccines of the present disclosure.

[0247] When an mRNA is designed to encode (at least one) HSV protein, the mRNA may contain a 5' UTR and / or a 3' UTR. The UTR of an mRNA is transcribed but not translated. In an mRNA, the 5' UTR begins at the transcription initiation site and continues up to, but not including, the start codon. The 3' UTR begins immediately after the stop codon and continues to the transcription termination signal. There is growing evidence of the regulatory role that UTRs play in the stability and translation of nucleic acid molecules. Regulatory functions of UTRs can be incorporated into the polynucleotides of the present disclosure, particularly to enhance molecular stability. Specific functions can also be incorporated to ensure control of downregulation of transcripts in case the transcripts are misdirected to undesirable organ sites. A variety of 5' UTR and 3' UTR sequences are known.

[0248] It should also be understood that the mRNAs of the present disclosure can include any 5' UTR and / or any 3' UTR. Exemplary UTR sequences include SEQ ID NOs: 83-93. However, other UTR sequences may be used or may be substituted for any of the UTR sequences described herein.

[0249] In some embodiments, a 5'UTR of the disclosure comprises a sequence selected from GGGAAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 83), GGGAAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGCGCCGCCACC (SEQ ID NO: 84), GAGGAAAUCGCAAAAUUUGCUCUUCGCGUUAGAUUUCUUUUAGUUUUCUCGCAACUAGCAAGCUUUUUGUUCUCGCC (SEQ ID NO: 85), and GGAAAUCGCAAAAUUUGCUCUUCGCGUUAGAUUUCUUUUAGUUUUCUCGCAACUAGCAAGCUUUUUGUUCUCGCC (SEQ ID NO: 109).

[0250] In some embodiments, a 3'UTR of the disclosure is UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 86), UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCC CCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 87), UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCAGGAGAUUGAGUGUAGUGACUAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 88), UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAG CCCCUCCUCCCCUUCCUGCAGGAUUGAGACUACGGGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 89), UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUU GGGCCUCCCCCCAGCCCCUCCUCCCCUUCUGCAGCAUAGACACUACGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 90), UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCU UCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCAGGAGAUUGAGUGUAGUGGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 91), UAAAGCUCCCCGGGGGC CUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCAGGAGAUUGAGUGUAGUGACGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 92),UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 93), and UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO: 110).

[0251] In some embodiments, each mRNA encoding a distinct HSV antigen comprises a 3' UTR comprising a distinct nucleotide sequence selected from SEQ ID NOs: 88-93. In some embodiments, an mRNA encoding HSV gB comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 88. In some embodiments, an mRNA encoding HSV gC comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 89. In some embodiments, an mRNA encoding HSV gD comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 90. In some embodiments, an mRNA encoding HSV ICP0 comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 91. In some embodiments, an mRNA encoding HSV ICP4 comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 92.

[0252] In some embodiments, the 3' UTR comprises, from 5' to 3', (a) the nucleic acid sequence UAAAGCUCCCCGGGGGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCAG (SEQ ID NO:94), (b) a discrimination and ratio determining (IDR) sequence, and (c) the nucleic acid sequence UGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (SEQ ID NO:95). In some embodiments, each mRNA encoding a distinct HSV antigen comprises a 3' UTR comprising, from 5' to 3', (a) the nucleotide sequence of SEQ ID NO:94, (b) a distinct IDR sequence, and (c) the nucleotide sequence of SEQ ID NO:95. IDR sequences are described herein in the section entitled "Discrimination and Ratio Determining (IDR) Sequences." Additionally, UTRs may be omitted from the mRNAs provided herein.

[0253] 5'UTRs do not encode proteins (are non-coding). Natural 5'UTRs have characteristics that play a role in translation initiation. They have signatures such as the Kozak sequence, which is commonly known to be involved in the process by which ribosomes initiate the translation of many genes. The Kozak sequence has a common sequence CCR(A / G)CCAUGG (SEQ ID NO: 96), where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another "G". 5'UTRs are also known to form secondary structures involved in the binding of elongation factors.

[0254] In some embodiments of the present disclosure, the 5' UTR is a heterologous UTR, i.e., a UTR found in nature associated with a different ORF. In other embodiments, the 5' UTR is a synthetic UTR, i.e., not found in nature. Synthetic UTRs include UTRs that have been mutated to improve their properties, e.g., to increase gene expression, and completely synthetic UTRs. Exemplary 5' UTRs include those derived from a-globin or b-globin from Xenopus or humans (8278063, 9012219), human cytochrome b-245a polypeptide, and hydroxysteroid (17b) dehydrogenase, as well as tobacco etch virus (US8278063, US9012219). The CMV immediate early 1 (IE1) gene (US2014 / 0206753, WO2013 / 185069), sequence GGGAUCCUACC (SEQ ID NO: 97) (WO2014 / 144196), can also be used. In other embodiments, the 5'UTR is the 5'UTR of a TOP gene (e.g., WO2015 / 101414, WO2015 / 101415, WO2015 / 062738, WO2015 / 024667, WO2015 / 024667) that lacks a 5'TOP motif (oligopyrimidine tract) and is encoded by the ribosomal protein Large 5'UTR elements derived from the 5'UTR of the 32 (L32) gene (WO / 2015101414, WO2015101415, WO / 2015 / 062738), the 5'UTR element derived from the 5'UTR of the hydroxysteroid (17-beta) dehydrogenase 4 gene (HSD17B4) (WO2015024667), or the 5'UTR element derived from the 5'UTR of the ATP5A1 gene (WO2015 / 024667) may be used. In some embodiments, an internal ribosome entry site (IRES) is used in place of the 5'UTR.

[0255] The 3'UTR is non-coding and does not encode proteins. Native or wild-type 3'UTRs are known to contain stretches of adenosines and uridines. These AU-rich signatures are particularly prevalent in genes with high turnover rates. Based on sequence characteristics and functional properties, AU-rich elements (AREs) can be classified into three classes (Chen et al., 1995). Class I AREs contain several dispersed copies of the AUUUA motif within the U-rich region. C-Myc and MyoD contain class I AREs. Class II AREs have two or more overlapping UUAUUUA(U / A)(U / A) nonamers. Molecules containing this type of ARE include GM-CSF and TNF-α. Class III AREs are less well defined. These U-rich regions do not contain the AUUUA motif. c-Jun and myogenin are two well-studied examples of this class. While most proteins that bind to AREs are known to destabilize messengers, members of the ELAV family, particularly HuR, have been demonstrated to increase mRNA stability. HuR binds to all three classes of AREs. Incorporation of a HuR-specific binding site into the 3'UTR of a nucleic acid molecule results in HuR binding, thereby stabilizing the message in vivo.

[0256] The introduction, removal, or modification of 3'UTR AU-rich elements (AREs) can be used to modulate the stability of the mRNAs of the present disclosure. When engineering a particular nucleic acid, one or more copies of an ARE can be introduced to reduce the stability of the nucleic acid of the present disclosure, thereby suppressing translation and reducing production of the resulting protein. Similarly, AREs can be identified and removed or mutated to increase their stability within the cell, thereby increasing translation and production of the resulting protein. Transfection experiments can be performed in relevant cell lines using nucleic acids of the present disclosure, and protein production can be assayed at various time points after transfection. For example, cells can be transfected with various ARE-engineered molecules, and ELISA kits for the relevant proteins can be used to assay protein production 6 hours, 12 hours, 1 day, 2 days, and 7 days after transfection.

[0257] Those skilled in the art will understand that heterologous or synthetic 5'UTRs can be used with any desired 3'UTR sequence, for example, heterologous or synthetic 5'UTRs can be used with synthetic or heterologous 3'UTRs.

[0258] Non-UTR sequences can also be used as regions or subregions within a nucleic acid. For example, an intron or a portion of an intron sequence can be incorporated into a region of the nucleic acid of the present disclosure. Incorporation of an intron sequence can increase protein production and nucleic acid levels.

[0259] A combination of features may be included in the flanking regions, among other features. For example, an ORF may be flanked by a 5' UTR, which may contain a strong Kozak translation initiation signal, and / or a 3' UTR, which may contain an oligo(dT) sequence for templated addition of a polyA tail. The 5' UTR may contain a first polynucleotide fragment and a second polynucleotide fragment from the same and / or different genes (e.g., the 5' UTRs described in US2010 / 0293625 and WO2015 / 085318A2, each of which is incorporated herein by reference).

[0260] It should be understood that any UTR from any gene may be incorporated into a region of a nucleic acid. Furthermore, multiple wild-type UTRs from any known gene may be utilized. It is also within the scope of the present disclosure to provide artificial UTRs that are not variants of the wild-type region. These UTRs, or portions thereof, may be positioned in the same orientation as the selected transcript, or their orientation or position may be altered. Thus, a 5' or 3' UTR may be inverted, shortened, extended, or combined with one or more other 5' or 3' UTRs. As used herein, the term "altered" with respect to a UTR sequence means that the UTR has been altered in some way relative to the reference sequence. For example, a 3' or 5' UTR may be altered compared to a wild-type or naturally occurring UTR by a change in orientation or position as taught above, or by the inclusion of additional nucleotides, deletion of nucleotides, exchange, or transposition of nucleotides. Any of these alterations resulting in an "altered" UTR (whether 3' or 5') constitutes a variant UTR.

[0261] In some embodiments, double, triple, or quadruple UTR can be used, for example, 5'UTR or 3'UTR.As used herein, "double" UTR refers to two copies of the same UTR that are encoded consecutively or substantially consecutively.For example, double beta-globin 3'UTR can be used as described in US2010 / 0129877 (hereby incorporated by reference).

[0262] It is also within the scope of the present disclosure to have patterned UTR.As used herein, " patterned UTR " refers to the UTR that reflects repeating or alternating patterns, such as ABABAB or AABBABBAABB or ABCABCABC, or their variants that repeat once, twice, or more than three times.In these patterns, each letter A, B, or C represents the UTR that is different at nucleotide level.

[0263] In some embodiments, the flanking region is selected from a family of transcripts (whose proteins share a common function, structure, characteristic, or property). For example, a polypeptide of interest may belong to a family of proteins expressed in a particular cell, tissue, or at a certain time during development. A UTR from any of these genes may be exchanged with any other UTR from the same or a different protein family to create a new polynucleotide. As used herein, the term "family of proteins" is used in the broadest sense to refer to a group of two or more polypeptides of interest that share at least one function, structure, characteristic, location, origin, or expression pattern.

[0264] The untranslated region may also include a translational enhancer element (TEE). By way of non-limiting example, the TEE may include those described in US2009 / 0226470, which is incorporated herein by reference, and those known in the art.

[0265] Open reading frame An open reading frame (ORF) is a contiguous stretch of DNA or RNA that begins with a start codon (e.g., methionine (ATG or AUG)) and ends with a stop codon (e.g., TAA, TAG, or TGA, or UAA, UAG, or UGA). ORFs typically encode proteins. The sequences disclosed herein may further comprise additional elements (e.g., 5' and / or 3' UTRs), although it will be understood that these elements, unlike the ORF, need not necessarily be present in the RNA (e.g., mRNA) of the disclosure.

[0266] 5'-end capping In some embodiments, RNA (e.g., mRNA) comprises a 5'-end cap. 5'-capping of polynucleotides can be completed simultaneously during in vitro transcription reactions using, for example, the following chemical RNA cap analogs: 3'-O-Me-m7G(5')ppp(5')G [ARCA cap]; G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G to generate a 5'-guanosine cap structure according to the manufacturer's protocol (New England BioLabs, Ipswich, MA). 5'-capping of modified RNA (e.g., mRNA) can be completed post-transcriptionally using, for example, vaccinia virus capping enzyme to generate the "Cap 0" structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). The cap 1 structure can be generated using both vaccinia virus capping enzyme and 2'-O methyltransferase to generate m7G(5')ppp(5')G-2'-O-methyl. The cap 2 structure can be generated by cap 1 construction followed by 2'-O-methylation of the third nucleotide from the 5' end using 2'-O methyltransferase. The cap 3 structure can be generated by cap 2 construction followed by 2'-O-methylation of the fourth nucleotide from the 5' end using 2'-O methyltransferase. The enzymes can be derived from recombinant sources. Other cap analogs may also be used.

[0267] Polyadenylation tailing A "poly(A) tail" is a region of an mRNA downstream, e.g., immediately downstream (i.e., 3') of the 3' UTR, that contains multiple consecutive adenosine monophosphates. A poly(A) tail can contain 10 to 300 adenosine monophosphates. In some cases, a poly(A) tail can contain up to about 400 adenine nucleotides. For example, a poly(A) tail can contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 adenosine monophosphates. In some embodiments, the poly(A) tail contains 50-250 adenosine monophosphates. In relevant biological environments (e.g., intracellular, in vivo), the poly(A) tail functions to protect the mRNA from enzymatic degradation (e.g., in the cytoplasm) and assists in transcription termination and / or transport and translation of the mRNA from the nucleus. In some embodiments, the length of the 3'-poly(A) tail can be essential for the stability of an individual mRNA. In some embodiments, the poly(A) tail has a length of about 50, about 100, about 150, about 200, about 250, about 300, about 350, or about 400 nucleotides. In some embodiments, the poly(A) tail has a length of 100 nucleotides.

[0268] Additional stabilizing elements In some embodiments, the RNA (e.g., mRNA) provided herein contains additional stabilizing elements. The stabilizing elements can include, for example, histone stem loops. A 32-kDa protein, stem-loop binding protein (SLBP), has been identified. It associates with histone stem loops at the 3' end of histone messages in both the nucleus and the cytoplasm. Its expression level is regulated by the cell cycle, peaking during S phase, when histone mRNA levels also increase. This protein has been shown to be essential for efficient 3'-end processing of histone pre-mRNA by U7 snRNP. SLBP continues to associate with the stem loop after processing and then stimulates translation of mature histone mRNA into histone protein in the cytoplasm. The RNA-binding domain of SLBP is conserved across metazoans and protozoans, and its binding to histone stem loops depends on the structure of the loop. The minimal binding site includes at least three nucleotides 5' and two nucleotides 3' to the stem loop.

[0269] In some embodiments, the RNA (e.g., mRNA) comprises an open reading frame (coding region), a histone stem loop, and optionally a poly(A) sequence or polyadenylation signal. The poly(A) sequence or polyadenylation signal should generally enhance the expression level of the encoded protein. The encoded protein, in some embodiments, is not a histone protein, a reporter protein (e.g., luciferase, GFP, EGFP, β-galactosidase, EGFP), or a marker or selection protein (e.g., alpha-globin, galactokinase, and xanthine:guanine phosphoribosyltransferase (GPT)).

[0270] In some embodiments, an RNA (e.g., an mRNA) comprises a combination of a poly(A) sequence or a polyadenylation signal with at least one histone stem-loop, which essentially represent alternative mechanisms but act synergistically to increase protein expression above the levels seen with either of the individual elements. The synergistic effect of the combination of poly(A) and histone stem-loop is independent of the order of the elements or the length of the poly(A) sequence.

[0271] In some embodiments, the RNA (e.g., mRNA) does not contain a histone downstream element (HDE). A "histone downstream element (HDE)" comprises a purine-rich polynucleotide stretch of approximately 15-20 nucleotides 3' of a naturally occurring stem-loop, which corresponds to the binding site for U7 snRNA, which is involved in processing histone pre-mRNA to mature histone mRNA. In some embodiments, the nucleic acid does not contain an intron.

[0272] RNA (e.g., mRNA) may or may not contain enhancer and / or promoter sequences, which may be modified or unmodified, activated or unactivated. In some embodiments, histone stem-loops are generally derived from histone genes and comprise two adjacent, partially or fully reverse-complementary sequences separated by a short spacer, which form the loop of the structure. The unpaired loop region typically cannot base-pair with any of the stem-loop elements. Because it is an important component of many RNA secondary structures, it is often present in RNA, but can also be present in single-stranded DNA. The stability of the stem-loop structure generally depends on the length, the number of mismatches or bulges, and the base composition of the paired region. In some embodiments, wobble base pairs (non-Watson-Crick base pairs) may occur. In some embodiments, at least one histone stem-loop sequence comprises a length of 15 to 45 nucleotides.

[0273] In some embodiments, an RNA (e.g., an mRNA) has one or more AU-rich sequences removed. These sequences (sometimes referred to as AURES) are destabilizing sequences found in the 3'UTR. The AURES may be removed from the mRNA. Alternatively, the AURES may remain in the mRNA.

[0274] Array Optimization In some embodiments, the open reading frame encoding a protein of the present disclosure is codon-optimized. Methods of codon optimization are known in the art. Any one or more open reading frames of the sequences provided herein may be codon-optimized. In some embodiments, codon optimization can be used to match codon frequencies in target and host organisms to ensure proper folding, bias GC content to increase RNA (e.g., mRNA) stability or reduce secondary structure, minimize tandem repeat codons or runs of bases that may impair gene organization or expression, customize transcriptional and translational control regions, insert or remove protein transport sequences, remove / add post-translational modification sites (e.g., glycosylation sites) of the encoded protein, add, remove, or swap protein domains, insert or delete restriction enzyme recognition sites, modify ribosome binding sites and RNA (e.g., mRNA) degradation sites, adjust translation rates, ensure correct folding of various domains of a protein, or reduce or eliminate problematic secondary structures within a polynucleotide. Codon optimization tools, algorithms, and services are known in the art, and non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park, CA), and / or proprietary methods. In some embodiments, the open reading frame sequence is optimized using an optimization algorithm.

[0275] In some embodiments, the codon-optimized sequence shares less than 95% sequence identity with the open reading frame of a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein antigen). In some embodiments, the codon-optimized sequence shares less than 90% sequence identity with a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein). In some embodiments, the codon-optimized sequence shares less than 85% sequence identity with a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein). In some embodiments, the codon-optimized sequence shares less than 80% sequence identity with a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein). In some embodiments, the codon-optimized sequence shares less than 75% sequence identity with a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein).

[0276] In some embodiments, the codon-optimized sequence shares 65% to 85% (e.g., about 67% to about 85% or about 67% to about 80%) sequence identity to a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein). In some embodiments, the codon-optimized sequence shares 65% to 75% or about 80% sequence identity to a naturally occurring or wild-type sequence (e.g., a naturally occurring or wild-type RNA (e.g., mRNA) sequence encoding an HSV protein).

[0277] In some embodiments, the codon-optimized sequence encodes an antigen that is the same as or more immunogenic (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 100%, or at least 200% more) than the HSV protein encoded by the non-codon-optimized sequence.

[0278] The modified mRNA, when transfected into a mammalian host cell, has stability for 12 to 18 hours, or for more than 18 hours, for example, 24, 36, 48, 60, 72 hours, or for more than 72 hours, and is capable of being expressed by the mammalian host cell.

[0279] In some embodiments, codon-optimized RNA (e.g., mRNA) may have an enhanced G / C level. The G / C content of a nucleic acid molecule (e.g., mRNA) can affect RNA stability. RNA (e.g., mRNA) with increased amounts of guanine (G) and / or cytosine (C) residues may be more functionally stable than RNA containing large amounts of adenine (A) and thymine (T) or uracil (U) nucleotides. For example, WO 02 / 098443 discloses pharmaceutical compositions containing RNA (e.g., mRNA) stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by replacing existing codons with ones that better promote RNA stability without changing the resulting amino acids. This approach is limited to the coding region of RNA (e.g., mRNA).

[0280] Unmodified nucleotides In some embodiments, the RNA (e.g., mRNA) is not chemically modified and comprises standard ribonucleotides consisting of adenosine, guanosine, cytosine, and uridine. In some embodiments, the nucleotides and nucleosides of the present disclosure comprise standard nucleoside residues, e.g., residues found in transcribed RNA (e.g., A, G, C, or U). In some embodiments, the nucleotides and nucleosides of the present disclosure comprise standard deoxyribonucleosides, e.g., deoxyribonucleosides found in DNA (e.g., dA, dG, dC, or dT).

[0281] Chemically Modified Nucleotides Compositions of the present disclosure, in some embodiments, include RNA having an open reading frame encoding an HSV protein, where the nucleic acid comprises nucleotides and / or nucleosides that can be standard (unmodified) or modified as known in the art. In some embodiments, the nucleotides and nucleosides of the present disclosure comprise modified nucleotides or nucleosides. Such modified nucleotides and nucleosides can be naturally occurring modified nucleotides and nucleosides or non-naturally occurring modified nucleotides and nucleosides. Such modifications can include art-recognized modifications in the sugar, backbone, or nucleobase moieties of the nucleotide and / or nucleoside.

[0282] In some embodiments, the naturally occurring modified nucleotides or nucleotides of the present disclosure are those generally known or recognized in the art. Non-limiting examples of such naturally occurring modified nucleotides and nucleotides can be found, inter alia, in the widely recognized MODOMICS database.

[0283] In some embodiments, the non-naturally occurring modified nucleotides or nucleosides of the present disclosure are those generally known or recognized in the art. Non-limiting examples of such non-naturally occurring modified nucleotides and nucleosides can be found in, among others, International Publication Nos. WO2013052523A1, WO2014093924A1, WO2015051173A2, WO2015051169A2, WO2015089511A2, or WO2017153936A1, each of which is incorporated herein by reference.

[0284] Thus, nucleic acids (eg, DNA and RNA, eg, mRNA) of the present disclosure can include standard nucleotides and nucleosides, naturally occurring nucleotides and nucleosides, non-naturally occurring nucleotides and nucleosides, or any combination thereof.

[0285] Nucleic acids (e.g., DNA and RNA, e.g., mRNA) of the present disclosure, in some embodiments, comprise a variety of different types of standard and / or modified nucleotides and nucleosides. In some embodiments, a particular region of a nucleic acid contains one, two, or more (optionally different) types of standard and / or modified nucleotides and nucleosides.

[0286] In some embodiments, modified RNA (e.g., mRNA) introduced into a cell or organism exhibits reduced degradation in the cell or organism, respectively, compared to unmodified nucleic acids comprising standard nucleotides and nucleosides.

[0287] In some embodiments, modified RNA (e.g., modified mRNA) introduced into a cell or organism may exhibit reduced immunogenicity (e.g., reduced innate response) in the cell or organism, respectively, compared to unmodified nucleic acids comprising standard nucleotides and nucleosides.

[0288] In some embodiments, nucleic acids (e.g., RNA, e.g., mRNA) contain non-naturally occurring modified nucleotides that are introduced during or after nucleic acid synthesis to achieve a desired function or property. Modifications can be in the internucleotide bond, the purine or pyrimidine base, or the sugar. Modifications can be introduced by chemical synthesis or can be introduced at the end of the chain or anywhere within the chain using a polymerase enzyme. Any region of a nucleic acid can be chemically modified.

[0289] The present disclosure provides modified nucleosides and nucleotides of nucleic acids (e.g., RNA, e.g., mRNA). A "nucleoside" refers to a compound containing a sugar molecule (e.g., pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as a "nucleobase"). A "nucleotide" refers to a nucleoside containing a phosphate group. Modified nucleotides can be synthesized in any useful manner, for example, chemically, enzymatically, or recombinantly, to include one or more modified or unnatural nucleosides. A nucleic acid can include a region(s) of linked nucleosides. Such regions can have variable backbone linkages. The linkages can be standard phosphodiester linkages, in which case the nucleic acid includes a region of nucleotides.

[0290] Base pairing of modified nucleotides encompasses not only standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides containing and / or modified bases, where the arrangement of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between the non-standard base and a standard base, or between two complementary non-standard base structures, for example, in nucleic acids having at least one chemical modification. One example of such non-standard base pairing is base pairing between the modified nucleotide inosine and adenine, cytosine, or uracil. Any combination of base / sugar or linker may be incorporated into the nucleic acids of the present disclosure.

[0291] In some embodiments, modified nucleobases in a nucleic acid (e.g., RNA, e.g., mRNA) comprise 1-methyl-pseudouridine (m1ψ), 1-ethyl-pseudouridine (e1ψ), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), and / or pseudouridine (ψ). In some embodiments, modified nucleobases in a nucleic acid (e.g., RNA, e.g., mRNA) comprise 5-methoxymethyluridine, 5-methylthiouridine, 1-methoxymethylpseudouridine, 5-methylcytidine, and / or 5-methoxycytidine. In some embodiments, a polyribonucleotide comprises a combination of at least two (e.g., two, three, four, or more) of any of the foregoing modified nucleobases (including, but not limited to, chemical modifications).

[0292] In some embodiments, an RNA (eg, mRNA) of the disclosure comprises 1-methyl-pseudouridine (m1ψ) substitutions at one or more or all uridine positions of the nucleic acid.

[0293] In some embodiments, an RNA (e.g., an mRNA) of the disclosure comprises 1-methyl-pseudouridine (m1ψ) substitutions at one or more or all of the uridine positions of the nucleic acid and 5-methylcytidine substitutions at one or more or all of the cytidine positions of the nucleic acid.

[0294] In some embodiments, an RNA (eg, mRNA) of the disclosure comprises pseudouridine (ψ) substitutions at one or more or all uridine positions of the nucleic acid.

[0295] In some embodiments, an RNA (e.g., an mRNA) of the disclosure comprises pseudouridine (ψ) substitutions at one or more or all of the uridine positions of the nucleic acid and 5-methylcytidine substitutions at one or more or all of the cytidine positions of the nucleic acid.

[0296] In some embodiments, an RNA (eg, mRNA) of the disclosure includes a uridine at one or more or all uridine positions of the nucleic acid.

[0297] In some embodiments, RNA (e.g., mRNA) is uniformly modified (e.g., completely modified, modified throughout the entire sequence) for a particular modification. For example, a nucleic acid can be uniformly modified with 1-methyl-pseudouridine. This means that all uridine residues in the RNA (e.g., mRNA) sequence are replaced with 1-methyl-pseudouridine. Similarly, a nucleic acid can be uniformly modified by replacing any type of nucleoside residue present in the sequence with a modified residue, such as those described above.

[0298] The nucleic acids of the present disclosure may be partially or completely modified along the entire length of the molecule. For example, within a nucleic acid of the present disclosure, or within a given sequence region thereof (e.g., within an RNA (e.g., mRNA) including or excluding a poly(A) tail), one or more or all or a given type of nucleotide (e.g., purines or pyrimidines, or one or more or all of A, G, U, C) may be uniformly modified. In some embodiments, every nucleotide X within a nucleic acid of the present disclosure (or within a sequence region thereof) is a modified nucleotide, and X may be any one of the nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C, or A+G+C.

[0299] Nucleic acids may contain from about 1% to about 100% modified nucleotides (either with respect to total nucleotide content or with respect to one or more types of nucleotides, i.e., with respect to any one or more of A, G, U, or C), or any percentage therebetween (e.g., 1%-20%, 1%-25%, 1%-50%, 1%-60%, 1%-70%, 1%-80%, 1%-90%, 1%-95%, 10%-20%, 10%-25%, 10%-50%, 10%-60%, 10%-70%, 10%-80%, 10%-90% , 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). It will be understood that any remaining percentage is accounted for by the presence of unmodified A, G, U, or C.

[0300] RNA (e.g., mRNA) can contain from as little as 1% to as much as 100% modified nucleotides, or any percentage therebetween, e.g., at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, a nucleic acid can contain modified pyrimidines, such as modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the uracils in a nucleic acid are replaced with modified uracils (e.g., 5-substituted uracils). The modified uracils may be replaced with a compound having a single unique structure, or with multiple compounds having different structures (e.g., two, three, four, or more unique structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the cytosines in a nucleic acid are replaced with modified cytosines (e.g., 5-substituted cytosines). The modified cytosines may be replaced with a compound having a single unique structure, or may be replaced with multiple compounds having different structures (e.g., two, three, four, or more unique structures).

[0301] Nucleic acid production chemical synthesis Solid-phase chemical synthesis. The nucleic acids of the present disclosure may be produced entirely or partially using solid-phase technology. Solid-phase chemical synthesis of nucleic acids is an automated method in which molecules are immobilized on a solid support and synthesized stepwise in a reaction solution. Solid-phase synthesis is useful for site-specific introduction of chemical modifications into nucleic acid sequences.

[0302] Synthesis of nucleic acids of the present disclosure by sequential addition of monomer building blocks can be carried out in liquid phase.

[0303] Each of the above-mentioned synthesis methods has its own advantages and limitations. Attempts have been made to combine these methods to overcome these limitations. Such combinations of methods are within the scope of this disclosure. The combination of solid-phase or liquid-phase chemical synthesis with enzymatic ligation provides an efficient method for producing long nucleic acids that cannot be obtained by chemical synthesis alone.

[0304] Ligation Ligase-mediated assembly of nucleic acids can also be used. DNA or RNA ligase promotes intermolecular ligation of the 5' and 3' ends of polynucleotide chains via the formation of phosphodiester bonds. Nucleic acids, such as chimeric polynucleotides and / or circular nucleic acids, can be prepared by ligating one or more regions or subregions. By joining DNA fragments using a ligase-catalyzed reaction, recombinant DNAs with different functions can be created. Two oligodeoxynucleotides, one containing a 5' phosphoryl group and the other containing a free 3' hydroxyl group, serve as substrates for DNA ligase.

[0305] purification Purification of nucleic acids as described herein can include, but is not limited to, nucleic acid cleanup, quality assurance, and quality control. Cleanup can be performed by methods known in the art, such as, but not limited to, AGENCOURT® beads (Beckman Coulter Genomics, Danvers, MA), poly-T beads, LNA™ Oligo-T Capture Probes (EXIQON® Inc, Vedbaek, Denmark), or HPLC-based purification methods, such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC). The term "purified," when used in reference to nucleic acids, e.g., "purified nucleic acid," refers to something that has been separated from at least one contaminant. A "contaminant" is any substance that renders another unsuitable, impure, or adulterated. Thus, purified nucleic acids (e.g., DNA and RNA) are present in a form or setting that is different from that in which they are found in nature or that is different from that in which they existed prior to being subjected to a treatment or purification method.

[0306] Quality assurance and / or quality control checks may be performed using methods such as, but not limited to, gel electrophoresis, UV absorbance, or analytical HPLC.

[0307] In some embodiments, nucleic acids may be sequenced by methods including, but not limited to, reverse transcriptase PCR.

[0308] Quantification In some embodiments, nucleic acids of the present disclosure may be quantified in exosomes or from one or more bodily fluids, including peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, earwax, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Cowper's or pre-ejaculate fluid, sweat, feces, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menstrual fluid, pus, sebum, vomit, vaginal secretions, mucosal secretions, stool, pancreatic juice, sinus lavage fluid, bronchopulmonary aspirate, blastocyl cavity fluid, and umbilical cord blood. Alternatively, exosomes may be collected from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.

[0309] Assays may be performed using construct-specific probes, cytometry, qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or a combination thereof, and exosomes may be isolated using immunohistochemistry, such as enzyme-linked immunosorbent assay (ELISA). Exosomes may also be isolated by size-exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunosorbent capture, affinity purification, microfluidic separation, or a combination thereof.

[0310] These methods allow researchers to monitor residual or delivered levels of nucleic acid in real time, which is possible because the nucleic acids of the present disclosure, in some embodiments, differ from endogenous forms by structural or chemical modifications.

[0311] In some embodiments, nucleic acids can be quantified using methods such as, but not limited to, ultraviolet-visible spectroscopy (UV / Vis). A non-limiting example of a UV / Vis spectrometer is the NANODROP® spectrometer (ThermoFisher, Waltham, MA). Quantified nucleic acids can be analyzed to determine whether the nucleic acids are of the appropriate size and to confirm that nucleic acid degradation has not occurred. Nucleic acid degradation can be confirmed by methods such as, but not limited to, agarose gel electrophoresis, HPLC-based purification methods, including, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE), and capillary gel electrophoresis (CGE).

[0312] In vitro transcription The cDNA encoding the polynucleotide described herein can be transcribed using an in vitro transcription (IVT) system. In vitro transcription of RNA (e.g., mRNA) is known in the art and is described in International Publication WO / 2014 / 152027 (incorporated herein in its entirety by reference). In some embodiments, the RNA of the present disclosure is prepared according to any one or more of the methods described in WO2018 / 053209 or WO2019 / 036682 (each of which is incorporated herein by reference).

[0313] In some embodiments, RNA (e.g., mRNA) transcripts are generated using an unamplified, linearized DNA template in an in vitro transcription reaction to produce the RNA transcript. In some embodiments, the template DNA is isolated DNA. In some embodiments, the template DNA is cDNA. In some embodiments, the cDNA is formed by reverse transcription of RNA, for example, but not limited to, HSV mRNA. In some embodiments, cells, e.g., bacterial cells, e.g., E. coli, e.g., DH-1 cells, are transfected with a plasmid DNA template. In some embodiments, the transfected cells are cultured to replicate the plasmid DNA, which is then isolated and purified. In some embodiments, the DNA template comprises an RNA polymerase promoter, e.g., a T7 promoter, located 5' to and operably linked to the gene of interest.

[0314] In some embodiments, the in vitro transcription template encodes a 5' untranslated (UTR) region, contains an open reading frame, encodes a 3' UTR, and a poly(A) tail. The specific nucleic acid sequence composition and length of the in vitro transcription template depends on the RNA (e.g., mRNA) encoded by the template.

[0315] In some embodiments, the nucleic acid (e.g., template DNA and / or RNA) comprises 200 to 3,000 nucleotides. For example, the nucleic acid may comprise 200 to 500, 200 to 1,000, 200 to 1,500, 200 to 3,000, 500 to 1,000, 500 to 1,500, 500 to 2,000, 500 to 3,000, 1,000 to 1,500, 1,000 to 2,000, 1,000 to 3,000, 1,500 to 3,000, or 2,000 to 3,000 nucleotides.

[0316] In vitro transcription systems typically include a transcription buffer (e.g., containing magnesium), nucleotide triphosphates (NTPs), an RNase inhibitor, and a polymerase (e.g., T7 RNA polymerase). In some embodiments, one or more of the NTPs are chemically modified NTPs (e.g., with 1-methylpseudouridine or other chemical modifications described herein and / or known in the art).

[0317] In some embodiments, the NTPs include adenosine triphosphate (ATP), cytidine triphosphate (CTP), uridine triphosphate (UTP), and guanosine triphosphate (GTP), or analogs of each NTP. The ratio of NTPs can vary. In some embodiments, the ratio of GTP:ATP:CTP:UTP is 1:1:1:1. In some embodiments, the amount of GTP or its analog is greater than the amount of UTP or its analog. In some embodiments, the amount of GTP is greater than the amount of UTP. In some embodiments, the amount of ATP is greater than the amount of UTP, and the amount of CTP is greater than the amount of UTP. In some embodiments, the amount of GTP or its analog is greater than the amount of UTP or its analog. In some embodiments, the IVT system comprises a ratio of GTP concentration to ATP concentration of at least 2:1, a ratio of GTP concentration to CTP concentration of at least 2:1, and a ratio of GTP concentration to UTP concentration of at least 4:1. In some embodiments, the IVT system comprises a ratio of GTP concentration to ATP concentration of 2:1, a ratio of GTP concentration to CTP concentration of 2:1, and a ratio of GTP concentration to UTP concentration of 4:1. In some embodiments, the IVT system comprises guanosine diphosphate (GDP). In some embodiments, the IVT system comprises a ratio of GTP + GDP concentration to ATP concentration of at least 3:1, a ratio of GTP + GDP concentration to CTP concentration of at least 6:1, and a ratio of GTP + GDP concentration to UTP concentration of at least 6:1.

[0318] NTPs may be produced in-house, selected from a supplier, or synthesized as described herein. NTPs may be selected from those described herein, including, but not limited to, natural and unnatural (modified) NTPs.

[0319] Any number of RNA polymerases or variants can be used in the methods of the present disclosure. The polymerase can be selected from, but is not limited to, phage RNA polymerases, such as T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, and / or mutant polymerases, such as polymerases capable of incorporating modified nucleic acids and / or modified nucleotides, including, but not limited to, chemically modified nucleic acids and / or nucleotides. Some embodiments exclude the use of DNase.

[0320] The IVT system, in some embodiments, includes magnesium buffer, dithiothreitol (DTT), spermidine, pyrophosphatase, and / or an RNase inhibitor. In some embodiments, the RNase inhibitor is omitted from the IVT system. The IVT system can be incubated at 25° C. or 37° C. Other temperatures can be used, depending in part on the polymerase (e.g., the use of a variant polymerase).

[0321] In some embodiments, the RNA transcript is capped via enzymatic capping. In some embodiments, the RNA comprises a 5' end cap, e.g., 7mG(5')ppp(5')NlmpNp.

[0322] Identification and Ratio Determination (IDR) Sequence In some embodiments, one or more nucleic acids comprise a discrimination and ratio determining sequence. A discrimination and ratio determining (IDR) sequence is a sequence of a biomolecule (e.g., a nucleic acid or protein) that, when combined with the sequence of a target biomolecule, serves to identify the target biomolecule. Typically, an IDR sequence is a heterologous sequence that is incorporated within or added to the sequence of a target biomolecule and can be used as a reference to identify the target molecule. Thus, in some embodiments, a nucleic acid (e.g., an mRNA) comprises (i) a target sequence of interest (e.g., a coding sequence encoding a therapeutic and / or antigenic peptide or protein), and (ii) a unique IDR sequence.

[0323] An RNA species (e.g., an RNA having a given coding sequence) may contain IDR sequences that differ from the IDR sequences of other RNA species (e.g., RNA(s) having different coding sequence(s)). Thus, because each IDR sequence distinguishes a particular RNA species, the abundance of the IDR sequences can be measured to determine the abundance of each RNA species in a composition. The use of different IDR sequences to distinguish RNA species enables the analysis of polyvalent RNA compositions (e.g., containing multiple RNA species) containing RNA species with similar coding sequences and / or lengths that may otherwise be difficult to distinguish using PCR- or chromatography-based analysis of full-length RNA.

[0324] Each RNA species in a multivalent RNA composition can contain an IDR sequence that is not a sequence isomer of the IDR sequence of another RNA species in the multivalent RNA composition (e.g., an IDR sequence does not have the same number of adenosine nucleotides, the same number of cytosine nucleotides, the same number of guanine nucleotides, and the same number of uracil nucleotides as another IDR sequence in the composition, even though these sequences have different sequences). Having identical nucleotide composition causes sequence isomers to have the same mass, making it challenging to distinguish between sequence isomers using mass-based discrimination methods (e.g., mass spectrometry).

[0325] Each RNA species in the multivalent RNA composition can comprise an IDR sequence with a mass that is different from the mass of the IDR sequence of each other RNA species in the multivalent RNA composition.For example, the mass of each IDR sequence can be different from the mass of other IDR sequences by at least 9 Da, at least 25 Da, at least 25 Da, or at least 50 Da.Using IDR sequences with different masses makes it possible to distinguish the RNA fragments that contain different IDR sequences using mass-based analysis methods (such as mass spectrometry) that do not require reverse transcription, amplification, or sequencing of RNA.

[0326] Each RNA species in an RNA composition can contain IDR sequences of different lengths. For example, each IDR sequence can have a length independently selected from 0 to 25 nucleotides. Because nucleic acid length affects the rate at which a nucleic acid passes through a chromatography column, using IDR sequences of different lengths for different RNA species allows for the use of chromatography-based methods (e.g., LC-UV) to distinguish between RNA fragments with different IDR sequences.

[0327] The IDR sequences may be selected so that there are no IDR sequences containing the start codon "AUG." The lack of a start codon in the IDR sequence prevents undesired translation of nucleotide sequences within and / or downstream from the IDR sequence.

[0328] The IDR sequences can be selected so that there are no IDR sequences containing restriction enzyme recognition sites. In one example, there are no IDR sequences containing the XbaI recognition site "UCUAG." The lack of restriction enzyme recognition sites (e.g., the XbaI recognition site "UCUAG") allows the use of restriction enzymes to generate and modify DNA templates for in vitro transcription without affecting the IDR sequences or the sequence of the transcribed RNA.

[0329] Non-limiting examples of distinct IDR sequences include GAGAUUGAGUGUAGUGACUAG (SEQ ID NO: 98), GAGAUUGAGUGUAGUGAC (SEQ ID NO: 99), GAGAUUGAGUGUAGUG (SEQ ID NO: 100), GAUUGAGACUACGGG (SEQ ID NO: 101), and CAUAGACACUACG (SEQ ID NO: 102). In some embodiments of the compositions described herein, each mRNA encoding a distinct protein comprises a 3'UTR comprising a distinct IDR sequence selected from SEQ ID NOs: 98-102.

[0330] lipid composition In some embodiments, nucleic acids are formulated as lipid compositions, such as compositions comprising lipid nanoparticles, liposomes, and / or lipoplexes. In some embodiments, nucleic acids are formulated as lipid nanoparticle (LNP) compositions. Lipid nanoparticles typically comprise amino lipids, non-cationic lipids, structured lipids, and PEG-lipid components along with the nucleic acid cargo of interest. Lipid nanoparticles can be produced using components, compositions, and methods generally known in the art. For example, see PCT / US2016 / 052352, PCT / US2016 / 068300, PCT / US2017 / 037551, PCT / US2015 / 027400, PCT / US2016 / 047406, PCT / US2016 / 000129, PCT / US2016 / 014280, PCT / US2017 / 038426, PCT / US2014 / 027077, PCT / US2014 / 055394, PCT / US2016 / 052117, PCT / US2012 / 069610, PCT / US2017 / 027492, PCT / US2016 / 059575, PCT / US2016 / 069491, PCT / US2016 / 069493, and PCT / US2014 / 066242, all of which are incorporated by reference in their entireties.

[0331] In some embodiments, the lipid nanoparticles comprise at least one ionic amino lipid, at least one non-cationic lipid, at least one sterol, and / or at least one polyethylene glycol (PEG)-modified lipid.

[0332] In some embodiments, the lipid nanoparticles comprise a molar ratio of 20-60% ionic amino lipid, 5-25% non-cationic lipid, 25-55% structural lipid, and 0.5-15% PEG-modified lipid.

[0333] In some embodiments, the lipid nanoparticles comprise a molar ratio of 20-60% ionic amino lipid, 5-30% non-cationic lipid, 10-55% structural lipid, and 0.5-15% PEG-modified lipid.

[0334] In some embodiments, the lipid nanoparticles comprise 40-50 mol% ionic lipids, optionally 45-50 mol%, e.g., 45-46 mol%, 46-47 mol%, 47-48 mol%, 48-49 mol%, or 49-50 mol%, e.g., about 45 mol%, 45.5 mol%, 46 mol%, 46.5 mol%, 47 mol%, 47.5 mol%, 48 mol%, 48.5 mol%, 49 mol%, or 49.5 mol%.

[0335] In some embodiments, the lipid nanoparticles comprise 20-60 mol% ionic amino lipid. For example, the lipid nanoparticles may comprise 20-50 mol%, 20-40 mol%, 20-30 mol%, 30-60 mol%, 30-50 mol%, 30-40 mol%, 40-60 mol%, 40-50 mol%, or 50-60 mol% ionic amino lipid. In some embodiments, the lipid nanoparticles comprise 20 mol%, 30 mol%, 40 mol%, 50 mol%, or 60 mol% ionic amino lipid. In some embodiments, the lipid nanoparticles comprise 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, 45 mol%, 46 mol%, 47 mol%, 48 mol%, 49 mol%, 50 mol%, 51 mol%, 52 mol%, 53 mol%, 54 mol%, or 55 mol% ionic amino lipids.

[0336] In some embodiments, the lipid nanoparticles comprise 45 to 55 mole percent (mol%) of ionizable amino lipids. For example, the lipid nanoparticles may comprise 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mol% of ionizable amino lipids.

[0337] Ionic Amino Lipids Formula (AI) In some embodiments, the ionic amino lipids of the present disclosure have the formula (AI): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 where R' 分岐状 teeth [ka] where [ka] indicates the point of attachment, where R aα , R aβ , R aγ , and R aδ is H, C 2~12 Alkyl, and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the point of attachment, R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R 5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R 6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are each independently selected from the group consisting of -C(O)O- and -OC(O)-; R' is C 1~12 Alkyl or C 2~12 is alkenyl, l is selected from the group consisting of 1, 2, 3, 4, and 5; m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0338] In some embodiments of the compound of Formula (AI), R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aα , R aβ , R aγ , and R aδ are H and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) n OH, n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0339] In some embodiments of the compound of Formula (AI), R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aα , R aβ , R aγ , and R aδ are H and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) nOH, n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 3, and m is 7.

[0340] In some embodiments of the compound of Formula (AI), R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aα is C 2~12 alkyl, and R aβ , R aγ , and R aδ are H and R 2 and R 3 are C 1~14 alkyl, and R 4 teeth [ka] and R 10 is NH(C 1~6 alkyl), n is 2, and R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0341] In some embodiments of the compound of Formula (AI), R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aα , R aβ , and R aδ are H and R aγ is C 2~12 alkyl, and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) n OH, n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0342] In some embodiments, the compound of formula (AI) is [ka] is selected from.

[0343] In some embodiments, the ionizable amino lipid of formula (AI) has the formula (AIa): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 where R' 分岐状 teeth [ka] where [ka] indicates the point of attachment, where R aβ , R aγ , and R aδ is H, C 2~12 Alkyl, and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the point of attachment, R 10 is N(R)2, and each R is C 1~6 Alkyl C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R 5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R 6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are each independently selected from the group consisting of -C(O)O- and -OC(O)-; R' is C 1~12 Alkyl or C 2~12 is alkenyl, l is selected from the group consisting of 1, 2, 3, 4, and 5; m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0344] In some embodiments, the ionizable amino lipid of formula (AI) has the formula (AIb): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 where R' 分岐状 teeth [ka] where [ka] indicates the point of attachment, where R aα , R aβ , R aγ , and R aδ is H, C 2~12 Alkyl, and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; Each R 5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R 6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are each independently selected from the group consisting of -C(O)O- and -OC(O)-; R' is C 1~12 Alkyl or C 2~12 is alkenyl, l is selected from the group consisting of 1, 2, 3, 4, and 5; m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0345] In some embodiments of formula (AI) or (AIb), ​​R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aβ , R aγ , and R aδ are H and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) n OH, n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0346] In some embodiments of formula (AI) or (AIb), ​​R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aβ , R aγ , and R aδ are H and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) n OH, n is 2, and each R 5 is H, and each R 6is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 3, and m is 7.

[0347] In some embodiments of formula (AI) or (AIb), ​​R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aβ and R aδ are H and R aγ is C 2~12 alkyl, and R 2 and R 3 are C 1~14 alkyl, and R 4 Ha-(CH2) n OH, n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0348] In some embodiments, the ionizable amino lipid of formula (AI) has the formula (AIc): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 where R' 分岐状 teeth [ka] where [ka] indicates the point of attachment, where R aα , R aβ , R aγ , and R aδ is H, C 2~12 Alkyl, and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 teeth, [ka] where [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R 5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R 6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are each independently selected from the group consisting of -C(O)O- and -OC(O)-; R' is C 1~12 Alkyl or C 2~12 is alkenyl, l is selected from the group consisting of 1, 2, 3, 4, and 5; m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0349] In some embodiments, R' a is R' 分岐状 and R' 分岐状 teeth [ka] and [ka] indicates the attachment point, and R aβ , R aγ , and R aδ are H and R aα is C 2~12 alkyl, and R 2 and R 3 are C 1~14 alkyl, and R 4 teeth [ka] and [ka] indicates the attachment point, and R 10 is NH(C 1~6 alkyl), n is 2, and each R 5 is H, and each R 6 is H, M and M' are each -C(O)O-, and R' is C 1~12 alkyl, l is 5, and m is 7.

[0350] In some embodiments, the compound of formula (AIc) is [ka] is.

[0351] Formula (AII) In some embodiments, the ionizable amino lipid has the formula (AII): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' 環状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ and R aδ is H, C 1~12 Alkyl, and C 2~12 alkenyl, wherein R aγ and R aδ At least one of the 1~12 Alkyl and C 2~12 alkenyl, R bγ and R bδ is H, C 1~12 Alkyl, and C 2~12 alkenyl, wherein R bγ and R bδ At least one of the 1~12 Alkyl and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R' is independently C 1~12 Alkyl or C 2~12 is alkenyl, Y a is C 3~6 is a carbocyclic ring, R*” a is C 1~15 Alkyl and C 2~15 alkenyl, s is 2 or 3, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0352] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-a): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ and R aδ is H, C 1~12 Alkyl, and C 2~12 alkenyl, wherein R aγ and R aδ At least one of the 1~12 Alkyl and C 2~12 alkenyl, R bγ and R bδ is H, C 1~12 Alkyl, and C 2~12 alkenyl, wherein R bγ and R bδ At least one of the 1~12 Alkyl and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R' is independently C 1~12 Alkyl or C 2~12 is alkenyl, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0353] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-b): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ and R bγ is C 1~12 Alkyl and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2)n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R' is independently C 1~12 Alkyl or C 2~12 is alkenyl, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0354] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-c): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ is C 1~12 Alkyl and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R' is C 1~12 Alkyl or C 2~12 is alkenyl, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0355] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-d): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ and R bγ is C 1~12 Alkyl and C 2~12 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is N(R)2, and each R is C 1~6 Alkyl, C 2~3 alkenyl, and H, and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Each R' is independently C 1~12 Alkyl or C 2~12 is alkenyl, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0356] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-e): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ is C 1~12 Alkyl and C 2~12 alkenyl, R 2 and R 3 is C 1~14 Alkyl and C 2~14 alkenyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; R' is C 1~12 Alkyl or C 2~12 is alkenyl, m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; 1 is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

[0357] In some embodiments of a compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), m and l are each independently selected from 4, 5, and 6. In some embodiments of a compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), m and l are each 5.

[0358] In some embodiments of a compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), each R' is independently C 1~12 In some embodiments of a compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), each R' is independently C 2~5 It is alkyl.

[0359] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' b teeth [ka] and R 2 and R 3 are each independently C 1~14 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. b teeth [ka] and R 2 and R 3 are each independently C 6~10 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. b teeth [ka] and R 2 and R 3 are each C8 alkyl.

[0360] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] and R aγ is C 1~12 alkyl, and R 2 and R 3 are each independently C 6~10 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. 分岐状 teeth [ka] and R' b teeth [ka] and R aγ is C 2~6 alkyl, and R 2 and R 3 are each independently C 6~10 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. 分岐状 teeth [ka] and R' b teeth [ka] and R aγ is C 2~6 alkyl, and R 2 and R 3 are each C8 alkyl.

[0361] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] and R aγ and R bγ are C 1~12 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. 分岐状 teeth [ka] and R' b teeth [ka] and R aγ and R bγ are C 2~6 It is alkyl.

[0362] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), m and l are each independently selected from 4, 5, and 6; and each R′ is independently C 1~12 In some embodiments of a compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), m and l are each 5 and each R' is independently C2~5 It is alkyl.

[0363] In some embodiments of compounds (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each independently selected from 4, 5, and 6; and each R′ is independently selected from C 1~12 alkyl, and R aγ and R bγ are C 1~12 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' is alkyl. 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each 5, and each R' is independently C 2~5 alkyl, and R aγ and R bγ are C 2~6 It is alkyl.

[0364] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each independently selected from 4, 5, and 6; and R′ is C 1~12 alkyl, and R aγ is C 1~12 alkyl, and R 2 and R 3 are each independently C 6~10 It is alkyl.

[0365] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] m and l are each 5, and R' is C 2~5 alkyl, and R aγ is C 2~6 alkyl, and R 2 and R 3 are each C8 alkyl.

[0366] In some embodiments of compound (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R 4 teeth [ka] where R 10 is NH(C 1~6 In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R 4 teeth [ka] where R 10is NH(CH3) and n2 is 2.

[0367] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each independently selected from 4, 5, and 6; and each R′ is independently selected from C 1~12 alkyl, and R aγ and R bγ are C 1~12 alkyl, and R 4 teeth [ka] where R 10 is NH(C 1~6 alkyl) and n2 is 2. In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each 5, and each R' is independently C 2~5 alkyl, and R aγ and R bγ are C 2~6 alkyl, and R 4 teeth [ka] where R 10is NH(CH3) and n2 is 2.

[0368] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each independently selected from 4, 5, and 6; and R′ is C 1~12 alkyl, and R 2 and R 3 are each independently C 6~10 alkyl, and R aγ is C 1~12 alkyl, and R 4 teeth [ka] where R 10 is NH(C 1~6 alkyl) and n2 is 2. In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] m and l are each 5, and R' is C 2~5 alkyl, and R aγ is C 2~6 alkyl, and R 2 and R 3 are each C8 alkyl, and R 4 teeth [ka] where R 10 is NH(CH3) and n2 is 2.

[0369] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R 4 Ha-(CH2) n OH and n is 2, 3, or 4. In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R 4 Ha-(CH2) n OH and n is 2.

[0370] In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each independently selected from 4, 5, and 6; and each R′ is independently selected from C 1~12 alkyl, and R aγ and R bγ are C 1~12 alkyl, and R 4 Ha-(CH2) n OH and n is 2, 3, or 4. In some embodiments of the compound of Formula (AII), (AII-a), (AII-b), (AII-c), (AII-d), or (AII-e), R' 分岐状 teeth [ka] and R' b teeth [ka] wherein m and l are each 5, and each R' is independently C 2~5 alkyl, and R aγ and R bγ are C 2~6 alkyl, and R 4 Ha-(CH2) n OH and n2 is 2.

[0371] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-f): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, R' a is R' 分岐状 or R' 環状 where R' 分岐状 teeth [ka] and R' b teeth, [ka] where [ka] indicates the point of attachment, R aγ is C 1~12 is alkyl, R 2 and R 3 are each independently C 1~14 is alkyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 1, 2, 3, 4, and 5; R' is C 1~12 is alkyl, m is selected from 4, 5, and 6; 1 is selected from 4, 5, and 6.

[0372] In some embodiments of compounds of Formula (AII-f), m and l are each 5; and n is 2, 3, or 4.

[0373] In some embodiments of the compound of Formula (AII-f), R' is C 2~5 alkyl, and R aγ is C 2~6 alkyl, and R 2 and R 3 are C 6~10 It is alkyl.

[0374] In some embodiments of compounds of Formula (AII-f), m and l are each 5; n is 2, 3, or 4; and R′ is C 2~5 alkyl, and R aγ is C 2~6 alkyl, and R 2 and R 3 are C 6~10 It is alkyl.

[0375] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-g): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R aγ is C 2~6 is alkyl, R' is C 2~5 is alkyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is NH(C 1~6 alkyl), and n2 is selected from the group consisting of 1, 2, and 3.

[0376] In some embodiments, the ionizable amino lipid of formula (AII) has the formula (AII-h): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R aγ and R bγ are each independently C 2~6 is alkyl, Each R' is independently C 2~5 is alkyl, R 4 is -(CH2) n OH, where n is selected from the group consisting of 3, 4, and 5; and [ka] wherein [ka] indicates the attachment point, and R 10 is NH(C 1~6 alkyl), and n2 is selected from the group consisting of 1, 2, and 3.

[0377] In some embodiments of compounds of Formula (AII-g) or (AII-h), R 4 teeth [ka] wherein: R 10 is NH(CH3) and n2 is 2.

[0378] In some embodiments of compounds of Formula (AII-g) or (AII-h), R4 is -(CH2)2OH.

[0379] Formula (AIII) In some embodiments, the ionic amino lipid of the present disclosure has formula (AIII): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R1 is C 5~30 Alkyl, C 5~20 selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are H, C 1~14 Alkyl, C 2~14 are independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R , -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n-OR, -N(R)C(=NR9)N(R), -N(R)C(=CHR9)N(R), -OC(O)N(R), -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)R, -N(OR)C(O)OR, -N(OR)C(O)N(R), -N(OR)C(S)N(R), -N(OR)C(=NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR; each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)-M″-C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl, or C 2~13 is alkenyl, R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8 is C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~15 Alkyl and C 3~15 alkenyl; Each R* is C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, where R4 is -(CH2) n Q, -(CH2) n When CHQR, -CHQR, or -CQ(R), (i) Q is not -N(R) when n is 1, 2, 3, 4, or 5, or (ii) Q is not 5-, 6-, or 7-membered heterocycloalkyl when n is 1 or 2.

[0380] In some embodiments, another subset of compounds of formula (AIII) includes: R1 is C 5~30 Alkyl, C 5~20 selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are H, C 1~14 Alkyl, C 2~14 independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocyclic ring, 5-14 membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2)n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N( R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R)2, -N(OR)C(=CHR9)N(R)2, -C(=NR9)N(R)2, -C(=NR9)R, -C(O)N(R)OR, and 5-14 membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S (oxo(=O), OH, amino, monoalkylamino or dialkylamino, and C 1~3 substituted with one or more substituents selected from alkyl, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, -SS-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C 2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~14 Alkyl and C 3~14 alkenyl; Each R* is C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; or a salt or isomer thereof.

[0381] In some embodiments, another subset of compounds of formula (AIII) includes: R1 is C 5~30 Alkyl, C 5~20 selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are H, C 1~14 Alkyl, C 2~14 independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocycle, 5-14 membered heterocycle having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N( R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -O(CH2) n and (i) R4 is -(CH2)N(R)-OR, -N(R)C(=NR9)N(R), -N(R)C(=CHR9)N(R), -OC(O)N(R), -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)R, -N(OR)C(O)OR, -N(OR)C(O)N(R), -N(OR)C(S)N(R), N(OR)C(=NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(=NR9)N(R), each n is independently selected from 1, 2, 3, 4, and 5; Q is a 5- to 14-membered heterocycle; and (ii) R4 is -(CH2)N(R), n Q (n is 1 or 2), or (ii) R4 is -(CH2) n or (iii) when R4 is -CHQR and -CQ(R)2, Q is either a 5- to 14-membered heteroaryl or an 8- to 14-membered heterocycloalkyl; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, -SS-, an aryl group, and a heteroaryl group; R7 is C1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C 2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~14 Alkyl and C 3~14 alkenyl; Each R* is C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; or a salt or isomer thereof.

[0382] In some embodiments, another subset of compounds of formula (AIII) includes: R1 is C 5~30 Alkyl, C 5~20 selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are H, C 1~14 Alkyl, C 2~14independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocyclic ring, 5-14 membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -O(CH2) n -OR, -N(R)C(=NR9)N(R), -N(R)C(=CHR9)N(R), -OC(O)N(R), -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)R, -N(OR)C(O)OR, -N(OR)C(O)N(R), -N(OR)C(S)N(R), -N(OR)C(=NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(=NR9)N(R), wherein each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, -SS-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C 2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~14 Alkyl and C 3~14 alkenyl; Each R* is C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; or a salt or isomer thereof.

[0383] In some embodiments, another subset of compounds of formula (AIII) includes: R1 is C 5~30 Alkyl, C 5~20selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are H, C 2~14 Alkyl, C 2~14 independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is -(CH2) n Q or -(CH2) n CHQR, where Q is —N(R)2 and n is selected from 3, 4, and 5; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, -SS-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C 2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~14 Alkyl and C 3~14 alkenyl; Each R* is C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; or a salt or isomer thereof.

[0384] In some embodiments, another subset of compounds of formula (AIII) includes: R1 is C 5~30 Alkyl, C 5~20 selected from the group consisting of alkenyl, -R*YR", -YR", and -R"M'R'; R2 and R3 are C 1~14 Alkyl, C 2~14 independently selected from the group consisting of alkenyl, -R*YR", -YR", and -R*OR", or R2 and R3 together with the atoms to which they are attached form a heterocycle or carbocycle; R4 is -(CH2) n Q, -(CH2) n -CHQR, -CHQR, and -CQ(R)2, where Q is -N(R)2 and n is selected from 1, 2, 3, 4, and 5; Each R5 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; Each R6 is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, -SS-, an aryl group, and a heteroaryl group; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is C 1~3 Alkyl, C 2~3independently selected from the group consisting of alkenyl, and H; Each R' is C 1~18 Alkyl, C 2~18 independently selected from the group consisting of alkenyl, -R*YR″, -YR″, and H; Each R” is C 3~14 Alkyl and C 3~14 alkenyl; Each R* is C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; or a salt or isomer thereof.

[0385] In certain embodiments, a subset of compounds of formula (AIII) includes compounds of formula (AIII-A): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M is a bond or M′; R is hydrogen, unsubstituted C 1~3 Alkyl, or -(CH2) n Q, where Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; and R and R are independently selected from H, C 1~14Alkyl, and C 2~14 alkenyl. For example, m is 5, 7, or 9. For example, Q is OH, -NHC(S)N(R)2, or -NHC(O)N(R)2. For example, Q is -N(R)C(O)R or -N(R)S(O)2R.

[0386] In certain embodiments, a subset of compounds of formula (AIII) includes compounds of formula (AIII-B): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein all variables are as defined herein. For example, m is selected from 5, 6, 7, 8, and 9; R4 is hydrogen, unsubstituted C 1~3 Alkyl, or -(CH2) n Q, where Q is H, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; and R and R are H, C 1~14 Alkyl, and C 2~14 alkenyl. For example, m is 5, 7, or 9. For example, Q is OH, -NHC(S)N(R)2, or -NHC(O)N(R)2. For example, Q is -N(R)C(O)R or -N(R)S(O)2R.

[0387] In certain embodiments, a subset of compounds of formula (AIII) includes compounds of formula (AIII-C): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; M is a bond or M'; R is hydrogen, unsubstituted C 1~3 Alkyl, or -(CH2) n Q, where n is 2, 3, or 4; Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~14 Alkyl, and C 2~14 alkenyl.

[0388] In some embodiments, the compound of formula (AIII) has formula (AIII-D): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as defined herein.

[0389] In another embodiment, the compound of formula (AIII) has the formula (AIII-E) [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as defined herein.

[0390] In another embodiment, the compound of formula (AIII) has formula (AIII-F) or (AIII-G): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as defined herein.

[0391] In another embodiment, the compound of formula (AIII) has the formula (AIII-H): [ka] or an N-oxide thereof, or a salt or isomer thereof, In the formula, M is —C(O)O— or —OC(O)—, and M″ is C 1~6 Alkyl or C 2~6 alkenyl, and R2 and R3 are C 5~14 Alkyl and C 5~14 alkenyl, wherein n is selected from 2, 3, and 4.

[0392] In a further embodiment, the compound of formula (AIII) has the formula (AIII-I): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein n is 2, 3, or 4, and m, R′, R″, and R2 through R6 are as described herein. For example, each of R2 and R3 is C 5~14 Alkyl and C 5~14 alkenyl.

[0393] In some embodiments, the ionic amino lipids of the present disclosure include compounds having the following structure: [ka]

[0394] In some embodiments, the ionic amino lipids of the present disclosure include compounds having the following structure: [ka]

[0395] In a further embodiment, the compound of formula (AIII) has the formula (AIII-J) [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M'; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; R2 and R3 are each independently selected from H, C 1~14 Alkyl, and C 2~14 alkenyl. For example, M" is independently selected from the group consisting of C 1~6 Alkyl (e.g., C 1~4 alkyl) or C 2~6 Alkenyl (e.g., C 2~4 alkenyl). For example, R2 and R3 are C 5~14 Alkyl and C 5~14 alkenyl.

[0396] In some embodiments, the ionizable amino lipid is of formula (AIII), or a salt or isomer thereof, wherein: R1 is -R″M′R′, R2 and R3 are C 1~14 Alkyl and C 2~14 alkenyl, R4 is -(CH2) n Q, where Q is OH and n is selected from 3, 4, and 5; M and M' are each independently -OC(O)-; R5, R6, and R7 are each H; R' is a linear C 1~12 Alkyl, or C 6~9 Alkyl-substituted C 1~12 is alkyl, R” is C 3~14 is alkyl, m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0397] In some embodiments, the ionizable amino lipid is of formula (AIII), or a salt or isomer thereof, wherein: R1 is R″M′R′, R2 and R3 are each independently C 1~14 is alkyl, R4 is -(CH2) n Q, where Q is OH and n is 4; M and M' are each independently -OC(O)-; R5, R6, and R7 are each H; R' is C 6~9 Alkyl-substituted C 1~12 is alkyl, R” is C 3~14 is alkyl, m is 6.

[0398] In some embodiments, the ionic amino lipids of the present disclosure include compounds having the following structure: [ka]

[0399] In some embodiments, the ionizable amino lipid is of formula (AIII), or a salt or isomer thereof, wherein: R1 is C 5~20 is alkenyl, R2 and R3 are C 1~14 Alkyl and C 2~14 alkenyl, R4 is -(CH2) n Q, where Q is OH and n is selected from 3, 4, and 5; M and M' are each independently C(O)O-; R5, R6, and R7 are each H; R' is a linear C 1~12 Alkyl, or C 6~9 Alkyl-substituted C 1~12 is alkyl, R” is C 3~14 is alkyl, m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

[0400] In some embodiments, the ionizable amino lipid is of formula (AIII), or a salt or isomer thereof, wherein: R1 is C 5~20 is alkenyl, R2 and R3 are each independently C 1~14 is alkyl, R4 is -(CH2) n Q, where Q is OH and n is 3; M is —C(O)O—; R5, R6, and R7 are each H; m is 6.

[0401] In some embodiments, the ionic amino lipids of the present disclosure include compounds having the following structure: [ka]

[0402] In some embodiments, the ionizable amino lipid is one or more of the compounds described in U.S. Application Nos. 62 / 220,091, 62 / 252,316, 62 / 253,433, 62 / 266,460, 62 / 333,557, 62 / 382,740, 62 / 393,940, 62 / 471,937, 62 / 471,949, 62 / 475,140, ​​and 62 / 475,166 and PCT Application No. PCT / US2016 / 052352.

[0403] The central amine moiety of a lipid according to formula (AIII), (AIII-A), (AIII-B), (AIII-C), (AIII-D), (AIII-E), (AIII-F), (AIII-G), (AIII-H), (AIII-I), or (AIII-J) can be protonated at physiological pH. Thus, the lipid can have a positive or partial positive charge at physiological pH. Such amino lipids are sometimes referred to as cationic lipids, ionic lipids, cationic amino lipids, or ionic amino lipids. Amino lipids can also be zwitterionic, i.e., neutral molecules with both positive and negative charges.

[0404] Formula (AIV) In some embodiments, the ionic amino lipid of the present disclosure has the formula (AIV): [ka] or a salt or isomer thereof, wherein W is [ka] and Ring A is [ka] and t is 1 or 2, A1 and A2 are each independently selected from CH or N; Z is CH2 or absent, where when Z is CH2, the dashed lines (1) and (2) each represent a single bond, and when Z is absent, the dashed lines (1) and (2) are both absent; R1, R2, R3, R4, and R5 are C 5~20 Alkyl, C 5~20 independently selected from the group consisting of alkenyl, -R"MR', -R*YR", -YR", and -R*OR"; R X1 and R X2 are each independently H or C alkyl, each M is independently selected from the group consisting of —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —C(O)S—, —SC(O)—, an aryl group, and a heteroaryl group; M* is a C1-C6 alkyl; W 1 and W 2 are each independently selected from the group consisting of —O— and —N(R6)—; Each R6 is H and C 1~5 independently selected from the group consisting of alkyl, X 1 , X 2 , and X 3 is a bond, -CH2-, -(CH2)2-, -CHR-, -CHY-, -C(O)-, -C(O)O-, -OC(O)-, -(CH2) n -C(O)-, -C(O)-(CH2) n -, -(CH2) n -C(O)O-, -OC(O)-(CH2) n -, -(CH2) n -OC(O)-, -C(O)O-(CH2) n independently selected from the group consisting of —, —CH(OH)—, —C(S)—, and —CH(SH)—; Each Y is independently C 3~6 is a carbocyclic ring, Each R* is C 1~12 Alkyl and C 2~12 alkenyl; Each R is C 1~3 Alkyl and C 3~6 are independently selected from the group consisting of carbocycles; Each R is C 1~12 Alkyl, C 2~12 independently selected from the group consisting of alkenyl, and H; Each R” is C 3~12 Alkyl, C 3~12 independently selected from the group consisting of alkenyl, and -R*MR'; n is an integer from 1 to 6, Here, ring A is [ka] in the case of, i)X 1 , X 2 , and X 3 is not -CH2-, and / or ii) At least one of R1, R2, R3, R4, and R5 is -R"MR'.

[0405] In some embodiments, the compound has the formula (AIVa)-(AIVh): [ka] [ka] It is one of the following.

[0406] In some embodiments, the ionic amino lipid is [ka] or a salt thereof.

[0407] The central amine moiety of a lipid according to formula (AIV), (AIVa), (AIVb), (AIVc), (AIVd), (AIVe), (AIVf), (AIVg), or (AIVh) can be protonated at physiological pH, and thus the lipid can have a positive charge or a partial positive charge at physiological pH.

[0408] Formula (AV) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein: R 1is an optionally substituted C1 to C 24 Alkyl or optionally substituted C2-C 24 is alkenyl, R 2 and R 3 are each independently an optionally substituted C1 to C 36 is alkyl, R 4 and R 5 are each independently an optionally substituted C1-C6 alkyl, or R 4 and R 5 together with the N to which they are attached form a heterocyclyl or heteroaryl; L 1 , L 2 , and L 3 are each independently an optionally substituted C1 to C 18 is alkylene, G 1 is a direct bond, -(CH2) n O(C=O)-, -(CH2) n (C=O)O-, or -(C=O)-; G 2 and G 3 are each independently —(C═O)O— or —O(C═O)—, and n is an integer greater than 0.

[0409] Expression(AVI) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein: G 1 is -N(R 3 )R 4 -OR 5 and R 1 is an optionally substituted branched saturated or unsaturated C 12 ~C 36 is alkyl, R2 When L is -C(=O)-, it is an optionally substituted branched or unbranched saturated or unsaturated C 12 ~C 36 alkyl or R 2 L is C6~C 12 Alkylene, C6-C 12 In the case of alkenylene or C2-C6 alkynylene, optionally substituted branched or unbranched saturated or unsaturated C4-C 36 is alkyl, R 3 and R 4 are each independently H, an optionally substituted branched or unbranched saturated or unsaturated C1-C6 alkyl, or R 3 and R 4 are each independently, L is C6 to C 12 Alkylene, C6-C 12 When it is alkenylene or C2-C6 alkynylene, it is an optionally substituted branched or unbranched, saturated or unsaturated C1-C6 alkyl, or R 3 and R 4 together with the nitrogen to which they are attached form a heterocyclyl, R 5 is H or optionally substituted C1-C6 alkyl, L is -C(=O)-, C6~C 12 Alkylene, C6-C 12 Alkenylene, or C2-C 12 is alkynylene, n is an integer from 1 to 12.

[0410] Expression (AVII) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof, wherein: Each R la are independently hydrogen, R lc , or Rld and Each R lb are independently lc or R ld and Each R 1c are independently -[CH2]2C(O)X 1 R 3 and Each R ld are independently -C(O)R 4 and Each R 2 are independently -[C(R 2a )2] c R 2b and Each R 2a are independently hydrogen or C1-C6 alkyl, R 2b is -N(L1-B)2, -(OCH2CH2)6OH, or -(OCH2CH2) b OCH3, Each R 3 and R 4 are independently C6~C 30 is aliphatic, Each I.3 is independently C1 to C 10 is alkylene, each B is independently hydrogen or an ionic nitrogen-containing group; each X 1 are independently a covalent bond or O, each a is independently an integer from 1 to 10; each b is independently an integer from 1 to 10; Each c is independently an integer from 1 to 10.

[0411] Formula (AVIII) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: X is N and Y is absent, or X is CR and Y is NR; L 1 is -O(CO)R 1 , -(C=O)OR 1 , -C(=O)R 1 , -OR 1 , -S(O) x R 1 , -S-SR 1 , -C(=O)SR 1 , -SC(=O)R 1 , -NR a C(=O)R 1 , -C(=O)NR b R c , -NR a C(=O)NR b R c , -OC(=O)NR b R c , or -NR a C(=O)OR 1 and L 2 is -O(C=O)R 2 , -(C=O)OR 2 , -C(=O)R 2 , -OR 2 , -S(O) x R 2 , -S-SR 2 , -C(=O)SR 2 , -SC(=O)R 2 , -NR d C(=O)R 2 , -C(=O)NR e R f , -NR d C(=O)NR e R f , -OC(=O)NR e R f , -NR d C(=O)OR 2 , or R 2 is a direct bond to L 3 is -O(C=O)R 3 or -(C=O)OR 3 and G 1 and G 2are each independently C2 to C 12 Alkylene or C2-C 12 is alkenylene, G 3 If X is CR and Y is NR, then C1 to C 24 Alkylene, C2-C 24 Alkenylene, C1-C 24 Heteroalkylene, or C2-C 24 Heteroalkylene, G 3 If X is N and Y does not exist, then C1 to C 24 Heteroalkylene or C2-C 24 heteroalkenylene, R a , R b , R d and R e are each independently H or C1 to C 12 Alkyl, or C1-C 12 is alkenyl, R c and R f are each independently C1 to C 12 Alkyl or C2-C 12 is alkenyl, Each R is independently H or C1-C 12 is alkyl, R 1 , R 2 , and R 3 are each independently C1 to C 24 Alkyl or C2-C 24 alkenyl, and x is 0, 1, or 2; Each alkyl, alkenyl, alkylene, alkenylene, heteroalkylene, and heteroalkenylene is independently substituted or unsubstituted, unless otherwise specified.

[0412] Expression (AIX) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, tautomer, prodrug, or stereoisomer thereof, wherein: L 1 and L 2 are each independently -0(C=0)-, -(C=0)0-, -C(=0)-, -0-, -S(0)x- s -SS-, -C(=0)S-, -SC(=0)-, -NR a C(=0)-, -C(=0)NR a -, -NR a C(=0)NR a -, -OC(=0)NR a -, -NR a C(=0)0- or a direct bond, G 1 is C, -C2 alkylene, -(C=0)-, -0(C=0)-, -SC(=0)-, -NR a C(=0)- or a direct bond, G 2 are -C(0)-, -(CO)O-, -C(=0)S-, -C(=0)NR a - or a direct bond, G 3 is a C1-C6 alkylene, R a is H or C1~C 12 is alkyl, R l a and R lb is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R la is H or C1~C 12 alkyl, and R I b together with the carbon atom to which it is attached, form an adjacent R l b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 2a and R 2b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2btogether with the carbon atom to which it is attached, form an adjacent R 2b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 3a and R 3b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom to which it is attached, form a carbon-carbon double bond with the adjacent R and the carbon atom to which it is attached; R 4A and R 4B is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 4A is H or C1~C 12 alkyl, and R 4B together with the carbon atom to which it is attached, form an adjacent R 4B and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 5 and R 6 are each independently H or methyl; R 7 is H, C, -C 20 is alkyl, R 8 is OH, -N(R 9 )(C=0)R 10 , -(C=0)NR 9 R 10 , -NR 9 R 10 , -(C=0)0R” 1 or -O(C=O)R", where R 8 Ga-NR 9 R 10 If G 3 is a C4-C6 alkylene, R 9 and R 10 are each independently H or C1 to C12 is alkyl, R" is aralkyl; a, b, c, and d each independently represent an integer of 1 to 24, and x represents 0, 1, or 2; Each alkyl, alkylene, and aralkyl is optionally substituted.

[0413] Expression(AX) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: X and X′ are each independently N or CR; Y and Y′ are each independently absent, —O(C═O)—, —(C═O)O—, or NR, with the proviso that a) if X is N then Y is absent; b) if X' is N then Y' is absent; c) when X is CR, Y is —O(C═O)—, —(C═O)O—, or NR; d) when X' is CR, Y' is -O(C=O)-, -(C=O)O-, or NR; L 1 and L 1’ are each independently -O(C=O)R', -(C=O)OR', -C(=O)R', -OR 1 , -S(O) z R', -S-SR 1 , -C(=O)SR', -SC(=O)R', -NR a C(=O)R', -C(=O)NR b R c , -NR a C(=O)NR b R c , -OC(=O)NR b R c , or -NR a C(=O)OR', L 2 and L 2’are each independently -O(C=O)R 2 , -(C=O)OR 2 , -C(=O)R 2 , -OR 2 , -S(O) z R 2 , -S-SR 2 , -C(=O)SR 2 , -SC(=O)R 2 , -NR d C(=O)R 2 , -C(=O)NR e R f , -NR d C(=O)NR e R f , -OC(=O)NR e R f , -NR d C(=O)OR 2 , or R 2 is a direct bond to G 1 , G 1’ , G 2 , and G 2’ are each independently a C2-Ci2 alkylene or a C2-C 12 is alkenylene, G is C2 to C 24 Heteroalkylene or C2-C 24 heteroalkenylene, R a , R b , R d , and R e independently in each occurrence: H, C1 to C 12 Alkyl or C2-C 12 is alkenyl, R c and R f independently in each occurrence, C1 to C 12 Alkyl or C2-C 12 is alkenyl, R, in each occurrence, is independently H or C1-C 12 is alkyl, R 1 and R 2 independently in each occurrence, branched C6-C 24Alkyl or branched C6-C 24 is alkenyl, z is 0, 1, or 2, and each alkyl, alkenyl, alkylene, alkenylene, heteroalkylene, and heteroalkenylene is independently substituted or unsubstituted, unless otherwise specified.

[0414] Formula (AXI) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: L 1 is -O(C=O)R 1 , -(C=O)OR 1 , -C(=O)R 1 , -OR 1 , -S(O) x R 1 , -S-SR 1 , -C(=O)SR 1 , -SC(=O)R 1 , -NR a C(=O)R 1 , -C(=O)NR b R c , -NR a C(=O)NR b R c , -OC(=O)NR b R c , or -NR a C(=O)OR 1 and L 2 is -O(C=O)R 2 , -(C=O)OR 2 , -C(=O)R 2 , -OR 2 , -S(O) x R 2 , -S-SR 2 , -C(=O)SR 2 , -SC(=O)R 2 , -NR d C(=O)R 2 , -C(=O)NRe R f , -NR d C(=O)NR e R f , -OC(=O)NR e R f , -NR d C(=O)OR 2 , or R 2 is a direct bond to G 1 and G 2 are each independently C2 to C 12 Alkylene or C2-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C2-C 24 alkenylene, C3-C8 heteroalkylene, or C3-C8 cycloalkenylene; R a , R b , R d and R e are each independently H or C1 to C 12 Alkyl, or C1-C 12 is alkenyl, R c and R f are each independently C1 to C 12 Alkyl or C2-C 12 is alkenyl, R 1 and R 2 are each independently a branched C6 to C 24 Alkyl or branched C6-C 24 is alkenyl, R 3 is -N(R 4 )R 5 and R 4 is C1~C 12 is alkyl, R 5 is the substitution C1~C 12 is alkyl, x is 0, 1 or 2; Each alkyl, alkenyl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, aryl, and aralkyl is independently substituted or unsubstituted unless otherwise specified.

[0415] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: L 1 is -O(C=O)R 1 , -(C=O)OR 1 , -C(=O)R 1 , -OR 1 , -S(O) x R 1 , -S-SR 1 , -C(=O)SR 1 , -SC(=O)R 1 , -NR a C(=O)R 1 , -C(=O)NR b R c , -NR a C(=O)NR b R c , -OC(=O)NR b R c , or -NR a C(=O)OR 1 and L 2 is -O(C=O)R 2 , -(C=O)OR 2 , -C(=O)R 2 , -OR 2 , -S(O) x R 2 , -S-SR 2 , -C(=O)SR 2 , -SC(=O)R 2 , -NR d C(=O)R 2 , -C(=O)NR e R f , -NR d C(=O)NR e R f, -OC(=O)NR e R f , -NR d C(=O)OR 2 , or R 2 is a direct bond to G 1a and G 2b are each independently C2 to C 12 Alkylene or C2-C 12 is alkenylene, G 1b and G 2b are each independently C1 to C 12 Alkylene or C2-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C2-C 24 alkenylene, C3-C8 heteroalkylene, or C3-C8 cycloalkenylene; R a , R b , R d and R e are each independently H or C1 to C 12 Alkyl, or C2-C 12 is alkenyl, R c and R f are each independently C1 to C 12 Alkyl or C2-C 12 is alkenyl, R 1 and R 2 are each independently a branched C6 to C 24 Alkyl or branched C6-C 24 is alkenyl, R 3a is -C(=O)N(R 4a )R 5a or -C(=O)OR 6 and R 3b is -NR 4b C(=O)R 5b and R 4a is C1~C 12 is alkyl, R4b H, C1~C 12 Alkyl or C2-C 12 is alkenyl, R 5a is H, C1-C8 alkyl or C2-C8 alkenyl, R 4b If is H, then R 5b is C2~C 12 Alkyl or C2-C 12 alkenyl, or R 4b C1~C 12 Alkyl or C2-C 12 When R is alkenyl, 5b is C1~C 12 Alkyl or C2-C 12 is alkenyl, R 6 is H, aryl, or aralkyl; x is 0, 1 or 2; Each alkyl, alkenyl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, aryl, and aralkyl is independently substituted or unsubstituted.

[0416] Formula (AXII) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: G 1 -OH, -R 3 R 4 , -(C=0)R 5 , or -R 3 (C=0)R 5 and G 2 is —CH— or —CR—(C=0)—, R is independently in each occurrence H or OH; R 1 and R 2each independently represents an optionally substituted branched saturated or unsaturated C 12 ~C 36 is alkyl, R 3 and R 4 are each independently H or an optionally substituted linear or branched, saturated or unsaturated Ci-C6 alkyl; R 5 is an optionally substituted, linear or branched, saturated or unsaturated Ci-C6 alkyl; n is an integer of 2 to 6.

[0417] Formula (AXIII) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: G 1 or G 2 and one of, in each occurrence, is selected from -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O), -SS-, -C(=O)S-, SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )-, or -N(R a )C(=O)O-, and G 1 or G 2 and the other of each occurrence is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O), -SS-, -C(=O)S-, -SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O-, or a direct bond; L, in each occurrence, is ~O(C=O)-, where ~ represents a covalent bond to X; X is CR a and Z is a monovalent moiety containing at least one alkyl, cycloalkyl, or polar functional group when n is 1, or Z is a polyvalent moiety containing at least one alkylene, cycloalkylene, or polar functional group when n is greater than 1; R a independently in each occurrence: H, C1 to C 12 Alkyl, C1-C 12 Hydroxyl alkyl, C1-C 12 Aminoalkyl, C1-C 12 Alkylaminylalkyl, C1-C 12 Alkoxyalkyl, C1-C 12 Alkoxycarbonyl, C1-C 12 Alkylcarbonyloxy, C1-C 12 Alkylcarbonyloxyalkyl, or C1-C 12 is alkylcarbonyl, R, in each occurrence, is independently: (a) H or C1-C 12 alkyl, or (b) R, together with the carbon atom to which it is attached, forms a carbon-carbon double bond with an adjacent R and the carbon atom to which it is attached; R 1 and R 2 Each occurrence of [ka] and a 1 and a 2 is independently in each occurrence an integer from 3 to 12, and b 1 and b 2 is independently 0 or 1 in each occurrence, c 1 and c 2 is independently in each occurrence an integer from 5 to 10, and d 1 and d2 is independently in each occurrence an integer from 5 to 10, y is independently in each occurrence an integer from 0 to 2, and n is an integer from 1 to 6; Each alkyl, alkylene, hydroxylalkyl, aminoalkyl, alkylaminylalkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, and alkylcarbonyl is optionally substituted with one or more substituents.

[0418] Formula (AXIV) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein: L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -R a C(=O)-, -C(=O)R a -, R a C(=O)R a -, -OC(=O)R a -, or -R a C(=O)O-, and L 1 or L 2 The other of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -R a C(=O)-, -C(=O)R a -, R a C(=O)R a -, -OC(=O)R a - or -NR a C(=O)O-, or a direct bond, G 1 and G 2 are each independently unsubstituted C1-C 12Alkylene or C1-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C1-C 24 alkenylene, C3-C8 heteroalkylene, C3-C8 cycloalkenylene; R a is H or C1~C 12 is alkyl, R 1 and R 2 are each independently C6 to C 24 Alkyl or C6-C 24 is alkenyl, R 3 H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 , or -R 5 C(=O)R 4 and R 4 is C1~C 12 is alkyl, R 5 is H or C1-C6 alkyl, x is 0, 1, or 2.

[0419] Formula (AXV) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, tautomer, prodrug, or stereoisomer thereof, wherein: L 1 and L 2 are each independently -0(C=0)-, -(C=0)0-, -C(=0)-, -0-, -S(0) x -, -SS-, -C(=0)S-, -SC(=0)-, -R a C(=0)-, -C(=0)R a -, -R a C(=0)R a -, -OC(=0)R a -, -Ra C(=0)0- or a direct bond, G 1 is Ci to C2 alkylene, -(C=0)-, -0(C=0)-, -SC(=0)-, -R a C(=0)- or a direct bond, G 2 are -C(=0)-, -(C=0)0-, -C(=0)S-, and -C(=0)NR a - or a direct bond, G 3 is a C1-C6 alkylene, R a is H or C1~C 12 is alkyl, R la and R lb is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R la is H or C1~C 12 alkyl, and R lb together with the carbon atom to which it is attached, form an adjacent R lb and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 2a and R 2b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom to which it is attached, form an adjacent R 2b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 3a and R 3b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3btogether with the carbon atom to which it is attached, form a carbon-carbon double bond with the adjacent R and the carbon atom to which it is attached; R 4a and R 4b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom to which it is attached, form an adjacent R 4b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 5 and R 6 are each independently H or methyl; R 7 is C4~C 20 is alkyl, R 8 and R 9 are each independently C1 to C 12 alkyl or R 8 and R 9 form together with the nitrogen atom to which they are attached a 5-, 6-, or 7-membered heterocyclic ring; a, b, c, and d each independently represent an integer of 1 to 24; x is 0, 1, or 2.

[0420] Formula (AXVI) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt, tautomer, prodrug, or stereoisomer thereof, wherein: L 1 and L 2 are each independently -0(C=0)-, -(C=0)0-, or a carbon-carbon double bond; R la and R lb is, independently in each occurrence: (a) H or C1-C12 alkyl, or (b) R la is H or C1~C 12 alkyl, and R lb together with the carbon atom to which it is attached, form an adjacent R lb and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 2a and R 2b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom to which it is attached, form an adjacent R 2b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 3a and R 3b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom to which it is attached, form an adjacent R 3b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 4a and R 4b is, independently in each occurrence: (a) H or C1-C 12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom to which it is attached, form an adjacent R 4b and together with the carbon atom to which it is attached form a carbon-carbon double bond, R 5 and R 6 are each independently methyl or cycloalkyl; R 7is independently in each occurrence H or C1-C 12 alkyl, and R 8 and R 9 are each independently unsubstituted C1 to C 12 alkyl or R 8 and R 9 together with the nitrogen atom to which they are attached form a 5-, 6-, or 7-membered heterocyclic ring containing one nitrogen atom; a and d each independently represent an integer of 0 to 24, b and c each independently represent an integer of 1 to 24, and e is 1 or 2. (however, R la , R 2a , R 3a , or R 4a At least one of C1 to C 12 alkyl or L 1 Or L 2 at least one of is -0(C=0)- or -(C=0)0-; R la and R lb is not isopropyl when a is 6 or n-butyl when a is 8).

[0421] Formula (AXVII) In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are the same or different and each represents a linear or branched alkyl having 1 to 9 carbon atoms, or an alkenyl or alkynyl having 2 to 11 carbon atoms; L1 and L2 are the same or different and each is a linear alkyl group having 5 to 18 carbon atoms or forms a heterocycle together with N; X1 is a bond or -CG-G- to form L2-CO-O-R2; X2 is S or O; L3 is a bond or lower alkyl, or forms a heterocycle together with N; R3 is lower alkyl, R4 and R5 are the same or different and are each lower alkyl.

[0422] Compounds (A1)~(A11) In some embodiments, the lipid nanoparticles comprise an ionic lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0423] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0424] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0425] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0426] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0427] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0428] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0429] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0430] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0431] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0432] In some embodiments, the lipid nanoparticles comprise a lipid having the following structure: [ka] or a pharmaceutically acceptable salt thereof.

[0433] Non-cationic lipids In certain embodiments, the lipid nanoparticles described herein comprise one or more non-cationic lipids. The non-cationic lipids may be phospholipids.

[0434] In some embodiments, the lipid nanoparticles comprise 5-25 mol% non-cationic lipids. For example, the lipid nanoparticles may comprise 5-20 mol%, 5-15 mol%, 5-10 mol%, 10-25 mol%, 10-20 mol%, 10-25 mol%, 15-25 mol%, 15-20 mol%, or 20-25 mol% non-cationic lipids. In some embodiments, the lipid nanoparticles comprise 5 mol%, 10 mol%, 15 mol%, 20 mol%, or 25 mol% non-cationic lipids.

[0435] In some embodiments, the non-cationic lipids of the present disclosure are 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dilinoleo ... 1-Oleoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3 -phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, or a mixture thereof.

[0436] In some embodiments, the lipid nanoparticles contain 5-15 mol%, 5-10 mol%, or 10-15 mol% DSPC. For example, the lipid nanoparticles may contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mol% DSPC.

[0437] In certain embodiments, the lipid composition of the lipid nanoparticle compositions disclosed herein can include one or more phospholipids, such as one or more saturated or (poly)unsaturated phospholipids, or a combination thereof. Generally, a phospholipid comprises a phospholipid moiety and one or more fatty acid moieties.

[0438] The phospholipid moiety can be selected, for example, from the non-limiting group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin.

[0439] The fatty acid moiety may be selected from the non-limiting group consisting of, for example, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.

[0440] Certain phospholipids can facilitate fusion with membrane.For example, cationic phospholipids can interact with one or more negatively charged phospholipids of membrane (for example, cell membrane or intracellular membrane).By fusion of phospholipid with membrane, one or more elements (for example, therapeutic agent) of lipid-containing composition (for example, LNP) can be able to pass through the membrane, for example, one or more elements can be delivered to target tissue.

[0441] Non-natural phospholipid species are also contemplated, including natural species with modifications and substitutions, including branching, oxidation, cyclization, and alkynes. For example, phospholipids can be functionalized or crosslinked with one or more alkynes (e.g., alkenyl groups in which one or more double bonds are replaced with triple bonds). Under appropriate reaction conditions, alkyne groups can undergo copper-catalyzed cycloaddition when exposed to azide. Such reactions can be useful for functionalizing the lipid bilayer of nanoparticle compositions to promote membrane penetration or cell recognition, or for conjugating nanoparticle compositions to useful components such as targeting moieties or imaging moieties (e.g., dyes).

[0442] Phospholipids include, but are not limited to, glycerophospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid. Phospholipids also include phosphosphingolipids, such as sphingomyelin.

[0443] In some embodiments, the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1 , 2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-Diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-Di-O-Octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-Oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3 -phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, or a mixture thereof.

[0444] Expression (HI) In certain embodiments, the phospholipid is an analog or variant of DSPC. In certain embodiments, the phospholipid has the formula (HI): [ka] or a salt thereof, wherein Each R 1 are independently optionally substituted alkyl, or optionally, two R 1 together with the intervening atoms form an optionally substituted monocyclic carbocyclyl or an optionally substituted monocyclic heterocyclyl, or optionally, three R 1 together with the intervening atoms form an optionally substituted bicyclic carbocyclyl or an optionally substituted bicyclic heterocyclyl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; A is a group having the formula: [ka] It is of L 2 Each instance of is independently a bond or an optionally substituted C 1~6 alkylene, wherein the optionally substituted C 1~6 One methylene unit of alkylene is O, N(R N ), S, C(O), C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), -NR N C(O)O, or NR N C(O)N(R N ), which is optionally replaced by R 2 Each instance of is independently an optionally substituted C 1~30 Alkyl, optionally substituted C 1~30 alkenyl, or optionally substituted C 1~30 alkynyl, and optionally R 2one or more methylene units in the formula (I) are independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N ), O, S, C(O), C(O)N(R N ), NR N C(O), NR N C(O)N(R N ), C(O)O, OC(O), -OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N ), C(S), C(S)N(R N ), NR N C(S), NR N C(S)N(R N ), S(O), OS(O), S(O)O, -OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R N )S(O), S(O)N(R N ), N(R N )S(O)N(R N ), OS(O)N(R N ), N(R N )S(O)O, S(O)2, N(R N )S(O)2, S(O)2N(R N ), N(R N )S(O)2N(R N ), OS(O)2N(R N ), or -N(R N )S(O)2O, R N each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; p is 1 or 2.

[0445] In certain embodiments, the compound has the formula: [ka] (In the formula, R 2 Each instance of is independently an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl.

[0446] In some embodiments, the phospholipid can be one or more of the phospholipids described in PCT Application No. PCT / US2018 / 037922.

[0447] In some embodiments, lipid nanoparticles comprise 5-25% non-cationic lipids by molar ratio relative to other lipid components. For example, lipid nanoparticles may comprise 5-30%, 5-15%, 5-10%, 10-25%, 10-20%, 10-25%, 15-25%, 15-20%, 20-25%, or 25-30% non-cationic lipids by molar ratio. In some embodiments, lipid nanoparticles comprise 5%, 10%, 15%, 20%, 25%, or 30% non-cationic lipids by molar ratio.

[0448] In some embodiments, lipid nanoparticles contain 5-25% phospholipids by molar ratio relative to other lipid components. For example, lipid nanoparticles may contain 5-30%, 5-15%, 5-10%, 10-25%, 10-20%, 10-25%, 15-25%, 15-20%, 20-25%, or 25-30% phospholipids by molar ratio. In some embodiments, lipid nanoparticles contain 5%, 10%, 15%, 20%, 25%, or 30% phospholipids by molar ratio.

[0449] structured lipids The lipid composition of the pharmaceutical composition disclosed herein can comprise one or more structured lipids. As used herein, the term "structured lipid" includes sterols and also includes lipids that contain sterol moieties.

[0450] Incorporating structured lipids into lipid nanoparticles may help reduce aggregation of other lipids within the particles. The structured lipid may be selected from the group including, but not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof. In some embodiments, the structured lipid is a sterol. As defined herein, "sterol" is a subgroup of steroids consisting of steroid alcohols. In certain embodiments, the structured lipid is a steroid. In certain embodiments, the structured lipid is cholesterol. In certain embodiments, the structured lipid is a cholesterol analog. In certain embodiments, the structured lipid is alpha-tocopherol.

[0451] In some embodiments, the structured lipid can be one or more of the structured lipids described in US Application No. 16 / 493,814.

[0452] In some embodiments, lipid nanoparticles contain 25-55% structural lipids by molar ratio relative to other lipid components. For example, lipid nanoparticles may contain 10-55%, 25-50%, 25-45%, 25-40%, 25-35%, 25-30%, 30-55%, 30-50%, 30-45%, 30-40%, 30-35%, 35-55%, 35-50%, 35-45%, 35-40%, 40-55%, 40-50%, 40-45%, 45-55%, 45-50%, or 50-55% structural lipids. In some embodiments, lipid nanoparticles contain 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or 55% structural lipids by molar ratio.

[0453] In some embodiments, the lipid nanoparticles comprise 30-45 mol% sterol, optionally 35-40 mol%, e.g., 30-31 mol%, 31-32 mol%, 32-33 mol%, 33-34 mol%, 35-35 mol%, 35-36 mol%, 36-37 mol%, 38-38 mol%, 38-39 mol%, or 39-40 mol% sterol. In some embodiments, the lipid nanoparticles comprise 25-55 mol% sterol. For example, the lipid nanoparticles may contain 25-50 mol%, 25-45 mol%, 25-40 mol%, 25-35 mol%, 25-30 mol%, 30-55 mol%, 30-50 mol%, 30-45 mol%, 30-40 mol%, 30-35 mol%, 35-55 mol%, 35-50 mol%, 35-45 mol%, 35-40 mol%, 40-55 mol%, 40-50 mol%, 40-45 mol%, 45-55 mol%, 45-50 mol%, or 50-55 mol% sterol. In some embodiments, the lipid nanoparticles contain 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, or 55 mol% sterol.

[0454] In some embodiments, the lipid nanoparticles comprise 35-40 mol% cholesterol, for example, the lipid nanoparticles may comprise 35, 35.5, 36, 36.5, 37, 37.5, 38, 38.5, 39, 39.5, or 40 mol% cholesterol.

[0455] Polyethylene glycol (PEG)-lipids The lipid composition of the pharmaceutical compositions disclosed herein may include one or more polyethylene glycol (PEG) lipids.

[0456] As used herein, the term "PEG-lipid" or "PEG-modified lipid" refers to a polyethylene glycol (PEG)-modified lipid. Non-limiting examples of PEG-lipids include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamine, and PEG-modified 1,2-diacyloxypropan-3-amine. Such lipids are also called PEGylated lipids. For example, the PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0457] In some embodiments, PEG-lipids include, but are not limited to, 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA).

[0458] In some embodiments, the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof. In some embodiments, the PEG-modified lipid is PEG-DMG, PEG-c-DOMG (also referred to as PEG-DOMG), PEG-DSG, and / or PEG-DPG.

[0459] In some embodiments, the lipid portion of the PEG-lipid comprises a PEG-lipid having a molecular weight of about C 14 ~About C 22 , preferably about C 14 ~About C 16 In some embodiments, the PEG moiety, e.g., mPEG-NH2, is about 1000 daltons, about 2000 daltons, about 5000 daltons, about 10,000 daltons, about 15,000 daltons, or about 20,000 daltons in size. In some embodiments, the PEG-lipid is PEG 2k -DMG.

[0460] In some embodiments, the lipid nanoparticles described herein can include a PEG-lipid that is a non-diffusible PEG. Non-limiting examples of non-diffusible PEGs include PEG-DSG and PEG-DSPE.

[0461] PEG-lipids, such as those described in U.S. Pat. No. 8,158,601 and International Publication No. WO2015 / 130584A2, which are incorporated by reference in their entireties, are known in the art.

[0462] Generally, some of the other lipid components (e.g., PEG lipids) of the various formulas described herein can be synthesized as described in International Patent Application No. PCT / US2016 / 000129, filed December 10, 2016, entitled "Compositions and Methods for Delivery of Therapeutic Agents," which is incorporated by reference in its entirety.

[0463] The lipid component of the lipid nanoparticle composition may include one or more molecules containing polyethylene glycol, such as PEG, or a PEG-modified lipid. Such species may alternatively be referred to as PEGylated lipids. The PEG lipid is a lipid modified with polyethylene glycol. The PEG lipid may be selected from the non-limiting group including PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof. For example, the PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0464] In some embodiments, the PEG-modified lipid is a modified PEG DMG. PEG-DMG has the following structure: [ka]

[0465] In some embodiments, the PEG lipid may be a PEGylated lipid described in International Publication No. WO2012099755 (the contents of which are incorporated herein by reference in their entirety). Any of these exemplary PEG lipids described herein may be modified to include a hydroxyl group on the PEG chain. In certain embodiments, the PEG lipid is a PEG-OH lipid. As generally defined herein, a "PEG-OH lipid" (also referred to herein as a "hydroxy-PEGylated lipid") is a PEGylated lipid having one or more hydroxyl (-OH) groups on the lipid. In certain embodiments, the PEG-OH lipid includes one or more hydroxyl groups on the PEG chain. In certain embodiments, the PEG-OH or hydroxy-PEGylated lipid includes an -OH group at the end of the PEG chain. Each possibility represents a separate embodiment.

[0466] Formula (PI) In certain embodiments, the PEG lipid has the formula (PI): [ka] or a salt thereof, wherein R 3 -OR O and R O is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r is an integer from 1 to 100, inclusive; L 1 is an arbitrarily substituted C 1~10 alkylene, wherein the optionally substituted C 1~10 At least one methylene of the alkylene is independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, O, N(R N ), S, C(O), C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, or NR N C(O)N(R N ) and D is a moiety obtained by click chemistry or cleavable under physiological conditions; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; A is a group having the formula: [ka] It is of L 2 Each instance of is independently a bond or an optionally substituted C 1~6 alkylene, wherein the optionally substituted C 1~6 One methylene unit of alkylene is O, N(R N ), S, C(O), C(O)N(R N ), NR N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(RN ), -NR N C(O)O, or NR N C(O)N(R N ), which is optionally replaced by R 2 Each instance of is independently an optionally substituted C 1~30 Alkyl, optionally substituted C 1~30 alkenyl, or optionally substituted C 1~30 alkynyl, and optionally R 2 one or more methylene units in the formula (I) are independently selected from optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N ), O, S, C(O), C(O)N(R N ), NR N C(O), NR N C(O)N(R N ), C(O)O, OC(O), -OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N ), C(S), C(S)N(R N ), NR N C(S), NR N C(S)N(R N ), S(O), OS(O), S(O)O, -OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R N )S(O), S(O)N(R N ), N(R N )S(O)N(R N ), OS(O)N(R N ), N(R N )S(O)O, S(O)2, N(R N )S(O)2, S(O)2N(R N ), N(R N )S(O)2N(RN ), OS(O)2N(R N ), or -N(R N )S(O)2O, R N each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; p is 1 or 2.

[0467] In certain embodiments, the compound of formula (PI) is a PEG-OH lipid (i.e., R 3 HA-OR O and R O is hydrogen). In certain embodiments, the compound of formula (PI) has the formula (PI-OH): [ka] or a salt thereof.

[0468] Formula (PII) In certain embodiments, the PEG lipid is a PEGylated fatty acid. In certain embodiments, the PEG lipid is a compound of formula (PII). In some embodiments, the compound of formula (PII) has the following formula: [ka] or a salt thereof, wherein R 3 -OR O and R O is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r is an integer from 1 to 100, inclusive; R 5 is an arbitrarily substituted C 10~40 Alkyl, optionally substituted C 10~40 alkenyl, or optionally substituted C 10~40alkynyl, and optionally R 5 One or more methylene groups in the formula (I) are optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N ), O, S, C(O), -C(O)N(R N ), NR N C(O), NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), NR N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), NR N C(=NR N ), NR N C(=NR N )N(R N ), C(S), -C(S)N(R N ), NR N C(S), NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, -OS(O)2O, N(R N )S(O), S(O)N(R N ), N(R N )S(O)N(R N ), OS(O)N(R N ), N(R N )S(O)O, S(O)2, -N(R N )S(O)2, S(O)2N(R N ), N(R N )S(O)2N(R N ), OS(O)2N(R N ), or N(R N )S(O)2O, R N Each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group.

[0469] In certain embodiments, the compound of formula (PII) has the formula (PII-OH): [ka] or a salt thereof. In some embodiments, r is 40-50.

[0470] In yet another embodiment, the compound of formula (PII) is [ka] or a salt thereof.

[0471] In some embodiments, the compound of formula (PII) is [ka] is.

[0472] In some embodiments, the lipid composition of the pharmaceutical compositions disclosed herein does not comprise a PEG-lipid.

[0473] In some embodiments, the PEG-lipid can be one or more of the PEG-lipids described in US Application No. US 15 / 674,872.

[0474] In some embodiments, lipid nanoparticles contain 0.5-15% PEG-lipid molar ratio relative to other lipid components. For example, lipid nanoparticles may contain 0.5-10%, 0.5-5%, 1-15%, 1-10%, 1-5%, 2-15%, 2-10%, 2-5%, 5-15%, 5-10%, or 10-15% PEG-lipid molar ratio. In some embodiments, lipid nanoparticles contain 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% PEG-lipid molar ratio.

[0475] In some embodiments, the lipid nanoparticles contain 1-5%, optionally 1-3 mol%, e.g., 1.5-2.5 mol%, 1-2 mol%, 2-3 mol%, 3-4 mol%, or 4-5 mol%, of PEG-modified lipids. In some embodiments, the lipid nanoparticles contain 0.5-15 mol% of PEG-modified lipids. For example, the lipid nanoparticles may contain 0.5-10 mol%, 0.5-5 mol%, 1-15 mol%, 1-10 mol%, 1-5 mol%, 2-15 mol%, 2-10 mol%, 2-5 mol%, 5-15 mol%, 5-10 mol%, or 10-15 mol%. In some embodiments, the lipid nanoparticles comprise 0.5 mol%, 1 mol%, 2 mol%, 3 mol%, 4 mol%, 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol%, or 15 mol% PEG-modified lipids.

[0476] Some embodiments include adding PEG to a composition comprising LNPs encapsulating nucleic acids (e.g., one that already contains PEG in the amounts listed above). In embodiments, this includes adding about 0.5 mol% or more of PEG, e.g., about 1 mol%, about 1.5 mol%, about 2 mol%, about 2.5 mol%, about 3 mol%, about 3.5 mol%, about 4 mol%, about 5 mol%, or more, to the LNP composition after formation (e.g., one that already contains PEG in the amounts listed elsewhere herein).

[0477] In some embodiments, the lipid nanoparticles comprise 20-60 mol % ionic amino lipid, 5-25 mol % non-cationic lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid.

[0478] In some embodiments, the LNPs of the present disclosure comprise an ionic amino lipid of Compound 1, where the non-cationic lipid is DSPC, the structural lipid is cholesterol, and the PEG lipid is DMG-PEG.

[0479] In some embodiments, the LNPs of the present disclosure comprise an ionic amino lipid of Compound 2, where the non-cationic lipid is...

Claims

1. 1. A herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein B (gB) that comprises a truncated C-terminus relative to wild-type HSV gB; (b) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC); (c) an mRNA comprising an open reading frame encoding HSV glycoprotein D (gD); (d) an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0); (e) an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4); (f) lipid nanoparticles; and The vaccine comprising:

2. 2. The HSV mRNA vaccine of claim 1, wherein the HSV gB comprises a truncated cytoplasmic tail.

3. 2. The HSV mRNA vaccine of claim 1, wherein the HSV gB does not include the cytoplasmic tail.

4. The HSV mRNA vaccine of any one of claims 1 to 3, wherein the HSV gC comprises an F327A substitution and a truncated C-terminus compared to wild-type HSV gC.

5. 5. The HSV mRNA vaccine of claim 4, wherein the HSV gC comprises a truncated cytoplasmic tail.

6. 5. The HSV mRNA vaccine of claim 4, wherein the HSV gB and / or the HSV gC does not contain a cytoplasmic tail.

7. The HSV mRNA vaccine of any one of claims 1 to 6, wherein the HSV ICP0 lacks a nuclear localization signal and / or a RING finger domain.

8. 8. The HSV mRNA vaccine of any one of claims 1 to 7, wherein the HSV ICP0 contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP0.

9. The HSV mRNA vaccine of any one of claims 1 to 8, wherein the HSV ICP4 lacks a nuclear localization signal and / or a RING finger domain.

10. 10. The HSV mRNA vaccine of any one of claims 1 to 9, wherein the HSV ICP4 contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP4.

11. 1. A herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein B (gB), optionally wherein said gB comprises a truncated C-terminus compared to wild-type HSV gB; (b) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC) comprising an F327A substitution and a truncated C-terminus relative to wild-type HSV gC; (c) an mRNA comprising an open reading frame encoding wild-type HSV glycoprotein D (gD); (d) lipid nanoparticles; and The vaccine comprising:

12. 12. The HSV mRNA vaccine of claim 11, further comprising an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0), which contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP0.

13. 13. The HSV mRNA vaccine of claim 11 or 12, further comprising an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4) that contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP4.

14. The HSV mRNA vaccine of any one of claims 11 to 13, wherein the HSV gB and / or the HSV gC comprises a truncated cytoplasmic tail.

15. The HSV mRNA vaccine of any one of claims 11 to 13, wherein the HSV gB and / or the HSV gC does not contain a cytoplasmic tail.

16. 1. A herpes simplex virus (HSV) messenger ribonucleic acid (mRNA) vaccine comprising: (a) an mRNA comprising an open reading frame encoding HSV glycoprotein C (gC) comprising an F327A substitution and a truncated C-terminus relative to wild-type HSV gC; (b) an mRNA comprising an open reading frame encoding wild-type HSV glycoprotein D (gD); (c) an mRNA comprising an open reading frame encoding HSV intracellular protein 0 (ICP0) that contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP0; (d) an mRNA comprising an open reading frame encoding HSV intracellular protein 4 (ICP4) that contains a higher density of CD8+ T cell epitopes compared to wild-type HSV ICP4; (e) lipid nanoparticles; and The vaccine comprising:

17. 17. The HSV mRNA vaccine of claim 16, wherein the HSV gC comprises a truncated cytoplasmic tail.

18. 18. The HSV mRNA vaccine of claim 16 or 17, wherein the HSV gC does not include the cytoplasmic tail.

19. 2. The HSV vaccine of any one of the preceding claims, wherein the vaccine induces a Th1 polarized CD4+ T cell mediated immune response against the HSV gC, gB, and / or gD.

20. 10. The HSV vaccine of any one of the preceding claims, wherein the vaccine induces more Th1 cells specific for an antigen selected from HSV gB, gC, or gD than Th2 cells specific for said antigen.

21. 2. The HSV vaccine of any one of the preceding claims, wherein the population of CD4+ T cells specific for an antigen selected from HSV gB, gC, or gD comprises greater than 50% Th1 cells.

22. 2. The HSV vaccine of any one of the preceding claims, wherein each of the HSV gB, gC, and gD comprises a transmembrane domain.

23. (a) the HSV gB has a length of about 798 amino acids; (b) the HSV gC has a length of about 469 amino acids; (c) the HSV ICP0 comprises a truncation in the nuclear localization signal, the RING finger domain, and / or the USP7 binding domain compared to wild-type HSV ICP0; and / or (d) the HSV ICP4 comprises a truncation in the nuclear localization signal and / or DNA binding domain compared to wild-type HSV ICP4; 2. An HSV vaccine according to any one of the preceding claims.

24. 24. The HSV vaccine of claim 23, wherein the HSV ICP0 does not contain a nuclear localization signal, does not contain a USP7 binding domain, and / or does not contain a RING finger domain.

25. 25. The HSV vaccine of claim 23 or 24, wherein the HSV ICP0 does not contain a nuclear localization signal and / or contains a truncated DNA binding domain.

26. (a) the HSV gB comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO:54; (b) the HSV gC comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO:63; (c) the HSV gD comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO:39; (d) the HSV ICP0 comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO:47; and / or (e) the HSV ICP4 comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO:49; 2. An HSV vaccine according to any one of the preceding claims.

27. 2. The HSV vaccine of any one of the preceding claims, wherein the molar ratio of the mRNA of (c) and (d) to the mRNA of (a), (b), and (c) is 0.8:1 or less.

28. 2. The HSV vaccine of any one of the preceding claims, wherein one or more of the mRNAs comprises a chemical modification.

29. 2. The HSV vaccine of any one of the preceding claims, wherein 100% of the uracil nucleotides of one or more of said mRNAs comprise a chemical modification.

30. 30. The HSV vaccine of claim 28 or 29, wherein the chemical modification is 1-methylpseudouracil.

31. 2. The HSV vaccine of any one of the preceding claims, wherein the lipid nanoparticles comprise an ionic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.

32. 32. The HSV vaccine of claim 31, wherein the lipid nanoparticle comprises 40-50 mol% ionic lipid, 5-15 mol% neutral lipid, 30-50 mol% sterol, and 0.5-3 mol% PEG-modified lipid.

33. The ionic lipid is compound (I): 【Chemistry 1】 The structure includes The neutral lipid is distearoylphosphatidylcholine (DSPC), the sterol is cholesterol, and / or The PEG-modified lipid is 1,2 dimyristoyl-sn-glycerol, methoxypolyethylene glycol (PEG-DMG); 33. The HSV vaccine of claim 31 or 32.

34. 13. A method comprising administering a vaccine according to any one of the preceding claims to a subject.

35. 35. The method of claim 34, wherein the subject has an HSV infection or has been exposed to HSV.

36. 36. The method of claim 34 or 35, wherein the vaccine is administered in an amount effective to prevent latent or active HSV infection in the subject.

37. The vaccine, preventing reactivation of a latent HSV infection in said subject, To prevent HSV replication, In reducing the duration of HSV infection in said subject, to reduce the number of replication-competent HSV particles in said subject, and / or reducing the number of cells in said subject that contain an HSV genome, 13. The method of any one of the preceding claims, administered in an effective amount.

38. 2. The method of any one of the preceding claims, wherein the vaccine induces a CD4+ T cell-mediated immune response against the HSV gB, gC, and / or gD, and the CD4+ T cells bind to one or more CD4+ T cell epitopes of the HSV gB, gC, or gD.

39. 39. The method of claim 38, wherein at least 50% of the CD4+ T cells produce one or more cytokines selected from the group consisting of IFN-γ, IL-2, and TNF-α.

40. 40. The method of claim 38 or 39, wherein less than 10% of the CD4+ T cells produce any one or more of IL-4, IL-5, IL-9, IL-10, or IL-13.

41. 10. The method of any one of the preceding claims, wherein the vaccine induces a CD8+ T cell mediated immune response against the HSV ICP0 and / or ICP4, and the CD8+ T cells bind to one or more CD8+ T cell epitopes of the HSV ICP0 and / or ICP4.

42. 42. The method of claim 41, wherein the CD8+ T cells are cytotoxic.

43. A modified herpes simplex virus (HSV) intracellular protein 0 (ICP0) that contains fewer amino acids than wild-type HSV ICP0.

44. 44. The modified HSV ICP0 of claim 43, wherein the modified HSV ICP0 comprises a truncation in the nuclear localization signal compared to wild-type HSV ICP0.

45. 44. The modified HSV ICP0 of claim 43, wherein the modified HSV ICP0 does not contain a nuclear localization signal.

46. The modified HSV ICP0 of any one of claims 43 to 45, wherein the modified HSV ICP0 comprises a truncation in the RING finger domain compared to wild-type HSV ICP0.

47. The modified HSV ICP0 of any one of claims 43 to 45, wherein the modified HSV ICP0 does not comprise a RING finger domain.

48. The modified HSV ICP0 of any one of claims 43 to 47, wherein the modified HSV ICP0 comprises a truncation in the USP7 binding domain compared to the wild-type HSV ICP0.

49. The modified HSV ICP0 of any one of claims 43 to 47, wherein the modified HSV ICP0 does not comprise a USP7 binding domain.

50. The modified HSV ICP0 of any one of claims 43 to 49, wherein the modified HSV ICP0 comprises a linker between the first portion of the modified HSV ICP0 and the second portion of the modified HSV ICP0.

51. 51. The modified HSV ICP0 of claim 50, wherein the linker comprises 2 to 10 glycine residues.

52. The modified HSV ICP0 of any one of claims 43 to 51, wherein the modified HSV ICP0 comprises an amino acid sequence having a length that is 65% or less than the length of the wild-type HSV ICP0.

53. The modified HSV ICP0 of any one of claims 43 to 52, wherein the modified HSV ICP0 amino acid sequence contains at least 65% of the T cell epitopes of the wild-type HSV ICP0.

54. The modified HSV ICP0 of any one of claims 43 to 53, wherein the modified HSV ICP0 comprises about 487 amino acids.

55. A ribonucleic acid (RNA) comprising an open reading frame encoding the modified HSV ICP0 of any one of claims 43 to 54.

56. A modified herpes simplex virus (HSV) intracellular protein 4 (ICP4) that contains fewer amino acids than wild-type HSV ICP4.

57. 57. The modified HSV ICP4 of claim 56, wherein the modified HSV ICP4 comprises a truncation in the nuclear localization signal compared to the wild-type HSV ICP4.

58. 57. The modified HSV ICP4 of claim 56, wherein the modified HSV ICP4 does not contain a nuclear localization signal.

59. 59. The modified HSV ICP4 of any one of claims 56 to 58, wherein the modified HSV ICP4 comprises a truncation in the DNA binding domain compared to the wild-type HSV ICP4.

60. 60. The modified HSV ICP4 of claim 59, wherein the modified HSV ICP4 does not contain a DNA binding domain.

61. The modified HSV ICP4 of any one of claims 56-60, wherein the modified HSV ICP4 comprises a linker between the first portion of the modified HSV ICP4 and the second portion of the modified HSV ICP4.

62. 62. The modified HSV ICP4 of claim 61, wherein the linker comprises 2 to 10 glycine residues.

63. The modified HSV ICP4 of any one of claims 56 to 62, wherein the modified HSV ICP4 comprises an amino acid sequence having a length no greater than 65% of the length of the wild-type HSV ICP4.

64. The modified HSV ICP4 of any one of claims 56 to 63, wherein the modified HSV ICP4 amino acid sequence contains at least 65% of the T cell epitopes of the wild-type HSV ICP4.

65. The modified HSV ICP4 of any one of claims 56 to 64, wherein the modified HSV ICP4 comprises about 687 amino acids.

66. A ribonucleic acid (RNA) comprising an open reading frame encoding the modified HSV ICP4 of any one of claims 56 to 65.

67. A herpes simplex virus (HSV) protein comprising an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs: 54, 63, 47, and 49.

68. 68. A messenger ribonucleic acid (mRNA) comprising an open reading frame encoding the HSV protein of claim 67.

69. A messenger ribonucleic acid (mRNA) comprising an open reading frame comprising a nucleic acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of any one of SEQ ID NOs: 19, 28, 4, 12, and 14.

70. 70. The mRNA of claim 68 or 69, wherein the mRNA comprises a chemical modification.

71. 71. The mRNA of any one of claims 68 to 70, wherein 100% of the uracil nucleotides of the mRNA comprise a chemical modification.

72. The mRNA of claim 71, wherein the chemical modification is 1-methylpseudouracil.